var title_f14_39_14960="Contents: Renal disease";
var content_f14_39_14960=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?0/41/670\">",
"       Nephrology and Hypertension",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Renal disease",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Renal disease",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Assessment for renal disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/45/36570\">",
"           Assessment of kidney function",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/37/13914\">",
"           Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/23/35190\">",
"           Calculation of the creatinine clearance",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/60/35785\">",
"           Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/39/20081\">",
"           Erythrocyte sedimentation rate in renal disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/59/34746\">",
"           Etiology and evaluation of hematuria in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/20/27973\">",
"           Exercise-induced hematuria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/2/35881\">",
"           Loin pain-hematuria syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/15/17655\">",
"           Orthostatic (postural) proteinuria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/18/32041\">",
"           Overview of heavy proteinuria and the nephrotic syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/7/28799\">",
"           Patient information: Split urine collection for orthostatic proteinuria (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/37/39509\">",
"           Radiologic assessment of renal disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/34/22058\">",
"           Urinalysis in the diagnosis of kidney disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Chronic kidney disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/57/13206\">",
"           Antihypertensive therapy and progression of chronic kidney disease: Experimental studies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/10/41130\">",
"           Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/31/34298\">",
"           Chronic kidney disease and coronary heart disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/29/5594\">",
"           Definition and staging of chronic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/2/25640\">",
"           Late referral to nephrologists of patients with chronic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/6/6248\">",
"           Lipid abnormalities in patients with chronic kidney disease not requiring dialysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/35/37434\">",
"           Overview of the management of chronic kidney disease in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/45/2777\">",
"           Protein restriction and progression of chronic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/18/28966\">",
"           Screening for chronic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/19/26938\">",
"           Secondary factors and progression of chronic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/6/30824\">",
"           Statins and chronic kidney disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Drug induced or toxic nephropathy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/5/38998\">",
"           Amphotericin B nephrotoxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/48/41738\">",
"           Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/8/29833\">",
"           Cisplatin nephrotoxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/43/27318\">",
"           Clinical manifestations and diagnosis of analgesic nephropathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/2/34857\">",
"           Crystal-induced acute kidney injury (acute renal failure)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/11/24760\">",
"           Epidemiology and toxicity of cadmium",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/31/34295\">",
"           Epidemiology and toxicity of mercury",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/29/14806\">",
"           Ifosfamide nephrotoxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/36/5705\">",
"           Lead nephropathy and lead-related nephrotoxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/0/24582\">",
"           NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/43/17081\">",
"           Nephrocalcinosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/40/4744\">",
"           Overview of renal disease associated with malignancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/14/32999\">",
"           Renal toxicity of lithium",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/32/35335\">",
"           Risk factors for and pathogenesis of analgesic nephropathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/18/39201\">",
"           Triamterene nephrotoxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/63/1012\">",
"           Urinary tract malignancy and atherosclerotic disease in patients with chronic analgesic abuse",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Malignancy and renal disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/8/29833\">",
"           Cisplatin nephrotoxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/60/4041\">",
"           Clinical course and management of monoclonal gammopathy of undetermined significance",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/2/34857\">",
"           Crystal-induced acute kidney injury (acute renal failure)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/59/15290\">",
"           Diagnosis of monoclonal gammopathy of undetermined significance",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/29/14806\">",
"           Ifosfamide nephrotoxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/36/1609\">",
"           Kidney disease following hematopoietic cell transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/40/4744\">",
"           Overview of renal disease associated with malignancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/1/22551\">",
"           Pathogenesis and diagnosis of myeloma cast nephropathy (myeloma kidney)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/44/30409\">",
"           Treatment of kidney disease in multiple myeloma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/1/19481\">",
"           Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/20/3402\">",
"           Tumor lysis syndrome: Prevention and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/48/27400\">",
"           Types of renal disease in multiple myeloma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/57/27541\">",
"           Uric acid renal diseases",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Nephrolithiasis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/2/30756\">",
"           Clinical significance of residual stone fragments following stone removal",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/62/25577\">",
"           Cystine stones",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/50/20266\">",
"           Diagnosis and acute management of suspected nephrolithiasis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/22/29033\">",
"           Evaluation of the adult patient with established nephrolithiasis and treatment if stone composition is unknown",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/18/40231\">",
"           Management of struvite or staghorn calculi",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/28/27079\">",
"           Management of ureteral calculi",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/28/38340\">",
"           Nephrolithiasis during pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/26/23973\">",
"           Nephrolithiasis in renal tubular acidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/62/30695\">",
"           Options in the management of renal and ureteral stones in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/54/40802\">",
"           Pathogenesis and clinical manifestations of struvite stones",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/2/38953\">",
"           Prevention of recurrent calcium stones in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/55/12154\">",
"           Primary hyperoxaluria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/10/27812\">",
"           Renal complications of extracorporeal shock wave lithotripsy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/53/33626\">",
"           Risk factors for calcium stones in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/58/39847\">",
"           The first kidney stone and asymptomatic nephrolithiasis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/62/3047\">",
"           Uric acid nephrolithiasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/57/27541\">",
"           Uric acid renal diseases",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Obstructive nephropathy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/21/34136\">",
"           Clinical manifestations and diagnosis of retroperitoneal fibrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/45/24276\">",
"           Recovery of renal function after relief of urinary tract obstruction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/35/14904\">",
"           Treatment of retroperitoneal fibrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/49/12050\">",
"           Urine output in urinary tract obstruction and postobstructive diuresis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/60/4041\">",
"           Clinical course and management of monoclonal gammopathy of undetermined significance",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/12/40137\">",
"           Clinical features and diagnosis of Fabry disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/59/15290\">",
"           Diagnosis of monoclonal gammopathy of undetermined significance",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/5/35925\">",
"           Endothelin and the kidney",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/36/1609\">",
"           Kidney disease following hematopoietic cell transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/50/39721\">",
"           Management of thromboembolic risk in patients with atrial fibrillation and chronic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/61/24533\">",
"           Nitric oxide and the kidney",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/12/20677\">",
"           Renal disease in Sj������gren's syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/31/40438\">",
"           Renal disease in sarcoidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/43/14005\">",
"           Renal disease in tuberculosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/3/6202\">",
"           Renal manifestations of sickle cell disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/16/2314\">",
"           Sleep disorders in end-stage renal disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/23/40313\">",
"           Treatment of Fabry disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pregnancy and renal disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/7/13434\">",
"           Management of hypertension in pregnant and postpartum women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/28/38340\">",
"           Nephrolithiasis during pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/61/34777\">",
"           Pathogenesis of preeclampsia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/20/27978\">",
"           Preeclampsia: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/62/11241\">",
"           Pregnancy in women with underlying renal disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/40/41609\">",
"           Prevention of preeclampsia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Tubulointerstitial disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/59/33721\">",
"           Autosomal dominant interstitial kidney disease (medullary cystic kidney disease)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/26/19878\">",
"           Balkan endemic nephropathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/36/27209\">",
"           Clinical manifestations and diagnosis of acute interstitial nephritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/21/37206\">",
"           Medullary sponge kidney",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/49/6933\">",
"           Nephropathy induced by aristolochic acid (AA) containing herbs",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/1/22551\">",
"           Pathogenesis and diagnosis of myeloma cast nephropathy (myeloma kidney)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/12/20677\">",
"           Renal disease in Sj������gren's syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/31/40438\">",
"           Renal disease in sarcoidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/3/6202\">",
"           Renal manifestations of sickle cell disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/28/34245\">",
"           Treatment of acute interstitial nephritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/44/30409\">",
"           Treatment of kidney disease in multiple myeloma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/0/20486\">",
"           Tubulointerstitial nephritis and uveitis (TINU syndrome)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/48/27400\">",
"           Types of renal disease in multiple myeloma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/57/27541\">",
"           Uric acid renal diseases",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Vascular disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/29/35287\">",
"           Antiphospholipid syndrome and the kidney",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/61/36826\">",
"           Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/42/6824\">",
"           Clinical features, diagnosis, and treatment of hypertensive nephrosclerosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/31/23034\">",
"           Clinical manifestations of the antiphospholipid syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/13/13528\">",
"           Clinical presentation, evaluation, and treatment of renal atheroemboli",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/6/11367\">",
"           Diagnosis and treatment of renal infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/29/27096\">",
"           Diagnosis of the antiphospholipid syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/1/29721\">",
"           Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/10/7337\">",
"           Overview of hypertension in acute and chronic kidney disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/16/35081\">",
"           Pathogenesis of the antiphospholipid syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/3/6202\">",
"           Renal manifestations of sickle cell disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/61/35801\">",
"           Scleroderma renal crisis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/31/42490\">",
"           Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/12/23754\">",
"           Treatment of the antiphospholipid syndrome",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-9B0A2A1AB0-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f14_39_14960=[""].join("\n");
var outline_f14_39_14960=null;
var title_f14_39_14961="Clenbuterol: International drug information";
var content_f14_39_14961=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"8\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Clenbuterol: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4324021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Broncodil (IT);",
"     </li>",
"     <li>",
"      Broncoterol (PT);",
"     </li>",
"     <li>",
"      Bronq-C (AR);",
"     </li>",
"     <li>",
"      Cesbron (PT);",
"     </li>",
"     <li>",
"      Clembumar (AR);",
"     </li>",
"     <li>",
"      Clenasma (IT);",
"     </li>",
"     <li>",
"      Contrasmina (IT);",
"     </li>",
"     <li>",
"      Contraspasmin (CZ, DE);",
"     </li>",
"     <li>",
"      Monores (IT);",
"     </li>",
"     <li>",
"      Novegam (MX);",
"     </li>",
"     <li>",
"      Oxibron (AR);",
"     </li>",
"     <li>",
"      Planipart (FR);",
"     </li>",
"     <li>",
"      Prontovent (IT);",
"     </li>",
"     <li>",
"      Spiropent (AT, CZ, DE, ES, GR, HU, IT, JP);",
"     </li>",
"     <li>",
"      Ventipulmin (CH, DE, FR);",
"     </li>",
"     <li>",
"      Ventolase (ES)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F1978349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Clenbuterol Hydrochloride",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1978351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Beta",
"       <sub>",
"        2",
"       </sub>",
"       -Adrenergic Agonist",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1978354\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bronchodilator in reversible airway obstruction due to asthma or COPD",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1978350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Oral: 20-40 mcg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Inhalation: 20 mcg 3 times/day",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1978353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Tablet, as hydrochloride: 10 mcg, 20 mcg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10358 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-D1AB04EF24-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_39_14961=[""].join("\n");
var outline_f14_39_14961=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4324021\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978349\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978351\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978354\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978350\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821253\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978353\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10358\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10358|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_39_14962="Calculator: MELDNa score for end-stage liver disease (not appropriate for patients under the age of 12)";
var content_f14_39_14962=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"MELDNa_form\" name=\"MELDNa_form\" onkeydown=\"clrResults();\" onkeyup=\"MELDNa_fx();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: MELDNa score for end-stage liver disease (not appropriate for patients under the age of 12)",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <div id=\"calc_equation\">",
"      <table cellpadding=\"10\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"       <tr>",
"        <td align=\"left\" bgcolor=\"#6c9a9c\">",
"         <span class=\"medCalcFontFormuli\">",
"          MELDScore = 10 * ((0.957 * ln(Creatinine)) + (0.378 * ln(Bilirubin)) + (1.12 * ln(INR))) + 6.43",
"         </span>",
"        </td>",
"       </tr>",
"       <tr>",
"        <td align=\"left\" bgcolor=\"#6c9a9c\">",
"         <span class=\"medCalcFontFormuli\">",
"          MELDNaScore = MELDScore - SerumNa - (0.025 * MELDScore * (140 - SerumNa)) + 140",
"         </span>",
"        </td>",
"       </tr>",
"      </table>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"     </div>",
"    </center>",
"    <div id=\"calc_main\">",
"     <center>",
"      <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"       <tr>",
"        <td align=\"right\" width=\"50%\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Input:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Creatinine",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Creatinine_param\" onblur=\"MELDNa_fx(); minMaxCheck();\" onchange=\"MELDNa_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Creatinine_unit\" onchange=\"MELDNa_fx();\" style=\"width:105px;\">",
"              <option value=\"100|0|gm/L\">",
"               gm/L",
"              </option>",
"              <option value=\"1000|0|gm/dL\">",
"               gm/dL",
"              </option>",
"              <option value=\"1|0|mg%\">",
"               mg%",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|mg/dL\">",
"               mg/dL",
"              </option>",
"              <option value=\"100|0|mg/mL\">",
"               mg/mL",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Bilirubin",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Bilirubin_param\" onblur=\"MELDNa_fx(); minMaxCheck();\" onchange=\"MELDNa_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Bilirubin_unit\" onchange=\"MELDNa_fx();\" style=\"width:105px;\">",
"              <option value=\"100|0|gm/L\">",
"               gm/L",
"              </option>",
"              <option value=\"1000|0|gm/dL\">",
"               gm/dL",
"              </option>",
"              <option value=\"1|0|mg%\">",
"               mg%",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|mg/dL\">",
"               mg/dL",
"              </option>",
"              <option value=\"100|0|mg/mL\">",
"               mg/mL",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              INR",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"INR_param\" onblur=\"MELDNa_fx(); minMaxCheck();\" onchange=\"MELDNa_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\">",
"             &nbsp;",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Serum Na",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Serum_Na_param\" onblur=\"MELDNa_fx(); minMaxCheck();\" onchange=\"MELDNa_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Serum_Na_unit\" onchange=\"MELDNa_fx();\" style=\"width:105px;\">",
"              <option value=\"0.001|0|mcmol/L\">",
"               mcmol/L",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|mmol/L\">",
"               mmol/L",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              Hemodialysis twice in week prior",
"             </span>",
"            </td>",
"            <td align=\"left\" colspan=\"3\">",
"             <span class=\"medCalcFontOne\">",
"              <input name=\"Hemodialysis_twice_in_week_prior_radio\" onclick=\"Creatinine_param.value = '4'; Creatinine = 4; MELDNa_fx();\" type=\"radio\" value=\"Yes\"/>",
"              Yes",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"left\">",
"             <br/>",
"            </td>",
"            <td align=\"left\" colspan=\"3\">",
"             <span class=\"medCalcFontOne\">",
"              <input checked=\"checked\" name=\"Hemodialysis_twice_in_week_prior_radio\" onclick=\"Creatinine_param.value = ''; MELD_Score_param.value = ''; MELDNa_Score_param.value = '';\" type=\"radio\" value=\"No\"/>",
"              No",
"             </span>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"        </td>",
"        <td align=\"left\" bgcolor=\"#eeeeee\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Results:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              MELD Score",
"             </span>",
"            </td>",
"            <td nowrap=\"nowrap\" valign=\"top\">",
"             &nbsp;",
"             <input name=\"MELD_Score_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              MELDNa Score",
"             </span>",
"            </td>",
"            <td nowrap=\"nowrap\" valign=\"top\">",
"             &nbsp;",
"             <input name=\"MELDNa_Score_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td colspan=\"3\">",
"             &nbsp;",
"             <br/>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <center>",
"          <span class=\"medCalcFontOne\">",
"           <input name=\"reset\" type=\"reset\" value=\"Reset form\"/>",
"          </span>",
"         </center>",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_hints\">",
"     <span class=\"medCalcFontOne\">",
"     </span>",
"    </div>",
"    <div id=\"calc_notes\">",
"     <span class=\"medCalcFontOneBold\">",
"      Notes",
"     </span>",
"     <ul class=\"medCalcFontOne\">",
"      <li>",
"       The Model of End-stage Liver Disease, or",
"       <b>",
"        MELD Score",
"       </b>",
"       is used to estimate relative disease severity and likely survival of patients awaiting liver transplantation.",
"      </li>",
"      <li>",
"       The MELDNa score system adds a",
"       <b>",
"        Serum Na",
"       </b>",
"       parameter, so the added risk of significant hyponatremia may be taken into account.",
"      </li>",
"      <li>",
"       Children under the age of 12 should be assessed by the",
"       <b>",
"        PELD Score",
"       </b>",
"       .",
"      </li>",
"      <li>",
"       If a patient has had 2 or more hemodialysis treatments or 24 hours of CVVHD in the week prior to the time of the scoring,",
"       <b>",
"        Creatinine",
"       </b>",
"       will be set to 4 mg/dL, the maximum creatinine level allowed in the model.",
"      </li>",
"      <li>",
"       For patients with hepatocellular carcinoma, the PELD/MELD score is increased according to an algorithm established by UNOS (United Network for Organ Sharing.)",
"      </li>",
"      <li>",
"       Additional information about the",
"       <b>",
"        MELD",
"       </b>",
"       and",
"       <b>",
"        PELD",
"       </b>",
"       scores is at the UNOS website, file://optn.transplant.hrsa.gov/resources/",
"       <wbr>",
"       </wbr>",
"       professionalResources.asp?index=8",
"      </li>",
"      <li>",
"       Please see appropriate UpToDate topic reviews for further information.",
"      </li>",
"     </ul>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_refs\">",
"     <span class=\"medCalcFontRef\">",
"      <b>",
"       References",
"      </b>",
"     </span>",
"     <ol>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Kim WR, Biggins SW, Kremers WK, Wiesner RH, et. al. Hyponatremia and mortality among patients on the liver-transplant  waiting list.",
"        <i>",
"         N Engl J Med",
"        </i>",
"        . 2008 Sep 4;359(10):1018-26.",
"       </span>",
"      </li>",
"     </ol>",
"    </div>",
"   </form>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_39_14962=[" ",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"var currenttimeout;",
"",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function MELDNa_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 3000);",
"",
"with(document.MELDNa_form){",
"",
"",
"doCalc = true;",
"if (Creatinine_param.value.indexOf(',') >= 0){ Creatinine_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Creatinine_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Creatinine_unit.options[Creatinine_unit.selectedIndex].value.split('|');",
"Creatinine = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Bilirubin_param.value.indexOf(',') >= 0){ Bilirubin_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Bilirubin_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Bilirubin_unit.options[Bilirubin_unit.selectedIndex].value.split('|');",
"Bilirubin = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (INR_param.value.indexOf(',') >= 0){ INR_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(INR_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"INR = param_value;",
"if (Serum_Na_param.value.indexOf(',') >= 0){ Serum_Na_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Serum_Na_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Serum_Na_unit.options[Serum_Na_unit.selectedIndex].value.split('|');",
"Serum_Na = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"dp = 0;",
"if (Hemodialysis_twice_in_week_prior_radio[0].checked){",
"Creatinine_param.value = '4'; Creatinine = 4;",
"for(i = 0; i < Creatinine_unit.options.length; i++){",
"if (Creatinine_unit.options[i].value == '1|0|mg/dL') Creatinine_unit.selectedIndex = i;",
"}}",
"MELD_Score =  10 * ((0.957 * ln(Creatinine)) + (0.378 * ln(Bilirubin)) + (1.12 * ln(INR))) + 6.43;",
"",
"if (doCalc) MELD_Score_param.value = fixDP(MELD_Score, dp);",
"",
"",
"",
"MELDNa_Score =  MELD_Score - Serum_Na - (0.025 * MELD_Score * (140 - Serum_Na)) + 140;",
"",
"if (doCalc) MELDNa_Score_param.value = fixDP(MELDNa_Score, dp);",
"",
"",
"",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.MELDNa_form){",
"",
"if (Creatinine_param.value && Creatinine < 1) {",
"Creatinine = 0;",
"Creatinine_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Creatinine is 1 mg/dL.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Creatinine_param.value && Creatinine > 4) {",
"Creatinine_param.value = \"\";",
"clrResults();",
"Creatinine = 0;",
"doCalc = false;",
"alert(\"The maximum value for Creatinine is 4 mg/dL.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Bilirubin_param.value && Bilirubin < 1) {",
"Bilirubin = 0;",
"Bilirubin_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Bilirubin is 1 mg/dL.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Bilirubin_param.value && Bilirubin > 200) {",
"Bilirubin_param.value = \"\";",
"clrResults();",
"Bilirubin = 0;",
"doCalc = false;",
"alert(\"The maximum value for Bilirubin is 200 mg/dL.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (INR_param.value && INR < 1) {",
"INR = 0;",
"INR_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for INR is 1 .\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (INR_param.value && INR > 100) {",
"INR_param.value = \"\";",
"clrResults();",
"INR = 0;",
"doCalc = false;",
"alert(\"The maximum value for INR is 100 .\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Serum_Na_param.value && Serum_Na < 125) {",
"Serum_Na = 0;",
"Serum_Na_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Serum Na is 125 mmol/L.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Serum_Na_param.value && Serum_Na > 140) {",
"Serum_Na_param.value = \"\";",
"clrResults();",
"Serum_Na = 0;",
"doCalc = false;",
"alert(\"The maximum value for Serum Na is 140 mmol/L.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.MELDNa_form){",
"",
"MELD_Score_param.value = '';",
"MELDNa_Score_param.value = '';",
"",
"",
"}",
"",
"}",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
""].join("\n");
var outline_f14_39_14962=null;
var title_f14_39_14963="Nystatin (topical): Drug information";
var content_f14_39_14963=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Nystatin (topical): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?34/55/35700?source=see_link\">",
"    see \"Nystatin (topical): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/24/16771?source=see_link\">",
"    see \"Nystatin (topical): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9490179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Nyamyc&reg;;",
"     </li>",
"     <li>",
"      Nystop&reg;;",
"     </li>",
"     <li>",
"      Pedi-Dri&reg;;",
"     </li>",
"     <li>",
"      Pediaderm&trade; AF",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9490180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Candistatin&reg;;",
"     </li>",
"     <li>",
"      Nyaderm",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F9490183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antifungal Agent, Topical;",
"     </li>",
"     <li>",
"      Antifungal Agent, Vaginal",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9490261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Mucocutaneous infections:",
"     </b>",
"     Topical: Apply 2-3 times/day to affected areas; very moist topical lesions are treated best with powder.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Vaginal infections:",
"     </b>",
"     Vaginal tablets: Insert 1 tablet/day at bedtime for 2 weeks. (May also be given orally.)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F9490259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/24/16771?source=see_link\">",
"      see \"Nystatin (topical): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Mucocutaneous infections:",
"     </b>",
"     Children: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F9490262\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9490314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical: 100,000 units/g (15 g, 30 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical [kit]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pediaderm&trade; AF: 100,000 units/g (30 g) [packaged with protective emollient]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical: 100,000 units/g (15 g, 30 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, topical: 100,000 units/g (15 g, 30 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nyamyc&reg;: 100,000 units/g (15 g, 30 g, 60 g) [contains talc]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nystop&reg;: 100,000 units/g (15 g, 30 g, 60 g) [contains talc]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pedi-Dri&reg;: 100,000 units/g (56.7 g) [contains talc]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, vaginal: 100,000 units [DSC]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9490181\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F9490225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of susceptible cutaneous and mucocutaneous fungal infections normally caused by the",
"     <i>",
"      Candida",
"     </i>",
"     species",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9490169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Nystatin may be confused with HMG-CoA reductase inhibitors (also known as \"statins\"; eg, atorvaSTATin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin), Nitrostat&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9490232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Frequency not defined: Dermatologic: Contact dermatitis, Stevens-Johnson syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Hypersensitivity reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9490230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to nystatin or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9490236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9490228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A (vaginal)/C (topical) (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9887306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Adverse events in the fetus or newborn have not been reported following maternal use of vaginal nystatin during pregnancy. Absorption following oral use is poor and nystatin is not absorbed following application to mucous membranes or intact skin.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9490229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9887307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion into breast milk is not known; however, absorption following oral use is poor and nystatin is not absorbed following application to mucous membranes or intact skin.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F9490316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Nystatin External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100000 units/g (15 g): $17.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Pediaderm AF Complete External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100000 units/g (144 g): $212.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Nystatin External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100000 units/g (15 g): $17.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Powder",
"     </b>",
"     (Nyamyc External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100000 units/g (30 g): $73.31",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Powder",
"     </b>",
"     (Nystop External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100000 units/g (30 g): $53.82",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9490242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds to sterols in fungal cell membrane, changing the cell wall permeability allowing for leakage of cellular contents",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9490249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Symptomatic relief from candidiasis: 24-72 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: None through mucous membranes or intact skin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9869 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-87E6A227E7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_39_14963=[""].join("\n");
var outline_f14_39_14963=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9490179\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9490180\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9490183\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9490261\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9490259\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9490262\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9490314\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9490181\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9490225\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9490169\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9490232\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9490230\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299778\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9490236\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9490228\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9887306\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9490229\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9887307\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9490316\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9490242\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9490249\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9869\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9869|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/17/11539?source=related_link\">",
"      Nystatin (oral): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/63/40947?source=related_link\">",
"      Nystatin (oral): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/52/14147?source=related_link\">",
"      Nystatin (oral): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?34/55/35700?source=related_link\">",
"      Nystatin (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/24/16771?source=related_link\">",
"      Nystatin (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_39_14964="Intertrochanteric fracture";
var content_f14_39_14964=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F78263&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F78263&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Acute hip trauma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 330px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Coronal T1-weighted (A) and coronal STIR images (B) of the left hip show the incomplete intertrochanteric fracture line which was not seen on the plain radiograph in this patient with hip pain following a recent fall.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Shahla Modarresi, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_39_14964=[""].join("\n");
var outline_f14_39_14964=null;
var title_f14_39_14965="Amlodipine and valsartan: Patient drug information";
var content_f14_39_14965=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Amlodipine and valsartan: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/36/20039?source=see_link\">",
"     see \"Amlodipine and valsartan: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F5086103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Exforge&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10019247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700281",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take if you are pregnant. Use during pregnancy may cause birth defects or loss of the unborn baby. If you get pregnant or plan on getting pregnant while taking this drug, call your doctor right away.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10019249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10019248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701508",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to amlodipine, valsartan, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3915366",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes) and are taking aliskiren.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10019253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697627",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697100",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a salt substitute that has potassium, potassium-sparing diuretics, or potassium, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10019254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High potassium level. Signs include feeling weak, lightheaded, dizzy, feel like passing out, or have numbness or tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in the arms or legs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698395",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Kidney function that gets worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10019256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699070",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of high potassium.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698650",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you have too much sweat, fluid loss, throwing up, or loose stools. This may lead to low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698670",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, if you get pregnant while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10019251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10019252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10019257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10019258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11719 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-F656983DA9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_39_14965=[""].join("\n");
var outline_f14_39_14965=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5086103\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019247\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019249\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019248\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019253\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019254\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019256\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019251\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019252\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019257\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019258\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?19/36/20039?source=related_link\">",
"      Amlodipine and valsartan: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_39_14966="Tenecteplase: Drug information";
var content_f14_39_14966=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tenecteplase: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?21/2/21539?source=see_link\">",
"    see \"Tenecteplase: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F228480\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      TNKase&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F228481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      TNKase&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F228508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Thrombolytic Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F228484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      STEMI:",
"     </b>",
"     I.V.: The recommended total dose should not exceed 50 mg and is based on weight. Administer as a single bolus over 5 seconds:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &lt;60 kg: 30 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &ge;60 to &lt;70 kg: 35 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &ge;70 to &lt;80 kg: 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &ge;80 to &lt;90 kg: 45 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &ge;90 kg: 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     All patients should receive 162-325 mg of chewable nonenteric coated aspirin as soon as possible and then daily. Administer concurrently with heparin 60 units/kg bolus (maximum: 4000 units) followed by continuous infusion of 12 units/kg/hour (maximum: 1000 units/hour) and adjust to aPTT target of 50-70 seconds (or 1.5-2 times the upper limit of control).",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F228485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Although dosage adjustments are not recommended, the elderly have a higher incidence of morbidity and mortality with the use of tenecteplase.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F228486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; tenecteplase is not renally eliminated.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F228487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustments recommended by the manufacturer for patients with mild-to-moderate hepatic impairment. In patients with severe hepatic failure weigh the risk of bleeding against the benefits with tenecteplase especially in those with a coagulopathy.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F228464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution [recombinant]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     TNKase&reg;: 50 mg [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution [recombinant, preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     TNKase&reg;: 50 mg [derived from or manufactured using Chinese hamster ovary cells; supplied with diluent]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F228449\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F228466\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tenecteplase is",
"     <b>",
"      incompatible",
"     </b>",
"     with dextrose solutions. Dextrose-containing lines must be flushed with a saline solution before and after administration. Administer as a single I.V. bolus over 5 seconds. Avoid I.M. injections and nonessential handling of patient.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F3149283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Incompatible",
"     </b>",
"     with dextrose solutions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Y-site administration: Variable (consult detailed reference):",
"     </b>",
"     Abciximab, diltiazem, dobutamine, dopamine, eptifibatide, heparin, labetalol, lidocaine, nitroglycerin, tirofiban.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F228465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of ST-elevation myocardial infarction (STEMI) for the lysis of thrombi in the coronary vasculature to restore perfusion and reduce mortality.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Recommended criteria for treatment: STEMI: Chest pain &ge;20 minutes duration, onset of chest pain within 12 hours of treatment (or within prior 12-24 hours in patients with continuing ischemic symptoms), and S-T segment elevation &gt;0.1 mV in at least two contiguous precordial leads or two adjacent limb leads on ECG or new or presumably new left bundle branch block (LBBB)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F228516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       TNKase&reg; may be confused with Activase&reg;, t-PA",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       TNK (occasional abbreviation for TNKase&reg;) is an error-prone abbreviation (mistaken as TPA)",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication (I.V.) among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F228506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As with all drugs which may affect hemostasis, bleeding is the major adverse effect associated with tenecteplase. Hemorrhage may occur at virtually any site. Risk is dependent on multiple variables, including the dosage administered, concurrent use of multiple agents which alter hemostasis, and patient predisposition. Rapid lysis of coronary artery thrombi by thrombolytic agents may be associated with reperfusion-related arterial and/or ventricular arrhythmia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Hematoma (12% minor)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Bleeding (22% minor: ASSENT-2 trial)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Stroke (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Epistaxis (2% minor), GI hemorrhage (1% major, 2% minor)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: GU bleeding (4% minor)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Bleeding (5% major; ASSENT-2 trial)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Bleeding at catheter puncture site (4% minor), hematoma (2% major)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pharyngeal (3% minor)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     The incidence of stroke and bleeding increase with age above 65 years.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylaxis, angioedema, bleeding at catheter puncture site (&lt;1% major), cholesterol embolism (clinical features may include livedo reticularis, &ldquo;purple toe&rdquo; syndrome, acute renal failure, gangrenous digits, hypertension, pancreatitis, MI, cerebral infarction, spinal cord infarction, retinal artery occlusion, bowel infarction, rhabdomyolysis), GU bleeding (&lt;1% major), intracranial hemorrhage (0.9%), laryngeal edema, rash, respiratory tract bleeding, retroperitoneal bleeding, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Additional cardiovascular events associated with use in MI: Arrhythmia, AV block, cardiac arrest, cardiac tamponade, cardiogenic shock, embolism, electromechanical dissociation, fever, heart failure, hypotension, mitral regurgitation, myocardial reinfarction, myocardial rupture, nausea, pericardial effusion, pericarditis, pulmonary edema, recurrent myocardial ischemia, thrombosis, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F228469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Active internal bleeding; history of cerebrovascular accident; intracranial/intraspinal surgery or trauma within 2 months; intracranial neoplasm; arteriovenous malformation or aneurysm; bleeding diathesis; severe uncontrolled hypertension",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F228453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Arrhythmias: Coronary thrombolysis may result in reperfusion arrhythmias.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding: Monitor all potential bleeding sites. If serious bleeding occurs, the infusion of tenecteplase and heparin should be stopped.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Conditions that increase bleeding risk: For the following conditions the risk of bleeding is higher with use of tenecteplase and the use of tenecteplase should be weighed against the benefits of therapy: recent (within 10 days) major surgery (eg, CABG, obstetrical delivery, organ biopsy, previous puncture of noncompressible vessels), cerebrovascular disease, recent (within 10 days) gastrointestinal or genitourinary bleeding, recent trauma (within 10 days) including CPR, hypertension (systolic BP &gt;180 mm Hg and/or diastolic BP &gt;110 mm Hg), high likelihood of left heart thrombus (eg, mitral stenosis with atrial fibrillation), acute pericarditis, subacute bacterial endocarditis, hemostatic defects including ones caused by severe renal or hepatic dysfunction, severe hepatic dysfunction, pregnancy, diabetic hemorrhagic retinopathy or other hemorrhagic ophthalmic conditions, septic thrombophlebitis or occluded AV cannula at seriously infected site, and/or any other condition in which bleeding constitutes a significant hazard or would be particularly difficult to manage because of location.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Follow standard management for ST-elevation myocardial infarction (STEMI) while administering tenecteplase.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticoagulants: Use with caution in patients receiving oral anticoagulants; increased risk of bleeding. Adjunctive use of heparin is recommended; however, concurrent heparin anticoagulation may contribute to bleeding.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; GP IIb/IIIa inhibitors: Use tenecteplase with caution in patients who had recent administration of GP IIb/IIIa inhibitors; bleeding risk increased.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in patients with advanced age; increased risk of bleeding. The 30-day mortality in the ASSENT-2 trial was 2.5% for patients &lt;65 years of age, 8.5% for patients 65-74 years, and 16.2% for patients &ge;75 years. The intracranial hemorrhage rate was 0.4% for patients &lt;65 years, 1.6% for patients 65-74 years, and 1.7% for patients &ge;75 years. The risks and benefits of use should be weighed carefully in the elderly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration: Avoid intramuscular injections and nonessential handling of the patient for a few hours after administration. Venipunctures should be performed carefully and only when necessary. If arterial puncture is necessary, use an upper extremity vessel that can be manually compressed. Caution with readministration of tenecteplase.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F228458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Thrombolytic Agents may enhance the anticoagulant effect of Anticoagulants.  Management: See full drug monograph for guidelines for the use of alteplase for acute ischemic stroke during treatment with oral anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprotinin: May diminish the therapeutic effect of Thrombolytic Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Thrombolytic Agents may enhance the anticoagulant effect of Dabigatran Etexilate.  Management: Carefully monitor for bleeding.  Dabigatran Canadian labeling recommends avoiding use with thrombolytic agents. Consider avoiding alteplase treatment of acute ischemic stroke in patients receiving dabigatran (see full drug monograph for details).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Thrombolytic Agents may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: Whenever possible, avoid use of drotrecogin within 3 days of a thrombolytic agent.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Thrombolytic Agents. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F228460\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F228471\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in some animal reproduction studies. The risk of bleeding may be increased in pregnant women. Administer to pregnant women only if the potential benefits justify the risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F228491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F17916902\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if tenecteplase is excreted in breast milk. The manufacturer recommends that caution be exercised when administering tenecteplase to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F228462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC, aPTT, signs and symptoms of bleeding, ECG monitoring",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F228472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Metalyse (AE, AT, AU, BE, BF, BG, BH, BJ, BR, CH, CI, CN, CO, CY, CZ, DE, DK, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, HK, HN, ID, IE, IL, IQ, IR, IT, JO, KE, KP, KW, LB, LR, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NL, NO, NZ, OM, PE, PL, PT, QA, RU, SA, SC, SD, SE, SG, SK, SL, SN, SY, TH, TN, TR, TW, TZ, UG, YE, ZA, ZM, ZW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F228452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Promotes initiation of fibrinolysis by binding to fibrin and converting plasminogen to plasmin. Tenecteplase is essentially alteplase with the exception of 3 point mutations and is more fibrin specific, more resistant to plasminogen activator inhibitor -1 (PAI-1), with a longer duration of action compared to alteplase. Produced by recombinant DNA technology using a mammalian cell line (Chinese hamster ovary cells).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F228468\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     is weight related and approximates plasma volume",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Primarily hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Biphasic: Initial: 20-24 minutes; Terminal: 90-130 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Clearance: Plasma: 99-119 mL/minute",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Anbe SC, Alpert JS, et al, &ldquo;ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction - Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction),&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2004, 110(5):588-636.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/39/14966/abstract-text/15289388/pubmed\" id=\"15289388\" target=\"_blank\">",
"        15289388",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Hand M, Armstrong PW, et al, &ldquo;2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 51(2):210-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/39/14966/abstract-text/18191746/pubmed\" id=\"18191746\" target=\"_blank\">",
"        18191746",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cannon CP, Gibson CM, McCabe CH, et al. &ldquo;TNK-Tissue Plasminogen Activator Compared With Front-Loaded Alteplase in Acute Myocardial Infarction. Results of the TIMI 10B Trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1998, 98(25):2805-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/39/14966/abstract-text/9860780/pubmed\" id=\"9860780\" target=\"_blank\">",
"        9860780",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      De Luca G, Suryapranata H, Stone GW, et al, &ldquo;Abciximab as Adjunctive Therapy to Reperfusion in Acute ST-Segment Elevation Myocardial Infarction: A Meta-Analysis of Randomized Trials,&rdquo; JAMA, 2005, 293(14):1759-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/39/14966/abstract-text/15827315/pubmed\" id=\"15827315\" target=\"_blank\">",
"        15827315",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Efficacy and Safety of Tenecteplase in Combination With Enoxaparin, Abciximab, or Unfractionated Heparin: The ASSENT-3 Randomised Trial in Acute Myocardial Infarction. Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2001, 358(9282):605-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/39/14966/abstract-text/11530146/pubmed\" id=\"11530146\" target=\"_blank\">",
"        11530146",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kushner FG, Hand M, Smith SC, et al, &ldquo;2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2009, 54(23):2205-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/39/14966/abstract-text/19942100/pubmed\" id=\"19942100\" target=\"_blank\">",
"        19942100",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Connor RE,  Brady W, Brooks SC, et al, &ldquo;Part 10: Acute Coronary Syndromes: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):787-817.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/39/14966/abstract-text/20956226/pubmed\" id=\"20956226\" target=\"_blank\">",
"        20956226",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Gara PT, Kushner FG, Ascheim DD, et al, \"2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 127(4):e362-425.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/39/14966/abstract-text/3247304/pubmed\" id=\"3247304\" target=\"_blank\">",
"        3247304",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Parsons M, Miteff F, Bateman GA, et al, &ldquo;Acute Ischemic Stroke: Imaging-Guided Tenecteplase Treatment in an Extended Time Window,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 2009, 72(10):915-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/39/14966/abstract-text/19273826/pubmed\" id=\"19273826\" target=\"_blank\">",
"        19273826",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Parsons M, Spratt N, Bivard A, et al, &ldquo;A Randomized Trial of Tenecteplase versus Alteplase for Acute Ischemic Stroke,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2012, 366(12):1099-107.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/39/14966/abstract-text/22435369/pubmed\" id=\"22435369\" target=\"_blank\">",
"        22435369",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Single-Bolus Tenecteplase Compared With Front-Loaded Alteplase in Acute Myocardial Infarction: The ASSENT-2 Double-blind Randomised Trial. Assessment of the Safety and Efficacy of a New Thrombolytic Investigators,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1999, 354(9180):716-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/39/14966/abstract-text/10475182/pubmed\" id=\"10475182\" target=\"_blank\">",
"        10475182",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sinnaeve PR, Alexander JH, Bogaerts K, et al, \"Efficacy of Tenecteplase in Combination With Enoxaparin, Abciximab, or Unfractionated Heparin: One-Year Follow-Up Results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) Randomized Trial in Acute Myocardial Infarction,\"",
"      <i>",
"       Am Heart J",
"      </i>",
"      , 2004, 147:993-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/39/14966/abstract-text/15199346/pubmed\" id=\"15199346\" target=\"_blank\">",
"        15199346",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Topol EJ, GUSTO V Investigators, &ldquo;Reperfusion Therapy for Acute Myocardial Infarction With Fibrinolytic Therapy or Combination Reduced Fibrinolytic Therapy and Platelet Glycoprotein IIb/IIIa Inhibition: The GUSTO V Randomized Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2001, 357:1905-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/39/14966/abstract-text/11425410/pubmed\" id=\"11425410\" target=\"_blank\">",
"        11425410",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Van de Werf F, Cannon CP, Luyten A, et al, &ldquo;Safety Assessment of a Single-Bolus Administration of TNK Tissue-Plasminogen Activator in Acute Myocardial Infarction: The ASSENT-1 Trial. The ASSENT-1 Investigators,&rdquo;",
"      <i>",
"       Am Heart J",
"      </i>",
"      , 1999, 137(5):786-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/39/14966/abstract-text/10220625/pubmed\" id=\"10220625\" target=\"_blank\">",
"        10220625",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9955 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-93025ABAAB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_39_14966=[""].join("\n");
var outline_f14_39_14966=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228480\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228481\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228508\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228484\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228485\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228486\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228487\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228464\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228449\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228466\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3149283\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228465\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228516\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228506\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228469\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228453\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300111\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228458\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228460\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228471\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228491\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F17916902\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228462\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228472\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228452\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228468\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9955\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9955|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?21/2/21539?source=related_link\">",
"      Tenecteplase: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_39_14967="Gene exp array meth";
var content_f14_39_14967=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F82165&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F82165&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 629px\">",
"   <div class=\"ttl\">",
"    Gene expression array methodology",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 609px; height: 417px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGhAmEDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKK85jfUruHxPq194x1jTLDTby4XyrWCyMcUMSgk/vLd2PGTyxrH8May/jDwJf+JPDXjzxQ0Vssy7Lm105WWSNd2GAtvQqeD0NAHr1FZ/h64lu9A0y5uG3zTWsUjtgDLFAScDjqa0KACiiigAooooAKKKKACiiigAorifEkmpXXjL7Bba9qOk2UOlteOLKK2dnYSbeTNE/bsMVwnhPxvb+JdS0ezt/Fvj+z/tcSGwnvNM09Ibkxglwri2IyADQB7jRXL+ALm+mstVg1LUJ9Qls9RmtkuJ0jR2RcYyI1Vc89lFdRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVxmvHUr/AMbx6Za+IL/SLKPTTdN9kitmLv5u3LGaJ8DHpigDs6K8X0DxRNr+oW8eleIfiLPpdxObeHWBpenfY3YEjIb7Pu25BG4rjPGa9A8AXN9NZarBqWoT6hLZ6jNbJcTpGjsi4xkRqq557KKAOoooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPIPEPh/WPFXgbxdoOgzQ28uoa7LDcTSsR5cG5DIRwckgYx7nkVB4U8B634Gj8cLc6jbahouo6d5ySJEIHSdI2Qjy14AK7ec/wjivRNQ8DeEtRvZrzUfC2g3d3M26SefT4ZHc+rMVyT9arH4c+BwMnwd4aAH/AFC4P/iaANbwn/yKujf9eUP/AKAK1axdG13S74vbaW6NHbgKojAC7Rx8vsMYrZVgwyOlVKLi7NExnGavF3FoooqSgooooAKKKKACiiigDjr+Jp/iLcQpjfJoLKM9MmbFeS/DP4PeJ/D2teFLmeLTdObSHka7vYdSnuHu42zmJYWURxg5AJGOmete5654X0DX5Ypdd0PS9TkiUrG95aRzFAecAsDgVm/8K48D/wDQm+G//BXB/wDE0AHgD/mY/wDsNXP/ALLXVVS0fSdO0WyFno2n2mn2gYsILWFYkBPU7VAGau0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcbqFql98RLm0mJEU+gtExXrhpsHH512VY+ueF9A1+WKXXdD0vU5IlKxveWkcxQHnALA4FAHC/DbSvHXhLTtK8LT6fok+kWDlDqwu3DyW+4kAQbOJOcZLY+vfqPAH/Mx/wDYauf/AGWj/hXHgf8A6E3w3/4K4P8A4mt3R9J07RbIWejafaafaBiwgtYViQE9TtUAZoAu0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABVe+VZLd4ZBlJFKsPUEYNWK5DUfF1rDezQ+RI/lsU3Bhg44q6cJTfuoic4wXvM8raK7+HPi9bYsx0yZt9rM3Tb3U/TofwNe4aPfxXtrFcQnMcg6Z6H0rz/AMY6jpnibQ5rC5tZFk+9DLuXMcg6H/Gue+E3iWayvn0bU327Tt5PQ/4f0r0atOVenzNe8vxPMhUjh6tov3Jfgz3SikQ5UGlryz1gooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqrqiXkmnXKaZNDBetGRDLNGZER8cFlBBI9sirVFAHhvhz4j+KLLRvFuv+KZ9NvdM8P6vJorW1laNDLNIJooxKHZyAv73O3HbrXV+I/inb6PrWqaXFo93eXdlqVjparHKi+dJdR70wWIAA6HJFXdd0HwRo+j6lpGr2iR6f4kvZ7u5hczSC5uCvmuQQSVbEW4BSOV+UZqj4a8IfD2eWEaHZGVpWs9cR/PuWDmMH7PLuZsEgE/Lnn+IGgCh4d+MSalq2nWmpeHbzTIbt72A3D3McqpPaqzyphTkqFU/Nxk8YxzUSfGq3j0qfUL/AEC8tYW0ptZsR56Obq3DhDnH3H+ZTg54PWutfwp4P0G40+/ngtrJ7e9nmtZLi7dV+0XQKyAbmwxfJAU568AVRufh14G0fRdYabSBHYXFo0F0BLO5W33bzHGAxZE3c7Y8DPagDF8UfF6Tw4NNGp+GLuye+R5ka+vIYoggIAHmqWTec52kjA6kV1ni/wAYDQIdFitdPk1HU9YnFvZ2scqorNsLszSHgKFB5Gc8YBpdb8E+G/FKWtxqdnLcRi3WJFW6niV4vvBXRWAcc9HB61c8V+H9C1fRFh12zV7GxxcRmIvG8BQHDRtGQ6kDP3TntQB51q3xP1Tw/rviK417TZIbHTNFt71tNV42dZXuGiJEg6ggKR7dga2fGHxXtvDd/r9mdHvLqXSJbKKSRGAj/wBJR2Du2CURRGQWweSoxzWrp/gHwdeaTI9vpfnWWp6elq5mmmYy25YyqG3tuDbnLbjh8nk8Vz+i+FPhnLfT6RpEUwvLiZvMEN5eLIXs8xk+YHyNnnMhIbBLY5I4AKum/FjUdR8U6FBb6PaNol9pk9/cTQ3iTNEI5djMrq2CoAyV27vmA4IIqHT/AI62d1pmp6i/h7UIrO209tSgk3hhNGHC7GIGEchg2MkYzzmu5tvh34VtZdIktdJWB9JDraNFNIhUO25g+G/eAtyQ+7J+tZl/8O/A2jaDq8l3YPb6P9kl+1R/bLgwxQffk2Rh8IPlz8gB4oAw/EfxjfRJ7e0n8K6iNRktDqDWj3EW8W24qrAoXDOxDYTjpyQcCqPjn4sah9nu18J6dNHDZXOnxXWoXBRdhuGRvLETAknY4BPGCfbNdr4j0LwZrWl2Ov60YobO3tV8nUvtslmUgfBAaVXQ7TkcMcZPrS6j8MPCGo332u60lmnxAG2Xc8av5OPKLKrhWKgAAkE44zQA/wAb+JH0LX/C1qsk6pqFzNG6RohDhIWfDFuQPl/h5ri4fjPdXul/aLfwvc2rXmjXGq6ZJPcxus/kj5gyqcqBnPUEj0Nen6z4e0zWbzTrrUrbzp9Pd5LZvMZfLZ0KMcAgHKkjnNZlr4B8M2sOmxQ6Woi060lsLZGmkYJBLgSIQWO4HHVsmgDibL4t6h/wj2jTXPhqSfV7nRDrt1DDcpHGlqqrmVCSfvFvlQnPqa9R0PU7fWtF0/VLIsbW+t47mEsMHY6hlyOxwRXLS/CvwdLplnp8mlSNa2aPFCDez7ljbG6Ivv3NGcAbCSvHSuyt4Ira3igt40ihiUJHGi4VFAwAAOgAoAkooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigCvqN0llYXN1KcJBG0jfQDP9K8zg+HFlfQR3Y1W/IuEE2eP4hn+tdZ8TTMPAmsG2BLiHnH93cN3/jua8k0/Xb+0s4LaNL6dYo1CvCWKlSPl6dOP5V34WnN03KDs7nn4iso1lTnG6tf5nZf8Kus/+gpqH6Vy/jjwOPDENtrNhc3FwqyiK48zqqtwDx78fjTf+El1L/n11T8mqpquuXl9p8tpc298iTjZmbcFz15z6Yz+FddONZSTcro58RKlKlJcttD2rwTqZ1fwvp94zbpHj2uf9pflb9Qa3K4b4Nhl8D2gbOGklZc+m8//AF67mvKrxUakoruz0sNN1KUJvdpfkFFFFZGwUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFMlk8vHGc0APoqD7R/s/rR9o/2f1oAbe2NrfeR9st4p/IlE8XmKDskGcMPQjJ5968a+IngjxLK/iu38I2UkOnzaHaWemxW9ykKLMlwWdVUsNmE78DtntXs/2j/Z/Wj7R/s/rQB4B4u+FWrtdeJoNI0u6utG/tHSr+wtX1MkzbA4utrPJlWORy5GeoPFauq+Adcv5vH99FZajBcTWFvH4fg/tQhUf7F5Ui7RLs3Bsrufv8wPevavtH+z+tH2j/AGf1oA8C8WfDnxTqtv4tu47W9bVVstK/sNk1Ly9txGmJyAJAoIx1cc84PJpdf8DeM7j4g67qOn6fPNbXQu/LuL27jJQNAyRiB0lDgbiMI6bVz14zXvn2j/Z/Wj7R/s/rQB4gngzxIk+gS6/oN34hhh0Cys44I9VWA6feIo812O8BiTg+Ym5vlxgjFey2Gh6Xp1wJ7GwtreYI8YeOMAhXcyMM+7ksfU81a+0f7P60faP9n9aAPFPEvgvxXe/GA6vYWUsunSXMRa4vrlDDBEqAMYSkgkQ5/wCWZjKk5JODWJb+EfiHeeHrPStR0WeL7F4c1TS3kOpxSLdzyx7Ymxu4yehbpk5x3+hvtH+z+tH2j/Z/WgD5uufhb4o1Pwd4hs4NFm0sS6NZ2sdhcaikn2y+icM9xlXZVG3KAMRnjIHbS1/RNSf4l+GfD2lfa9L0vXbOG41XTZLoyy2sdpIWGXDMBvyqZDHJHWvf/tH+z+tH2j/Z/WgD558H6Pr2veOL680u3u4G07xjqDT6zLegxraqzA2qw79xyWU/dCjHX0i8NfDzxvYQ6ot/FrX9pTafcWs93a6nCqXjs2VdWZy+/wBCypgZGcV9F/aP9n9aPtH+z+tAHnHwK8Oa74c0rVYdfsYrNZJ1NsNw850C4LSKkkkanP8AdbnkkDgV6dUH2j/Z/Wj7R/s/rQBPRUH2j/Z/WpIpPMzxjFAD6KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigCtqEST2zwzDdFKCjj1BGDXjHgzVJfCeuahot6rSG3YoozjemcqR+Bz9Ca9ouj90V5R8YtFkj+zeJLEbZLfEdyR/dz8r/gTg+xrtwcotunPaX5nn4+E+VVafxR1+XU6OTxvaRRs8kDKijJPmLXnnjLxFeeKNStrGyjdPOIjt7c9Ru6s3uf0Ga59H3f6XaW73DzMEiiB3CKU9sd89q9W+HXgw6Iranq2JNYmHc5ECnqAf7x7mu2UKWEXP9roedCpVzF8m0Fv5+R2PhzT00nTLLT4jlLeIR59SByfxOTWxVKI4kX61drx5Nt3Z78UkrIKKKKkoKKKKACiiigAooooAwPEXjPw34auorbX9c0/TriVPMSO5nVGZckZAPbINJqXjPw3pmrWul6hrdhb6hdBTDBJKAzBjhfpuPAz17V5z8avCWva14it9Q8K6PfPq6WSW1vq0OpwwQ2580syyxONzrjB4znOMDHOD8QPhz4t1TVvGNraWUN5F4pj0of2ms8ca2DWpXzCUYh8HaSNgPWgD2b/AITHw7/wkn/CP/2zY/2znH2TzRv3Yzt/3sc7euOcUaT4x8O6vrVxpOmazY3WpW+7zLeKUFhtOGx64PBxnHevH/8AhXnif/hL/sn9np/Zv/Ca/wDCVf2v9ojx5G3/AI99mfM3Z46bfej4ZfDzxPo/iHwPb6pp6W1l4U/tPzNQFxG41H7Sx2bVUlxgHJ3gdKAPfqK+aP2i7iez8Waqk5kvbm80eKPRooL4Ry2kpkYOyw7gzl8YyoY8YOBW1feBfGEnxKTVZ01G5gW8tJ7S8tbuJRbxIqh4ZFdwwX7+QqsHzzzQB77RXgnh74d+KLDUPDeqrHd2+sLqGoi/uHv/ADVS2kEnkZTzCpXJQ7VGQeSAaufBTwX4o8OeJjdeIINRjkNm8F3O15FLb3cm9WEmA5kZz83zMqkAkc0Ae30V4L4q8H+Mr74vW+t2elPHaw6zZyi8tbuNVkslCLLvDSb84BBRVCkZ+8Tkpp3w28QJ4D8Nw3EWpjXX12GXV8au+UsluZj8pEu1f3bqcR4Y59RQB73RXz54+8A+K5fGcMnhrSJlsNPex/s69gv13+WhXzRK0svmZA3YCjDDkknitHwZpepz/HXXtON/LP4d8P3EmoxqJGOLi8jTELc4KoBKwHbcPbAB7lRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVBdfw/jU9QXX8NAEFFISB1IH41RuNSENw8SWd5Psxl4VUqCRnHLDsaltLccISm7RL9FcuPEup+cqN4S1VEZwgke4twvJwCfnyK5efxL4qjlZZJoEfqUhtoJVTPQBvO5wMc1VOMqvwK5osPVbso39NfyPUKxrqbUp9ZntLC4tLeKGCKUma3aUsXaQdnXAGwevWuettQ12W1jmk10RMygsn9hlyhPGMrIQee4q9BpOvG5kv08T2mZ40jJOlADapYjgycHLmqlTlD4lYmdKdPWasav2fXf8AoJ6d/wCAD/8Ax2j7Prv/AEE9O/8AAB//AI7VFrbX1+94q04D30xf/jtQW11rVvqaCfVbfUrZG2ypDZxQ5yueGMxOQSO1ZSmo7mEqkY7s1fs+u/8AQT07/wAAH/8AjtH2fXf+gnp3/gA//wAdqVtb0+JEN3cx2rtkeXOwVhhip746g1h3nj3SY4z9lkLyBgD5ilVAJ6nv9PWuilh6tZXpxbRlPFUaavKSRr/Z9d/6Cem/+AD/APx6j7Prv/QT07/wAf8A+PVg32sapd2n2yxuhaxKh2xJAWaZuTkbo24+UjPAHeoLPVr46Yb2+1m5WIRlwbSKGfecgbQvlBs/MOCKt4OsunkKOLpSfKmb90+s2IgmnvbCeIzxROiWbISHdVOG8w4I3Z6Gt2vMb7xIktnA15e+J0idlnQHTIAco24EjbkcoTg9QDWdq/xNs9Lmjin1DxKzuu4KNOtg2PXBGce9awyzF1HaFNs1daC1bPX6K8Q/4XDpoxm+8UAHjJ061x/KtrR/jJocscVqyane3u4xkx2w3Odx2/KvQ4xwB1rZ5Jj4q7pMlYik/tHqtFcbc+P7K0so7u703U4IXyfmiBZQD1ZQcj2z1qxafEPwhdQtLF4gsVRWKnzWMZBHswBrmeAxKXN7NteSv+RftIbXOqqe1/i/CsDTvE+halcrb6drOn3U7fdjhnV2PfoPoa37X+L8K550503aaafmUmnsT0UUVJQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAVrr76j2rxz4k+IDrGqtodrIRp1q2bt058x/7o9eeMev0r0fx7q/9h+Hr29UgTKmyL/fbgf4/hXjWheH9cmgiurDTzcpuLNI7AbpO5564/nmvRwVOK/ez2W3qeVmFWcmsPS3lv6FbWNC1TwZ5GphUfT58GSJHybck8K30459a9T8B+LIdbs0ilmDTgYVj1b2b39+9cdLo3iyWNo5dHR0YYKs4IIrkrvQfEPg+Yao1nJb2QcAkNuCZ7HHauqShXjyykr9DBRnh37Smnbqu59IKcMD71erjPBHiOLxBpqsG/wBIjUFwe4PGfzGK7MdK8irBwlyy3PXo1I1YKcdmFFFFZmoUUUUAFFFFABRRRQAUUUUAcr8Tteu/Dng27vNLWNtTlkitLTzPuCaaRY0ZvYF8n6VgfEPxL4j8ITeB7e2exvLXUtXtNKvbu4BEztITuKxqAi5Csc54OBg9a63xt4dh8V+F77RriZ7f7QqmOdBloZVYPHIB3KsqnHfGKztf8B6T4qg0tvFyS6he2AV0mt7me0TzR/y0WOOTCtnODkkZ4NAFb4v+K9T8G+Eo9U0Wxgvblr23tmSY4VVkcKT94c8gDngsCeAaztU+KUGlWXiiW+0e5jn8Ptp6XMAlRiz3QjIUMOPkMmCe+OK7DXvDmla/oLaLq9qbrTmCAxtK4b5CCp3ghgQQDnOfeue1T4UeC9UuTcX+jmadooYXkN3OGkWHAjLkP8zAKBuOWI6k0AYWrfFySy8Qz6bbeF768ij1YaILhLqFA900e+NQrEHBxyxwB7nimW/xiF9penyab4durjU54Lu5nsjcon2eO2cpIfMPDEt90Ac98V2cngbw7JeG6fTsznU01gt58n/H2qbFkxuxwpxt+77VSuvhj4QutOgsZdJ/0eB55I9lzMjgzMWlG9XDFWJ5UnafSgDP8PfEuPxNr0Gm6Fot/cQS2VrfSXvmRItvFOpKllZskjGMKG59q0vhxrWoajHrum63Ks+o6NqUlk9wqBPPjKrJG5UcAlJFBA7g1r6X4Y0jSNRuL/SrKO1u5raG0ZkLbBFECI0CZ2gKCegFVvBHho+G7G+FxefbtR1C8lv7y68vyxJI5A+VMttVVVVAyeFoA6KiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKoazH5tk8fzEONp2kg4JGeRyPwq/Xmf7R9zPafBzxBPaTy286JEVkicoy/vo+hHIpNXVhxdmmVbTwtbr5rw/bYWIMhw5cM22M5+cHuzVYi0ORjcgzz/APTPFtDlOXH9zn7oPPrXyVqWvEW0Ui6vrSuRuL/2sx3KOoIBJDHtnisi+8Uao135Wl6vqsVrNEu43N7I+w9c5zx25FebTjCW0Wv68md8s7qylKNr2bV7p7PfXXXpp62PtrTLWWKHEiK0gwDItusRYZjODtABwSastp8Uls5ks42IBxuiBxw3tXw7F411SCCP7JqupveMjIztfSKpzx93d1x0qlN4o1eBEiXWtZW8wA5a/cr7j73HNd+GrSopxSHHGSqSbtZd/wCvw/Q+9LS0FvuaC2EZ3qfkjx/GvpVS/sTe6YFvomuWQMQzpz91nxxjvj8hXwxY+L9VNyTqGrazLA/3xDfODkDjBJ456+tSar4t1hJd1nrupxbV2Kv2uX5l9c7uTVV6zrp05R36mGKUcTSnGT7brffb9T7XsrC802OQpbQXyLIAlu0AGUDbcbmzhunoKv3scN5bw3Fvpi26+VIrxSWqhwWQkcjjjAPfrXwi3i/xBcwSD+2NSVcDBN7IzA9/4uPypYvF+riwkg/tHUWmLgicXsucY6YLfrXHGhZcp5DwUYLlhK69Fp+P6n3kYpcr+7f/AFrfwn/nqageBzarmFjmMZynX5Fr4Mm8Ua2tvGBrOsrdAnczX7429sDNT/8ACUamJoSNb1oIeXUX7nBz655r0qeK9nBR5dv0NHgk7JT3t+X6H3ncQu8SgxswLOCCpORl+tVtShcWsAWJwAFAAU8fNHXxNq/iDV10K3u4PE15K7zMhUX0nmhQAQCM9PeotE8Z+IbOeSdtbvY4GADJLcyybhjoOePrRDH6c8Y7f12IdFcrnTfNbya17a6/gfad5FN5MeI5P9X/AHT/AHJqdqFvLLJ5ZWdVkzGxjLI20vACNwwRxnoa+JL7xVrc1zNNZ6nqMds/GxL6XnnOB8x56f4VOmteIo4oYb3VNZtlB/eM91IhGT8uQWH4Vq8y5bS5fxOqjQ9q1BuzfQ+yYtMWwhEVpBMkTIHKlncbvLm5+YnH4VZlsEi1xriK0CTSSKryLHguBLGeSOvJJr4n1vxBrEEqpa65rJKna0rX0jI3+0MHgexqxH451r7Rb3P9oaqwjUxyf8TCVQ+RgYw39KTzWcrTUW7+YsThp4efs0uZrt6fI+0ZYpRcA+XJ93+6f7jUoswdTkX7MCkkxLjyuHy5yTxzketfE8virXk1ON4NS1i1hWZXIa+lkC4P97dgirN14x16K3DXGsXs1tLIxZY7mSN+CDkEn+VP+0XbSP4kcnX/AIfa9u34n2b4c06OxvrWK0tBBAsgYKkeAMiNj+pJ/E10d3qmu219NFYeHfttsu3bP9ujj3cZPykZGDkfhXxR4I8Wanc/EDw6r6hq5in1G3D/AGq6eUN+8UY4Nfe9v95/rWVXEyxL5pK34jpXtqrGL4Z1+51a91Oyv9MbTruwaMOhnWUMHXcCCtdBXK+Hf+R78Xf9uf8A6KNdVWZqFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHmfxxlMeh2GeYzeKXHrhWIFYek+OVsdNtraK4tgkaADKfn+ua7X4oaV/a3hm5RVJkgZbhQOuF+9/wCOk15/8NdT0RYptG8QWdqLy3Y+TK8eTKnp9R/KvUo8ssPqr2Z5NVOOLbva6Vvle5rf8LEb/n6tv++KjuvHkd3bS29zNaSwSqUdGjyGB7V1GPCX/PrZf9+aQ/8ACJAEm1sgB/0xqean/wA+2b8sv+fh5f8ADa+GleOLS0t5vMtZpGhDeqOvA/Ahfyr6JX7o+leHv9h1H4l6KNIgjihSYNiNcDCZYn+n4V7gn3F+lRj3eUZWs2iMt2mk7pSdvuX6i0UUVwHpBRRRQAUUUUAfOX7aN9d2Xh3w21ldT27NdShjFIUJ+UdcV8yKPFhQv5uvbBEJy373AjPR8/3T69K+k/23P+Rb8Mf9fcv/AKAteE6XqmqldPmkvEcQQiNVltlk/dR/MP8AWfKcb8YHUCuTF1qlJJwt87jSu7GNDD4vuFma3PiGVIWCSMizMEYkABsdCSRwfUVED4qyw87XcrwQPN4+bb/6Fx9eK68yeJJ5p4leFGe3Exe1s40V2V+m4DH3sjPTOF6YFb2l6zrmkXdvcwX0Umj3iyM7W1tDF5pwVOVVM5RmHBwD1HHI8upmVeK05W+1322233t/w4RSZ5Y134iW4Fub3WBO3SIvJuP4dabJf+II1VpL/VkVl3gtJIAV9Rz05HNdzcWOv3XiO4SOznub6LT0m2izV2SNnLZXyOCDu6n1Knpipmk12MSW0y6VbRrC5zcaQsLxyY+ZY/k3hlPyjkDI46YGv9py0tyv5v8ADQaj3PP/AO0NfAUnUNWAfO0mST5sdcc0+5u/EVoN1ze6zCn96R5E/nXoehJfpb3cTahcJIl0rJcwiJbeRApMir5xUsQq5UAYzx6ViavcatdaTqELNPKURpJWaFciL5T8xDHHUjp14JyOHDMZzny6fe+vyHy2WpyzXniJU3Ne6wF45LyAcjcPzHP05po1DxAxYLf6sSg3OBJJ8o9T6Dkc+9dppul+Kr/StPNpa6kxtoR5fmWkjrgnjDONqqAc+nze4rSu9R8QXV/fww2li6BA1zHa2IW3dgBgAAYyRyWzg4GelKWZSUnFcrtvrtr6dSlS0u9EecNqGviV4xqOps6feCzOcfkf85q9DD4xlYrH/wAJE5EAuiFSYkQnOJP9zg/N04616Auk6/FFci0VZILhrcLJb2FupI3HlwMMQGGABkHkk4AJw9GvNU1LxBqMlpJPMr2q2svmW0kiqjSYRAiH5VJxwcDJIxzUrM5zjKUOXTzb7eSt1I5dEzkjceJAgb7XrO0gEHdJgg8j8x09afbSeJ7lY2guNclWU7YzH5rB254GOv3W6eh9K9F07XNetNTt5bCHSbJJd2GmsGtUjLRlhiTbu4ViF5I4BwRUd1ceILTxDbXccjpueNWS1tlPl5OVCF9oZ9275uATxnrU/wBp1r2tFaXWr/yLjTT2uedtdeI1Exa81kCEZlJaT92M4+b0545r2v8AY61G/u/iZq0V5fXVzGNIdgssrMAfOh5wT7mvONdk1S8sdSit3uBbRq9xKkiIh8nzOBwxI5IyvTOevJrvv2Mf+Spav/2B5P8A0dDXpYSvKsm5W+RlqnqfZlFFFdgBRRRQAUUUUAFFFFABRRRQAUUUUAFeXftM/wDJFPEeTgbIv/R0deo15f8AtL8/BbxHkZGyL/0dHSY1ufBM1xPgMB5agbRsyBjuAPShr6XYFDydAOGwPp9PanXZTyYmicZcfdVicDPcE8H2qIAxTxlmUAKCccfyrNJNbEKMGkTQvCZNt3EyIiHBhQElscZzW/bLo40m3vZbGeQZEcuwBiZAMknJ6flVCR7fCFYoLQj5ZArk+ZnoRkkY9fSqmoNHFMIbbasYGcxy7wT7H09q5pL2rSV0ell2LjShJ8q8k1d379Vb59TT1X7AdLSW1spIy5+Vtq+v8Ryce2K5+fzXmVGDE/dQMeg9B7VOshCSCRyJsr0f7w/A4qW4Q3d1DGqxou0ZIk3BBnqx7VrTj7PTcnG1VXftbJNJaJf8D+vMRZwtoxEUhmHAcoNo/HFVrMhVlZztAU4bB69gCO9aVpYxPp1+xuQxi2bFQglstjgEiqkcEm2Rp2EahTIFPBJHTgdKqEo3aR5tKpGUny7r/JEVpcR/bI5L1XniGcruJJ445pI/ICwFhNuDDdkjbjPanxOzkYVTN27E/wCNLLBc2ZHmxlDIpOMYp3V/+CdcYScVponvbvbRv9P8yOSWN2KMX8sOSMHnHao0bYV2KGwcsrDIP5VdtEaeMJ+6dxyC7cD+hP1FT6Oqx3TGWVFgQhTKo4BPQ57fWk5qKfkc8rtuSV93oUnnnd9o2wxlt2xRhAfpTr+WRgyTSmUrja3m7sfTP9Ku38f+kyqgYl3OJslxKM/eLH19RTtTnEunWFj5aMbffmZDvLbjnp2x9eahTV4tIinGMoppde+2jf52RirM6xmNZJBGeSobgn6VcmklWJAYFCnodpC8e1RtCquFEcjtuwMoV3e1X7RYr+6aJZUgcqAjzuFVCB8wOeOegrSckve6GrcKak3r6Wf9fmWfNtBYWrK000s8wNxDE+Nw5BXAPfisi9maYbMShY3YKkjElR2HPpip54pbCVAdoBOBIp5U+xB/rVe8gKCM+a0jMSxVuo9+p61FOKTve5pWjGU+aKSSSWj/AB/E6H4a3lyPiD4XR5JDGdTtsKWOP9avOK/R+D7z/Wvzp+E3mN8SdAkWRLcfb4ATuCq37xflGe59K/RaD7z/AFrWNrtJGCetrHN+Hf8Ake/F3/bn/wCijXVVyvh3/ke/F3/bn/6KNdVWhQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAU7gAysCMg9Qa8Y+Jngx7eddQ0oMvPy7eCD2A9/wCde0XH+taqt3bxXdtJBcIHicYYGurD1nRldbHJisOq8bdVseA+DjfeIb17CTV4rK9X7kcyn9764Pr7Vq+JtE1PRRGtxrEMrO33UUghR95j7Dj8TiofHnhiTT9VTY5S5YmS0uFO0y47H0cfrVDRRqfjTVYtLnkYXDfNdXDHpEvoP6epzXrb/vE/dPGdWUouio+/e39f15nYfB3SzcXd5r0qERAG1td3cfxt/IfXNexR/wCrX6CsnT7K306xgs7OMR28CBEUdgK1k+4v0rxsRVdWbme5haCoU1TXQWiiisDoCiiigAooooA+a/22WK+HvC7DqLyUj/vla+e9B1SW4MNvewxz2sK5TzMgoAD8oc8KrN1B49xX0H+25/yLfhj/AK+5f/QFr5rsbiCzCm482aLZtlSC+2GQEEgY2ngEjjnkH1448ZBTja12Jp7o6G1wIIY4rq7sLYQFiYrhCsikB2DfMq4yF+XqcjuOZ9KubPTbWxuW06a+115jNK11c+WjAuPLRFVgZMnBZWHfpiuOfV7xk2JcyRwgOoiU4XawAIwOMEAD8Kkt3guYme9vnjuBIojLl22rjk8A+wGDkYrglhJNe89PK/n219dRxlY6+eW1l8QalftHq9rHPZEgtcByGZtjAnvEGDLgsDjqe1SW17pge5ufsmqaUJYigSIrKCWcL+7YlcjaeQQ2c9utctCLdbt1s9TtIE8qMiRvNC7wfRhk5I3dMDNR6ndTSxrK9+ZJllJOJwecdQB17/N+HGKz+q8zUbvouu3z/wCCPdXLeoNPqMpmt55MqFST7RIoJcDoOFwqrgcjjB5qxNpdl/Y195+3zooGlt5UZmeQBxgPGG2pweck4BzzVe+8U3lzYwWsl3dOhj2zq8uUkboG4GQQMZ55x9Qa1/c20ttJbRXxMEcYKoVdhJIAATnAIJ5xkcAAHoDWsYVfdVuVJ9PL+tu34U5Jm3pmrxX+kTf2vNMLqBYUjC7x9si3KrJK5boqqu3AxwKn8QaxdWs19ZE3VhHM3lS+TcMQ+wkhXTedyg/d9BzyTWHHqF5babHJBqMnllfLlie7Vzg9AqdQARnH0qC11VilwlzcS/NExiLHzMSFQCTk5G4Dt04POMVH1b3nJLS+3bb/ACv1/QHJNaGxpt8Ejgt/sk2pvLIqkJN9mZgflEZAyWB9/rWr4P8A7Js7vWBqVjfwaM9tF823zJM+YxR8BlRueASccdM5rjbK4he+ElxeyRfMN8zFg5HHIIDEMBnBqeyEUsV3Ba3ESh0VkM9ysWwhzwS2MnGMgevbpRWw3NGUbtXtrr3+7T0Fz2Wh2l1qpjhnazjvdPs1ygtYoVc3Ee3yyJMyFQ+FORt7cACubvdTbWLhbl7y5jn+ziJmPG7Z8q5wem3JJxzyAKzZLplvZ2/tOeWKLISQSBJD2DYyQeuSAc4zyOtQW13H5r20k6/ZZpRumkj+YDP3mxknjPy89e/FFLCKC5lv+n3XffXUJSvZFq8hu5tLheaMtbwwyLE/J6N8xGcHGT749Oa9X/Yx/wCSp6x/2B5P/R0NeN3zxIbhLW9MkDu2EJYlgDwSSozn8PoK9l/Yz/5KprGOn9jyf+joa9LDJpO5mt9D7MooorrKCiiigAooooAKKKKACiiigAooooAK81/aMKj4PeIDIjSLsjyq9T+9SvSq8w/aUd4/gx4iaNirhIsHOP8AltHUyV00XTkoTUn0Z8KXs2ns7SRLNLKepkO0Z+nP86mgmRLiOW2s51hkiVX44LjkkYHT9az/ACp2h3sFdSCQ5bt3q1ay3NzIkMbqo2BVjjIXzPr71zyikv8AgnbCHM4qd/LS93533J7B7drjZdyTLbgFgvLtGRyPbr37VNrbafI9u/nXcmQDI0igEr6KcYP1rMlHlGMGICUKwdWfAH65qnNLK0SRMzmNRkKTkCkqXNJSTLVX6vCdOyd7PbZ/h+N7dDXiTTbmFiY7lJgyjao3cZ6k8Y4p9+NOguJ47JLmWVEO2SRx8pz/AA4/xrOt90iyMAisMDgdfwqJswS9lIHfnf8Al2p+z13ZzV8SqkHBRSb8v6t5lyztri6t70RW0sjKqFj1Yc/Sm2e6CF/tJeJD824IMk+hPUj2osLhoLe92SIkkgTbKA2V57EdPSrV1cvdadHJcXf2gw4CqQ4XucEkYJ/GhuSla2n/AADy5upzuLjpft5fcVT5CGCV4VkyzZUgqpGOOfX8afbQERwNLBIVZg8jLGchQeSCO1QQXO6WATLHIiljtl+706Zq6mqtHAhRLWH5DG0aowJz/F6ZHrSkpLRL+tT36EaLiueVkv8A7X+t+4lwLSGYK00bQOS37oHOw9AT/e9Rin6Z5CLdpJBcFyQUSFs4ABzkd/8APSqd1EtxHE8EQCk4aQZLE454qK1W5j3XVoVAgYAunHXnp36VSheO5yzrOlL92k7X1+Vu3Q0JrhN4R4ldXG0iTKso9Pb681ZaGDhbI2s7xqflZ2DPkZ+XAGce9ZyXMqait5eS7pCfNGD1yew//VU+oSXM0cck3kASn9wi5I64O09Bz1rOUWnZaHkzhJytorrv/XbyY6Wxle0hmmlhhlkl8nY4cBRjO9jzg9sda24NFt7SAS6kk0LRgeRE8TOJ933ioIGQODnjr3rl54bixlDzeXLH5mShO5S38jV9IdTnguVZlnXCN5LSktg9Nv071E4tpe9p/WxlOnzRj+8STf4XW2/psyVkS58Qwx2kcLw+csYGxju56Yfkn9atapNHDo8kAjmZvOZfNZPlXDD5c4yMdMVj21lJe6jHbTHyZ2GDuUlmbPYDvzWvZ2qWHh+9Nw9svmymIPJlnyrDOAOnWiolHl62t/V+oq6UeS93a3e/39dDc+HNnbS/FLw9FPB5Sx3UMiLAwYbhKuM57V+gNv8Aef61+ffw3vZf+FjeHreBrRI1voBlEbaw8xegP86/QSD7z/WuigpW1N8NzW97yOb8O/8AI9+Lv+3P/wBFGuqrlfDv/I9+Lv8Atz/9FGuqroOoKKKKACiiigAooooAKKKKACiiigAooooAKKKKAKlx/rTWbrOpwaTYPdXOTj5UjX70jdlHvWldEK5LEAAZJPYV4f461271zxAunaSDJcOTFCo6Rr3b2JHJPYcV14aj7WWuy3OLF4h0Y2j8T2MjxTrV94j1lbWJg9wWBZl5SBQei+w7nuaW6+1aDrMOrWbb57WQGRgMCVem7How4I9a6vSvhU9vAHGtPHNIAX2xj/OKtTfDye0hmuF1V7wpG2bdkA8wY5XPr6e+K9JYmj8Ceh5VTAVUvar41rc9F0+8h1Cwt7y2O6CeMSIfYitZfuj6V5n8Jb4rZXujSPvNm4lgJ/ihfkfkc/nXpo6CvIr0/ZzcT28PVVamprqFFFFYm4UUUUAFFFFAHzV+27/yLfhj/r7l/wDQFr5/0t9CNggn052uCgVGEkYRpDhTncC2O/XqTjAr6A/bc/5Fvwx/19y/+gLXz5pUlw0MNrZLamSc+WZtgLxgpk4Iyy8BgSB6561wY9Xiv87AW5r3R4Z3gPhaPeqEA/aioQHBDlhwf5dh1xV9LSwa6u5X0DTppbVhJNHHqCiMptxwANu0cMSD396wru/ktSiwtarJs8qR0jHMa8Dg454I4AyCM5Oa2tH8R6yHFl4bXUTbrMNrWiOdwIG7fGM7m6EZPGB24ry6tOajeH4yl/n/AMHr0HF+RSS50mw8RWktxo8E1mtnmK3Tb+8LOSryBwckBuh9Bg4xWw2oeHJ5ITB4UZYp7aO3AZYy3mKcMygEFTz94kkn0GaxRe3eteJoU1oveXJtDAjXi4PyZZRgkY5UqTnufWujstV0+y0x9+qWStsBlsdoV5dzlWzIvDMOcd9rdccDLERa5W03Ky2cv08+rS+RcHul+hHcXOmnT7Gzs/CemrcrmOO6kkQhwwBBkI+8FUZYt0JPQdMvWLSys7K9hk0XSV1NkZR5d5vSNNu4PHhuTx1OT+eKLrUZJ7MaeNPN7YB3ntYLKUiO3U79wwAzHJ3cuc4X0q7q+vW66PqEM1ld21/exCOSCSIOxdVwWZ2jGFwAQgwQTnPelCFSEkop6v8Amff1vbe6ta+l7alNqV7/AKFCB9FM1t5Wgm4jSFJSVfHI2eYWXltvDcn+90xxUtpDDcxQva+GtMis7qbykmu7ojackqm/OFP1UEgc5FTadqNpLZqt7uCShUM8RXam5VBJOGYEBcZUZGee1SeJvFV1qV/p8iyoZbVmeTf/AKltrEqdgUNxuPJ654AwTTftXLljF+rlL/Pv/wANqLmjo3uU3t7GSB5W0bTJnWfEiQXDj90qZLqAvCk9TnOR0xVezn0y21vUorvRob1JbREC2sibYpOCHUlPTGcYJOc1rxeK9VtbZW0m3e5uIokhud6yN9nLFh5ajdtOWJZcDjLe9Y1msmrajq17LauzwQRmRbiZt5OcZ3sOTkbcE5OeMkVcOa0vaKy/xPuvPT9fQm75lY14tT8Oy6jdSHwtH9nkAKxxSKzvKcKNo2lUH3zsBA5Hpg17jU9H1CyeWPT9Kt503SPG8SQ+WzMwABCfvAAQNoAxx35p134gdbQRvPbXhmQebGMsiHbu+bag5BJ6dCoJzjNUbec39xcE2Wn3ImxKCsrkxdQAiD5uG6noSRk4OaiNGy5pJq395v8AP+ti24vRv8P8jO1b7NLY3LQ2emwRLiKCSMyB5AuDuXOQc8E7ufm7cCvUP2MePilq/wD2B5P/AEdDXCavqOy01O1urV7JJBLJFGsOV3ZVcYZjsGVOcdOBzgV3f7GX/JU9Y/7A8n/o6GvXy+TcXf8AO5jJpy0PsyiiivRAKKKKACiiigAooooAKKKKACiiigArzT9o5tvwc8QnKDCR8v0/1yexr0uvL/2l13fBbxGMgZSLknA/10dKSuioNqSaPg2fKbd9v5KsPvbcBv0pHRVVdkgljHJEeRt/4ERxV25tgEVYbmC7m8svJ94+SB2BJweOc1WmtIdsSwTRziRAd+NhVz1Ug8nHr0rBSRUKlX+V636Po9f6ZZv4187I+ySpGAGkUj5iRkD5e/aqt89vjKQsrbcOrnlT3INWbSxxasfPjJMiqI1VmZgSc8jpUN9a29pqckcbmWKP5mVo2Tac8rgnJx61EWk+W+wLFVOeUJK8n5eS/wAyKMwPcqduxDgpuYkAgc5wM9amuTDc3aIfKbc26WZSy7fXqOB36GoQqRXTLBOypxzgpnI5/L9asHSWlPmWd3HO27IH3Dt/vEnofbP41TcU7t2HPEP2DbVr9bf1+RLBayiO+VIBJtCfMn3UBPBYjHXtST2Qs/LnuntfvgfZvMcvj+8eOg6evtVnS/7QutO1SO0jjygj8492w3GBnnpStpl5cq13NbiJI4i0kgQlWxzyc8N7Vip2k1Jpf8MjyI1eWbUpJa/PZfmZcr2+75oGVCf+WcmQfzFOaQHUSWiaQP8AKqxkLnPpxUR2RMsYQ8fMXXuD0zU0k8DeSfOnmbG0qeAFJ5GSa2t5HvQowtaT12/L+vUS7kRYEtzbJGElZi2d0p4xgtjpUaJAuPMAlK8MEb7+e4wO3vVtLdWQytO4iT7kJ6n24P61TYos0itEIAWXjzCQnvjqfWnBrZHPUhyVWmv607evY0Ybgu5CWitEigeXKd5dc/d4I/Sr1xqgsbuKRbdZLdVKpsZlCEj+EMPlGevHNYd0nkny4buOZCfNDKGVsnjuBz+lTX8MS7JJpbpg+PKZl+96nkkjBrKVKDavs/U5vYUKjXMt9v1v/X5E+oapPdCJGa2dVk8/aAzYPTBJHP0FOtro2lhdrJYoxlZCrRyFdmDzkc5zVR7VE8kxyO1xM3y+YCn/AAIHOMVHCi+ci7rQMCc72OCfc4pqnBxstjdYfD8l7Wjfpfdf8EmE8f257gMkLFt6rFuG1u3OM4+hBqXUoo1htciKO5dndpBv5BwQTuGfWmSWEs2oxRllJYjd9lUsVGeuOMn8aZeQIzlVkefyyVK7WyuOM8nr6imrNppjhKlJJ6XVravbU6L4czQHx/4XdEaZ/wC0bdXlkmJO7zVwQMZxiv0Tg+9J9a/OD4bWjJ498KSSgokmp2zI56NiVePzFfo/B96T61vBJbGSUfs/mc34d/5Hvxd/25/+ijXVVyvh3/ke/F3/AG5/+ijXVVoUFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHHfFDWBo3h2Rw2JZv3a/Tqf8Pxrx7w7o+vRlr9NIuZ5bpRIsvQ+WeRj6133x3tjLaaNK7H7OsrpKPY7f6A1nwfEPykws9uvTgIOABgAfQV62HUo0FyK973PIquM8TL2n2bJfmUfL8U/9AS6/wC+v/r0uzxT/wBAW6/76/8Ar1o/8LIP/Pzb/wDfFH/CyD/z8wf98VX73+VFfuu7MXwZLf6N8RbGHUreS1+1K0Ijf+62SPw3Cveq8Ij1n/hJ/iP4dYOjNBIoLIuOhLY/T9a93rmx9+aLe7RWWe6qkFspafNJ/qFFFFcB6YUUUUAFFFFAHzV+25/yLnhj/r7l/wDQFr5jtr0I0KiKQAL5eUkO7PPT05PSvpz9tz/kXPDH/X3L/wCgLXz/AKfZ+HDHZPNcX8c7wrJJsm2+Uw3ZYEpgjIXAByORz248XNQS5k36CtdmVcak3lW6RPMyJFsdZjuCsc7tgP3QSSfqSas/25fQ2UMlpqJ83y5FuB5SxsN5IKg5zICO+Bjj0BrcudK8DG3mZNc1I3bBjFCYMjGPlLuB94dSoB9M96n0Xw94Pnt44Ztf1RLyQsk2y12xbAcl+hOFwCQfzFebLE0OW8oS/wDAX/kUoyTOYu9QlGpW08s5kdbYQ5hXy2iGCpVh0J655OQ3XPAuTW93p8dpf6nbksGETrcJ5gSNiSrhcgg/eOCcHI9amk0LRodajthd332WayMyTyAQ7Hzk7gFYlAAc8AkjjjGbF5pdrJYmG38XrPp26MLC002xhk5wrRj/AFeSx+X+L5ck05VYe6o3t6Pb5bddxpO9+pnSanHOjGwgihaAFnlLrE8qiTcMeh7YXJwBjvVa+vH1JZ5YEeBZE2zB7neHcElSxc56cD3HHWtu78LeHYraM2niCTUJ8/vY7eJgsOSuAzFMjOTghTyQDjHMer6F4ajsLqfS77U7loSUAdFG9sEnop2heMk4znjGDRCvQuuVP7n+N/w/DQGpXs/UxItUuUa3WxiHkxjaI0Ur5jH1UHk56U2K8vdOV2BENzFKo5P7xCMkDaewPtwcCnaZZ6S8Qa61SWC5C7oxHGxDPxtXdjC4ySWzWpfaRoIaVYNbutQu3YrEqwNub5AQx65y5IJz0XPOa3lOnGXK4v8A8Bf57EqPUYfEuo6W89tZ6kJ1eVZWuiiNLvwdxV+SQS2evJUdKr6dqTG+uY7c745LcRM0z7Hba2VK7SMHpxk9zzitKPw94Y8gJda1exXwi3NGlmzAScgqRgEDOOx/Wsj+zLC1ubyG6uJR5OzZKAV3fvCGIXGSCo4/yKyg6Ek1GLv/AIWr+fS/yKfOtL9y3Zanq3hy6RWtxEk3z7bmJXDIykcFhjO125xwTzzUsGuAzwuItHjjCfZvs/2QKFUk4kYoo3OMA7xz+orT1PQPCsMphk8Q3ErxAybVRn3qQGxnGAQTgkZzgmobHSfCN7Fc7Z9XSQxn7KI4Wlw4JJD4X+6N2B681i6tCa9o4O73ai/1/pAk9kctPIWtQzTQbh+6ESLzt5O7pjrx617P+xsrJ8VNXDKVzozkZHUedDzXk+s2ejW8Nw9l/aXLbIDLHtVtv3iSQCc/Lx1G7n39W/Yx/wCSpav/ANgeT/0dDXrYWSkrr8VYztZ2Z9mUUUV1lBRRRQAUUUUAFFFFABRRRQAUUUUAFeXftM5HwU8R467Iv/R0deo15n+0gGb4N+IRGnmNsiwu3dn98nak3ZFQV5JHwVcxSwrbmcSqknKMXzlc849KWQMNSh2RyocAqJXOWHrkc4+lampC6ldYxZLH5UZLp5BjVB14+Y/XHFQaC9umoKupJLPbOB8sLEOB6KO59q5VU93m39ApLmhzt6q+3ldr7+5atZ9QW3xNFJcB2WSOT5gp25zg45qPXNamuNTF1Nb/AGdzCIzGHLZ5J3c9vaoIpZTfSSQwMoKMIUaL5QmPmIBJ+vWk1VIAtqbeCYwmBGmaTPzSfxMCcYB4rJU4qpeSIoqq66rST59Wn2ule/ySKbG4u2nuwSyptVmJLYyMAfpWiuqXFjAttd2+yIwbVG3B+pz/APWp2izta+day2zXFo+PMhVeXOCVJ57E+9M1VBCd09hJFlNkavliD2bJ/liqk1KXJKOnQ7Z4VSwkk3fXbXpbV3VvTUm0PVJbOW/vPItCwWMYI6A8cAfrzWjLdPJBJJNLGEnQyeQqMkcg6ZJA59K5xzCHMVqZlV1GQ0XJIGTxu5q5bT2i6ZJBcWck0rSAR3AA/dnH3dmefXrUzoxb57f52+Z5OIy1RqOW+y0t8t2UXlKXAuYWRVUbdhJ5xx6dPrU95LLfzQqI4kZVIxGDluenufpVWXJkjhnfEWT9zGcY4z/hVmBYW+wC3NxMQhM0ZYAD5ugHpj1rZpK0up6v1uz9mn7st3bS/f8AAsQXs1nZvaSR4Rzw6EjB4+U54BGKq6ejBJ/LLm5V1KlUJXHOeg69MVr6t9ilsYra3s5oJ929CxXDEgZyO4x9Kq2bQm0vvsMQDCaJkjPzSgAHJUdSPXt0zWdKSabta5ONjKhP2Ts/Ppqkrartb7husXd6Gh3xiKYwKNzF9xTPBO/pz6cU/XWuX1OK4kaKGEgeSAxaM8ANtbGDz1x3p2qubu3BuYbs3p+VHZeqdl2EnHOTwR9Kso+m3llapb2syXaBtwZgY8542nHHv/SoT5Uny97nlxqSw7pya0jf5ee+m2hjXd4JPMt2QOXlLea7kAZ9sDFRrBOfKSK2kQg5WQBj+lbt7Hpjabm5iMepQNvkdZVIk9RgE9+9V7hGjksxFZ3RuDku8yNl142456Ad6qFVOySsdkcQ6sJOmtXJqztdp6332v2vq0huvXl3NIiT20i3Jbc0ikjzJOcPgdD2wKp3893NZQQyooKk8KrBn6dcjn861r7ym1qT7ZaB0Mm2Mo4LGTtliRvHvjNQSWso0u782182Z3xCwUMYwG5GQT24xTpcqinbb9f8isBVc4ewTtp6p2vJJb9dLd/ItfCtp4fiJ4d227t/xMLdH3A/LmVeeBxxX6NQfef61+dPwyuWi+JPhv7DAYt9/Aro53DBlXJHvj61+isH3pPrXVDduwTk/hXwq9jm/Dv/ACPfi7/tz/8ARRrqq5Xw7/yPfi7/ALc//RRrqq0ICiiigAooooAKKKKACiiigAooooAKKKKACiiigDg/jLCD4ViuCpZYLhS/+6wKn/0IVmaHqXha60+H7Tp9st2qASqsGRn+8PY9a9C1jToNW0u5sLoZhnQo3qPce4rzSL4VXcdm8KawEccRyIpBA7g+1d9CpTlT5KjtZnmYilWhX9rSV01Zr06lnUNf8CWAYXEFqJAM+WLfLH8K8/8AEnjK11RTa+HdCtrRH+Xz3iBkI/2R2rrbT4LoJvMvNT83ucKcn8TXU6F8PNP05w8gRiOgUfzJ5raNTD09eZsmaxVT3YxS8zj/AIP+EpYNVi1G5QqlsrEZ/ikYYx+AJz7kele01BbW626BYwqoBgADAFT1w4is60+ZnbhcOsPT5F8/UKKKKwOgKKKKACiiigD5q/bc/wCRb8Mf9fcv/oC14LpNi00kMf220upJIImSOSWUOR1MaAJkYxg/iBnt71+23z4c8Mf9fcv/AKCtfOulXcljpV5aKHMsqMShjidNowSwJUkYAPIYcke9cGOjKUVyvUFbZnS6vqFm9klne6NcCzjYym5tR5nD7jGqtIAQvIXJzkD2FRaJc6VPogk1DSWVY2EENxFKIyigfMD0MgLHngsAevAFVdQigsIHe0sRLp9xbqLjEsMsqbiNrsU5RsnIBAOeO1YqSWkWox29npk15MpkjcXRw0jkMoOF6Y4OCTyOpFeXToRnTtG/ff7+uj/TyuW9Gk2dDo9k+ueLJLe0a4ihFhLLG0bJuEa5c7w55B5yAckHI9KvXWpWEcK22qC2v3s4oXlC277pZCx3xeZ5YMbYJBzkAg45rldOgS3vEvHjmg0qQS27y2sqNJlRllySApIIHoQTjNa9tP5WlvJpt1qvn2IE7yaZukjhV2UhpHIBD9ieBlRU1qKclrdaffd3u9fT/gig7K7L/iTVrS2nR4bLV9AuzG5jfy3iLNvDr5gY4OM/wjjIPsKF7qF/qGlz2MrSvqBae5klF5tTYUBbgErnO4knlt+30FMtLnTYpUkmW9vIbySQK2owBnCAYVt27B3MHDEZxt4OatI9jcac81jfQxXCQSme4itwE2GDkOqgbNzFYwMEBjndzipjCNNJcrdurvv+dvL7htp63MTSXlms9lstoyRRJNLDM8rCXbuwCoGOM57Acc1q6qtjAJZ4bS6mXJgMQmaWJMbcDOF4ycqBnrziuYsrjyYrqOZ4EE0UYJCq6jkYyBz9dvPqD0rR1G4s9MmEUFtLDcwbWQhw+5sk79wAOCCMd+ue2OypSbqaX/qxPNdakGlQJc3Quv7NkmtrcqZozPzISw4HQ47YGeoyR1rTgt7O78RX0aW0l1CsLCNEuXV3Bc4y2w84Iz0GBnNZK6hpCyxGTT7t1aICffcAs7hs5U7eFI4KnPSk0+e0gvvOlidI5oC8aWsilhIGO0HOdgyOnXbj1q5wnK7s1ppr/wAH/IltHU6BfW0t7EfsGoXl7ECsRhdnjJC9DkHd0YFhgYA44o1vxPZXCxQ31hK6eRvidEEW9txKkgcbDkghSMj6VnWuvaKmrLM1lfR2csW25WG5+fccZKZHHPOBjnjOKo2txpS+RcRxSedHbMr27KMPL/eLDGUwc+oxjkc1yfVk5884Py19fPT8h303K0zLc2V6EiEVvCBIsfm/MhJwAcn5uvYZ4HSvW/2Myf8Ahaer5OcaM4/8jQ15TqV6Htrma3SOEXrF2jjJCxqWJ8sA9cYBzz1HvXq37GuP+Fq6ztBC/wBjyYBOSB50NethL63ViVvufZdFFFdpQUUUUAFFFFABRRRQAUUUUAFFFFABXmf7SDInwb8QtLGZUCRZQNjP75O9emV5r+0XL5Hwf8QSbnXCR8ocEfvUqZ/CxqPM+XufDcz208kKE+VG7AbXnkPy554KnFT3umwWN9F9tdXtGUFGMjZKdgrbeKyLktDPGvMbAfek2kk9jxnH86sWyXN+0jswlhhH709dozjdz0Ga43Bx1UtD0qeNpqCXIm7qz6dte99N9fU1FeIypdpbTP8AunR0R9/UYGCVI6deh9KzL1LORbeNSYEWNWcvM0hz3UDbwfanyXRFtby7wyoCGhIKc54Iww3fXtVXVFzsuPs8kSSqDuZgxZup55JH1pU4WktfxOVU3W5sRt0sk0rapOy0Vn/TLNjFAsFzcmKdypURgEIH6g/l7VVu5oHf5YZCxi+bdIflfPbj9KtfZ7qzikW5jlWA7GGWGV78KCaTzy13G1mmcSCQlJipI/8AZapNX5lr8yYYOdOT57862Vnt81Yo6f5aXB3sc443ZHb2p+0yBT+64PysoZVUeuNvNTW+6WaZT5Y849SA23HPYj9aSOJHkMJKSSn93HGAeSeh5OAPetbpvU3VKpCndX102V7/AIhGYfOZri3yQoG9ZSEHoeATzVm0FtZsIJLOSWSZCD5xZcHp8uFJ/SqRdbUH/R5YwOBukDAN34xzRNNOZbWeW4uGdzuV9xymD2J/pWbjzenqcv1mdLl5Fa190n069/mvQttarBJHFcWMrI7FgiPgkEcfNj+fNM05ms5GUqGTerHKsQ2O2NuSPWn6lbR+RHOlyZLqRjuiYkY77yxwCTzx+ppNICjTbq5mACpIgB8wq2DnIHHTjnn8DQpJxu/QiFWNWjFzj17fLr0v/wAAu6ndRXNxP5ls8SyRAoIlIVDn7xHJC44xwaolIFlRYbd4bXGXMjkBmHTJK4654qI6nPaPcG1adIrldoBkbAGc+vPTvWrG9sqWL3sQT7UH8zyrgBxtOASMHHtnrUNOmv8Ag+RxVHKhLmSdumvl208zOW1e9WSWGRI3eQp9nAIynXcDtwBnjJrqdHvbjTbOeHTI4I53CiVribDqAOgVkxggnp1rnN8MepvBa3NzJuk2R+ZIU2r23H1/DFTwXEV5LJaD7Q24ZzvwQUGeGJ56VFSHtFZrTR6/r/wR4iNPEr37taPVfnqtNt/xIL6KIXtvLFCElMqnyvmC4z1O5Rj8Ke+mS3NvPM/neVAd0mWOAGPG0YORn0/Goo5Li/1e183zXluGCEzyMerepxWrqVm1tp1zNqa3EYB2WzmZjvIOGC9egx1NaOXLaN1f738jonXhS5YytfT5/LT7162ND4fNb3nxK8Oh4ZIQt/bvE8k7HgSL8o4Gcmv0Hg+9J9a/Or4aSWr/ABB8MpDbyyf8TG3I/eYKfvV68cjv2r9FYPvSfWumkuVWL91JKPbtaxzfh3/ke/F3/bn/AOijXVVyvh3/AJHvxd/25/8Aoo11VagFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHEfFPU9a0PRRqmjX8EEcbpE8ElsJN5dwu7duGMZ6YOadP4quNCGqWOqAajeaXp39oSXEaiATAs2FCfNtwABnJrqNY0uy1ixaz1KAT2zMrlGJAypyDx7gVynjAeBbjWRH4oaw/tFYhGfPYqRGx4BIwMZ6Z6VzVFKLclK3q/X/AIB7eCq0K1OFCpScmm2+WKvb3baqzf2k7vqt7K1XVPiNLZ3dwkOiSXFvbfYzPILlVK/aB8uFI5OeOoHuKltvH1xc+VaRaL/xOpNQn08WrXYEYaJA7N5u3ptI/h61eu7fwgt7qlpcm1FzHBDc3kZkbcsUAzGx56KCOn40anaeDxDaxX4tFXV7r7XblpGVppnCjehzkEgqOMdaj97dvnX4d/Q3X1FqMfq8r231191a/Fqr3eltLarUqaP4+bWbzS7bTNHmme8tDduWnRPJCzeU+c/eAIPTrxx6d1WZY6DpdhdQXFlZRQTQW32SMx5AWLcG2gdOoznrWnXRTU0vfd2eTjKmHnP/AGaHLHz1e/q+luwUUUVocYUUUUAFFFFAHzV+23/yLnhj/r7l/wDQVr5xj0jUNQsI5RAiRRBVJWAg7DzuJHXqPc9q+jv23P8AkW/DH/X3L/6AtfPWnWMElpCxupWLxBmEcUhAxncMgdFXJPbgjjrXFjJuCTX5XE/MujwfPeI8lz4k0KNApmEkkpCliPuk7eGOBx2zmqc+jXei3ctlHrun/vZFiZ43zEzbQcbyMYG8gnoOtVdTsrO2SOW2lnmVmk3QvbMvlAcKSx+8OR6c1r6Dc6HDKsviFonRRzbJYAHB5BDDuCAc9CDg56V5zlVjHmvzLty/8D/gGnKnpIigs9aPiGXdcaZqVza2km9wouYo0OVOdi43AtkE9CQc1NH8P/FN5NE0VrDDFcpvGZhGkanLBcE5wO3Ue5rNhsrS/wBfkg0uc2sLW29zM+xHIGZASOinnA57Ct6w0aaGOya3SC6eSSa2iilVyssQXCuzAjA+Y4I4OAT6VFWrOlZwkk7dY+TfdeYkl20Rj2PhHUbq5lgi1HTFnt8t5clwBnaAxPIwByME8E+tPnh8QQaLfO0+mC2tWa2uIU+zb8EDnAGXBzhWGcEHBFaH/CMQ2c1ukF9pF+UhF4CW2pkgbY3bI2ndkEdenY1D4h0e0WykME+nJPHb+bItpFlDuAkA8wuSSOV6ZG0565oWJVSaTaa03j/Vrk8tnexjf2PPeRWsVn5UsRjWSSaOArsbbkqT/FjHarNp4KvJ/sph1CwDXPzRoZCrlc43bcf/AF8c9Kv6Xo4u/DVs0dy8k+7EcKea+4sfuBFXCtwW3ZOQDxxVC50RrFrV7xpvKnjzbyGB9skQz+8BYjPToPStfrEm3CM7NX6Aoq97aE8Phm5W3tzFr2ki3uoo542MmMuf4GyMqw2854PXmp9JtdWsNev9Mg1XSRcXNqVMjFJUfDbwqvjCsWXIPHUetalgdAhQqLq1e5uUjMMlxpy7YT3D5J24K9hj5jx0xiyaJHJrN9bW0trLKYd6IzFPNO8jCKg9AG246Vgqzqc0aj084+mvy/qxpZaKI+bwZqszym81LT4bjyknSCSX5plcA/JgbSORznntmqp8Oz6dqaIdd06CdYzKkiykg4JG0EDqSOncHPStWw0SC40S5jZ5oIY/KlNzLBISgOQIix+RRnGGOM9vSq9vpunBmUazpEm53LuC67VwQuBj6nAPcZ9KqOInqnLbtHy+f3E2W5F4i0/ULexuJR4i0/UbNX2M0LY8wr02gqNw6cjpuwa9F/YyJPxT1gnqdHkP/kaGvNtZsrMpO1pqNjPbxwuqSQQCMSMpBIUNhuQc7jyenavSf2Mv+Sp6xj/oDyf+joa9DL37v/At+iJlvofU/jHxvoHg6bS4vEN99lfUp/s9sNjNubIBzgcAbhkn1rcl1CzhmaGW7t0lXGUaRQwznHGe+D+VeUfE/wCFerePvEWq3Vzq9tZ6d/Zi2FhAsfmlmLeZI0m5fk+dYwChJwvboZNF+GuqTavqeseLE0S+1a40a3sYJ1DStFcxxujygtGCobcpyOevHr6IHpNzr+jWtsLi61bT4bckASyXKKuSMgZJxyOasDU7AoWF7alRELjPmrjyz0fr9336V5BN8JtRtfA3hTR9Ii0GKey2nWFCmEXrCIpvE6xl8gk9gWBxkVyur/CnWrXS/hz4eDSPdSRTaVrd1Yo7wGw84TlWkKjb0woIGSxA6UAfSSOsiK8bBkYZVlOQR6inU2NEijWONVRFAVVUYAA6ACnUAFFFFABRRRQAUUUUAFeb/tDxtL8IdfRCysUj5XGf9anrxXpFebftFRmb4P8AiBBA9wSkf7pDgt+9TocH61M/hZdKSjOMpbJo+Km0a3ubqYW95Myx4whjzlccg84z6CqdvbWo1U2Yt5o9/BLPs2jPU8/pUt/d20CQQGAy5HUJtB5+8G6kj2pi3kGq6hBavpzSSBRCrpkyED2I5Nebaor3bt8vv6HvTrYF09oxad2ne297X9639XsRWtiBcKI5JZV2PgCNS2e2FbjHuMmqV9bOZ4lvFe0lbG4vkqo9SOSPwFaMlhHpl0rS2lwxaKTiWEqX46qB0x6/jWVfW7yTWv2aFzLLGpWNUJJzn2+Y+/et6bu+ZPTueLUxFOopSp2V0tnp+Wr9Xp95Lpq2l1cPbzXTW8bfddozJkgHg49TwOOM1emsLZbOd1ubiMxxkiJ1IDSD0Pp7dao2M0kcNx5UbRzArk9++eAMVK85ZmaVH2su6M7cMPQg9x9aJxlzaOy+R2YWrHnkp2ba0389fL8tNupDpSxyXpW+uZUXb1Cknp25rS/s7TWt2mnv97A44+8fbriqukyRrfSErKx2j5FGM8HOQalvXgKtFZrNNE49AQG7EHtUzcnOybX3HoUYwhQcpRUnd97/AJ6ldrSAW9wJpkR8KY1YbhgkckqMDj8a0TpRiuBdQuZ4E5kUx9F7ggqAOPY1heWHibyBMXHDIVBqaGCVZFiuIneZYyBEsYLL7nvn605Rf8x8lVw1Vvmi93bb8F93c2NasLFoUNnJEzOBIYyjh+f4c42gD1xzVCxhjjWW386K5TcCOCUY+wO0/jTtVcHS7SNLWZJw5BfyyobgcYPf1OKrWV0baOdpHQFSFUxrnGQeQRSpRlyblYaLp00p3bvaz8mvT+mXru0t4oLl5d1u3l7kEKBhuz0PXA9+taGh2cUFnBNcyAzybi8LwiTcAeoHOOO/H41n3CnUNOlNpaO0sSCSW43Mu9cgY245Oec5pumC7kMWHuUjjDBLeIks+eu1ccj1+tTNOUJK9v6/r/gHPi05qdny67eVv131/A2Nat7W8i+1velEiXbbwJakYPUKWA5P+0fzp+hx6fFb3vmW9jHG/l8zhncnnOCDgc9elYV7d3MkUttuvovJlLbWBGwYxtwAAKVJ7OSU7rOSW52rjfhQeOSVCkH8TWcKEuTlk3by9V6GFLC1PZ8jbcfLpqn5LXre/Ufcqia5IY5YoLVJQ8PkRnazDGEXOcE8/eOKZfwLdWc8gvoR5Tb9jsSXLEcBQMAjue9SXMkM+o2Ef2Fo4CR923Adzu7cDP45qDU2RoblHE48pvuPDscLnjJAxj0roitFrr/X5np0sM+W0k+Zd7aJefmu+/Sz1Nr4Wpt+JGg+fbtHN/aNv+72mNV/eLzk8/h3r9EYPvP9a/Oj4aTCT4jeGmuWbYmo26IjKGIJlUjg9vfrX6Lwfek+tdMEWr2V+xzfh3/ke/F3/bn/AOijXVVyvh3/AJHvxd/25/8Aoo11VaDCiiigAooooAKKKKACiiigAooooAKKKKACiiigArybx94J13WfEWs3un7TaTW9sn2dpFVbwI+WjY/eXsQeP149ZorKrSjVXLI7sBj6uAqe1pWvtr6p/p/lqeReK/Amra1feI9Us4BZ309tbJZAyr8y+S8c8LYOACGAz0yBUfiDwJ4i12JVP2S2Gn6XBa2Yk+dmmUK7shDDY25FTcc8Z4r2GisnhKbvfqd9PiHF0+XlS92yWm1kl1fZfi+5U0l7uTS7R9SiEN6YlM8asGCvj5gCOCM5q3RWDeeLNIs/Ec+hXE7rqUOmtqzxiNiBbB9hbdjGdw6da6UrI8ST5pN2sb1FYuheKNH1zRrbVLC+iNpPB9qQyHy2EWSN5VsEDIPJqrpXjXQ9S13UdIhvEjvbKdbfZM6r57NGJB5XOXG1h0pknSUVj6n4isLFIisgumedYPLt3RmUs23JBYcA9e/tVTWvGei6RrmmaPcXSSajf3K2qQQsrPGxUsDIucquF649KAOjorC03xVpV5pdpez3MVgLlC6Q3ksaSYDEcgMR1B6E1oHVdOXUU0839oL+Rd6WxmXzWXrkLnJHvQB87/tuf8i54Y/6+5f/AEBa+c9Om2W9vcSK0qx4DYVVRFDAEOdmem3nnr74r6M/bc/5Fzwx/wBfcv8A6CtfMqW11Pb26rZREHAVsBWf7x5OcngH8APbPLioqSVxPc02mttS1K4vb2SCyRULMbCDd83ZgmRtyep/hJ6dKa8Gk28MzpfXTMYFELNCY/MYk5GAxxjjr19uKzEt79MmC3ljiuhwi5IZDyB7jjPPpntVjVI9XhSOyvUmEUfMceQyrkZ+XGccVx+zs1GM7LtdbL5fqJs6C3htrzU7W5sLySyePTN8LeXK214ztKqc7mOAcEDGeMAUo1S6mFrHJdrCqyb47u4QxqpzuIDA/cJXJKjdu7jNczb6Vqbz7obWQyRwrc9Qp8s42t175HTmm3NpqPmx3MlrMhuWMkW0E5OT06kHPY81n9Xg3ZzT7bXQ1J9je1Ywaxq1zJdy6aJMNO/9noqRhDt+WPOAWHGBjnnJJqDUtQiktbq3v3klkCMYUhlHlpwuwjIPHL8A55xxWVb2ep6qsUdvayyiEeWhChQCcnk8Ak8+/FT6tFeww+RLpXkIYgynez7VBOWBzjnHP07VUaUYyjC+3S60G2zSsT5FisiX9i8b26vJFNKV2FQc4UKPm5wOucnGeyLHZw3c9pr7/ZR5yu0lgizlQ2SUyGC8cED1znmsjS1vrYXBjsYp4ngKSLOisApx8y56MOMMOQaptHdAv+5kjUtv2nI9x164BqvY3k/e/K/9fIHbdrU27kQR/wBoxG8v2iflPOR42kI6715AGTnknqORViC6s4dfku7LzLy1SDa8twhbbnKjO4sVx8qg57A8VVkm1+SKzvdSNxLZlT5T3BMiOpO47hnLKSBnOc4+lY9t9ohna4FpvCLuKvGSoDcA49PSlGlzRacr9N9O3Za6feS1ZnSRiYfZI7u+tQ0saSwi5iaXhsgMcBjuGc4I5/KrniLZZ3j2dzBbz6laXAiuBbxnbcb0zuztG05OAoUYIJrmDbalcPbr9kdpGwIdijcQMAAY/Cn/AGLWdTmEP2WeaSNmIXaAQWbJ575NS6MeZSlJWV77L+v6fQd9C/ejT5/DnnNeSHU0kYvbmFtnzH76kHaBwAeB2616l+xpn/hamr56/wBjP/6Ohrx6607VorYz3lrcpA3Bdh/wLkdh3r2D9jMk/FPVyTk/2M//AKOhrtwqSvaV/u08tBdT3L4qfEnXPCmv6jY6Npum3MGnaMmszvdyurMhnaJkQKCM8AgnHfrVI/FrVtPvbuz13T9Lhlttb02wllhnfykt7uPzN5ZgPmRepIAPoK7vVL3wbd+K7nRdWTSZtck04NPFdW6sz2m8kIzsuCu4FthP+1jvVy703wrcw3i3lloc0V9ElxciWKJluI0ACO+R8yqMAE5A4xXYUeYSfEDUvEPjHQ4dLmjgtoPE19pOIJiYruOK0DozkdRubPHpWb4K+IHiK/0fwPd+ILiC7ub/AFC+iL20xiJWJZsCaNVCn7gAHoATzXrGnweCbaW3GnxeHIpUvG8kQLApW6ZAp246SFcA4+bGB0p0WjeD/wC1J7O0sdCi1YM1y6QRQrcI7rtMuANwYhsbu4NAHj2pfFzXtU8G3TNDY2kupeG7rVLaTTp3M9k8fH7zPQHPBGMEY561rXXxZ12y1uPSdO0eK+j061sJL15pCJZxNGrM6MSFUKG6tnJBHFdp4Y8NeAvCPhRrG3/sVtPNutvdXd19nLXMZJCidwAHzgjng4PpXQzeHvDOtiyvZtI0bURCii1ne2im8tR08tiDgDtigDdooooAKKKKACiiigArzb9oqaG3+D/iCW6txcwqkW6IuU3fvk7jkV6TXm37RW3/AIU/4g3khdkWSOv+uT2NTP4Xcipbldz4s1a+sre/hlTQHijaFljR5ZIy5J+9g56HsDzUNve6XdajbwXWiussiqDNA7rIvvtJAY++Rmq2o3aS6xEZry7mijwYy5EjL0OMj37itRtQ046m9xcyyErbIAobDsc9ASDz9cV5bjypaO9ujZ50oyppWUm0uje99N3Z+d9O+hQubcxvaOba5jaSKVnLRgebjpwG6AcE8fjWRNf28k1s5tciPAKq5UkD+EEdB79fetDUr37PHBLDe3kspVhGzwKowTz83Ofw/Ssy9vvtCxiXDN5QG/Ym7PuRz+fNdFKLaTfn3R34emp04873vsrW366P5dASWFobt2hnOWTH7zOPqcUly9u6oUj2PjOVYtk+4P8An2qO2EYSVHkA3Y25GM/jg4rRtLmERQR3cgkUXIzsx9zHXBHX3NbT93VanpYW026e3rb/AIH9dehL4dVZL5jPsiZUwEkYpvyD7HOOtT3MVlaW+Hdbp9uW2Nx+IyP0ratbu1vdQeW0YBY1UFH2rnjHXFZmuzwzM0t1vKBTHGsIRgQe+T0/CuCNSU6uqt5H01TDwo4X3ZKTu7O33vquhz6mB4HzCqOTxKZDlBn+6OvpWimp6f8A2VDBPY+bcKNpuPOYbck87STn8MCsKcAPlMlexq5ayL5iLPHhHU8lQMnsc4ruqU00m7992fDYikrttt2d9Hb9fw2Lc4txZ/aUICE+X5QfLMRj5++M/So7SOyumnLxT7VGRIjDpjkEMf1z+FWNXs4bfQraQ4E7zsNuRu2bRg4Hb8aztOJJePzmWAkM6ZA3AfXilC0oOVx0HGa5oy08/wCmXNRWyYxjToWhUW6mQvNu3nPJ9u1W7XUNLt4tNabS4JQqypIpkOW3HALcdu2Kzb2+WedkcI1sg8qPbGoYIDxzjk+9WpZp5oNMafPkL5nl7iWPUZycVMoXilL832f9eQYil+75J93s/J7Pf+vJEuoXmmOvl2tjBbxRy7jtkkLzLjGMtkAVPoNzZmZIoNOiWR926WWTcQMdR6Y9hVXWmjW3jhgG6WV9+CdxUEY2jjp71XtLsWayW6fPIwBD5VQn94YIOTUKmp07K/3v7yMJUdOm/Z7v+a0uu/vXNJ305dWu4TGmoMQVjukcqN/GGUAYP0IFZ8qRCzu+ZjIxAO8qc4PQcZotP3OoReRwr/c8xiN4z9MA/XioZXhaK8MwK3CN+72kd25zgc1cI8u3l/VunyOylUVKTjo3tdX7W22S9El30Oj+Gf2FfHfhmGTcz/2nbN5inHzeauByeR+FfotB96T61+cHwqhSX4h+GxO4jA1C3dWYj5iJV45r9HoPvSfWumKs2gqT57bfI5vw7/yPfi7/ALc//RRrqq5Xw7/yPfi7/tz/APRRrqqszPGfEvxK1WLX/Ewg1PRdC0TQJ4rIzahYz3TXNw6F8N5bL5ceAQGwf1ArVufjHpNt4vj0H7FcXBW6hsZ7qF02pNIAQVjJ3sg3DLY496seJfCvw+8T+M7zT9SYNr9zAhvrS1vZoTcxLygnWNgGwACN3OMe1b03w/0B9cbVoor21upGjeZbW/ngiuGjxsMkaOFfGB1HPfNAHNaV8YbG+1TT4p9D1Oz02+muraHUZWiMbS24YuNqsWAwh5IHP4kWfh38WdN8b62dOs9Pu7bzLU3lvNI8brJGGC4YIxMb8g7T2rcs/h/4dtE0tIbNtmm3U95bq0rMFkm3eYTk/MDvbg8c1DpnhXw14DguNVt5byy0+0hc+XNqE8ltaxk7n2RM5VRx2HHbFAGRdfFjTbfx7deGJLKWOS1cJNPPcRQk/JvLxxMweRQO6g/THNcrf/H2C48O6xe6Fodw9xbWJv7UzyRtHJGJFQ+YEfKMAwbYece/Fd5e+EfCM2qW/ibUneVfNFzB9rv5TarK4Ch1id/LDEEAcd/Wkt/hf4Xt7C8sEt75tNuYHtjYyajcPbxRuQWEcZfanIHKgEdsUAYd98XotO1rSdH1HQrm01K8gineO5u7eFVDttARmk2yHjOFJ6gdeK9TriJ/hf4auvsi3qandw2/lnyLnU7iSKUxnKGRC+1yD0yD0A6cV29ABRRRQAUUUUAFFFFABRRVXVbKPU9MvLCdnWG6heB2jOGCspUkHscGgDjvHfje58NeOfBGhQWcM8XiCeeGWV2IaIRiMgqB1zvPX0ru6+U/iF8EtH0nx/4C03TJdfuLDU7i4S9mefzGhVRHtKsFwmdzdeuK+gfh34F0zwFpdzYaPPfzw3E3ns15N5rBtoXAOBxgCgDq68p8d/CxvF3xGn1y+aFtN/4R5tNgjW7mhlW685nV28vGY9rHIJPP8J616tWfda1pVpO0F3qdjBMuN0cs6KwyMjIJz0NAHgPiL4W6vFYfDjQIjKbl7Z9I1u5so3aA2KukzK0hUbeVwucZLEV0Os/CjWdQ8X6tPEugwaVf6tZ6gt2Gf7ZbR26oPLjURhQSVxnfgA9DXrH/AAkeh/8AQZ03/wACk/xo/wCEj0P/AKDOm/8AgUn+NAHlkfwhuY9ElWOLRV1qXxINVe9CkO1qLnzRGX2bicfw/dz370yy+Fmu2vjG0vQdDksYPEU2tteF5BeSpIrDy2GzGV3YHzYIHbHPq3/CR6H/ANBnTf8AwKT/ABrw/wAcftHw+EfiJqmhzaPFqelWxi8q8s7oByGiRzxgq2CxHBHSgCZvhF4jHhTwZodxZeFNStdHRmvRcTSxvcv5jukYkELN5Q3AkYG48dOumfhLqifEV9bZ9OurKTV4dWV3uZIprYrtBjVVjIdQFIXLKMHkdq0PDH7Qvw+10okuqS6VO3/LPUIjGB/wMZQfi1eo6Xqdhq1sLnSr61vbc9JbaVZEP4qSKAPnX9tz/kXPDH/X3L/6AtfOemIg+zvpV3fR3ZXDH5FIYr823nJXHHrX0Z+25/yLnhj/AK+5f/QVr58sta1C4t9PjkCvFaRpBFH9nGxwrlk34BBILNzjJGRk5rixvNyrl/r8ATV9R0dneLPFHY38wDDHyMMoRwOAfX8g2alvRq73QM+oyJdsm9A1zu4CnPzLnk+nvVa4uTc3IW/06AXU8jyHarwiME5ICoo4wPfiqDJFY3JhmFxE5ILPHIV+Ug53ZH+0Onb61wxhKT1te3Zfn/wAbsXriGJdasoo7qbz5IIw0iyKWhcnkA5AGR6+vODV+yXVfNe6i1C5DKWdXMkTBiocdN3I4APB4J68ZzdIS7S41BQkG24tHkDMNquAch0+XqCMgcZIwfStu1lNxpUqSxao6lg7LDJHcYDA/NlwSh+Xnbg+prOs3Fcuj2WtghaTV3Yzry3uliawinu54ImUDzNiqqhOMc8YLMOuMdfSsfU2vQZIZ2ZjswTIVY7evDfXPT1I9at3Fnq2sJLdkX1wYolDM5eRivJJ5zgdeM9iaatstvo7TuIJpZ0dCJXx5AAVgV+YEsRkcj6A81vTaha7Tf6it710S2wnmtlkub244hUoAY2AXon8WeuRjGe9Xx9rneG2utQ1D7J5RmgLKgYjHQAtgDgDrx6VF4Z1mK1sLw3FpBczeRHDbiW3QqpDZJ+4cnHXuR3qPUbqXWbi5tpNOsRdPLJKGtkMWzhchUVc4+XoeOTjHJrKSm6jTSSXXT8CrLlVmRtHqr3rrdXO6RIBGWM44jJAGGxgjoOKgYS2upXEj3V0GRVkZopQ7Dk9TxnB9Bxmo77TmgujDHuFvndE1w5QNgDIIwMckDPA461DYO0st0IEh2GL5hJJycdwxHX24reKTjdWtbtYiTfU2NP1PVJokWPVbuKYksVJUjheMHPHBxg4xUd7d38lwsVxPcOYlEMHmnJ4yFHp3z14qNIpoo5rJ8yzoTM1xBOjDocfMAe5OefaoIbeS/mtBF9oICnJmZjxu+8uB8oJ9+uazUIJuVlb0RXM7WQmu39zchTPd3UziMqwecPwT1wvGDgZ9TXrP7GQx8UtX4P/ACBn/wDR0NeT+VINMmla7SNZoWfa4I8zDfdDfxEn6jjrXrP7GZP/AAtPV8knGjP/AOjoa7sJZJxj0F1PfPGHw7u9Y+IlzrtpHpBtL7Q5NJnedT58EhL4njAUhjhgpyynA6npXKW/wq8Y3GnzW+q3Xh9TH4QfwzbG2lm5behSR9ydMIc46HoDXtV1rWlWk7QXep2MEy43RyzorDIyMgnPQ1F/wkeh/wDQZ03/AMCk/wAa7Bnjd38EbjzdWlsYNAt5JjpDWbqhQwG2/wCPggiP5S+BjH3sfNitjSPhdqtl44t9QkuNL/s+21q61lb2MP8Abp/OUjyH+XbtG7k7jkAfKK9M/wCEj0P/AKDOm/8AgUn+NeA3f7UFvo/i7WtJ1fQTcWVnfT28V3YXAJeNJGVW2NwSQAchgKANdPgld2vw48PaTZ2mhr4hspWlu76GZ7dpX+fY3mCFt+0PjEiHjIGO/r/gXSLzQfCGlaXqdzb3V7bQhJpreEQxs2SThQAB164GeuOa4zwx8d/h74gKomupp87f8stRQwY/4Gfk/wDHq9Ksru2vrZLiyuIbiB+VkhcOrfQjg0ATUVn3WtaVaTtBd6nYwTLjdHLOisMjIyCc9DUX/CR6H/0GdN/8Ck/xoA1aKyv+Ej0P/oM6b/4FJ/jXgN3+1Bb6P4u1rSdX0E3FlZ309vFd2FwCXjSRlVtjcEkAHIYCgD6Tory/wx8d/h74gKomupp87f8ALLUUMGP+Bn5P/Hq9Ksru2vrZLiyuIbiB+VkhcOrfQjg0ATV5r+0ZII/g94gYwJcYSI+U6lg375Owr0qvM/2jlLfB7xBsEe/y4wDIcD/XR9/wqZ/CxSi5JpHxFcfYLmdlhjtbVFhZ1URyNvYdADk5PueBTdJvSLqO1gsrX98qh2kgaTa3dsZ6/pVi8hWaRJ7lUktWtJTb3HlOplYdCRnqDkenFY+nQI95HGZFG9FLMVI2H3BHP4Yrhiozi1/X9epxU+Zw59Vbbe2j790979fMszyRPqDrAlgIxG58tldVU47bjnJ69aZrUUIsNPnjUCZokUp5ZUEYznknP1GPpUiWE637RhI5W8tslMgkY64GD/T1qjfbBGimKJCn7shGLdP4uvX36VpGzlHlZ2YeLn726t1/Mhtht8y4YBzGVABTcpz6ntituyvZblkjmMT27OFkKw7iB3HIGPwNZ1ksi2F4oAMTFM5jJ3dcc54pYLWeQDybMF4+Sylh5eP7/oaqqoyTuelgpVqdXZ28r6+tt+vkdZ4OxLf6grRxwsqqFeNADjnqO/HtTfFkkmn7IbSWERNCWxJGGPUjjIxTfD4eK9kW0iht2dBvzI2X4PY5zVDxJpt3cSARxiVlGf3IZwevfpn2rzYRi8TeT0t19D6zETqRyzkppuV3qr979l89DH1tbeKWKOFIlDxI7sqHgkAnnJ71HYyrMABZxM0akbirMCfU89f09qins5XnKkoXRF3bWyq+zHsfb1qzYwf6OUFujOHAdnJb8lyOK9LSMEr3Ph8ZPlc5JWu/6WpYnaefRnSfayK58v8Ad8g8fKv4Umh3IBuPNFnaqFwXkthIRweAPU+5pNS0qWDT0uAnlhpDyflY8DoueF9KqWFn5sE0k0qQxoQdzKxyeemP61MIwnB2ehzRlGpR921vJLu/6+Wpf1u3CBDGsUkTWyyh4otmMnqy5PP5VWtrtYLO3EVpub5vM8wNsbnjGOv49Kk1RYbFFiWS2uvtNssgkRSSjE9Cc8Hj9aZJGktlAzHPl5A8hC27J784H5D8aFZxSlqjOPv01z66799H/X6CXerLLYCEWtvHibeAEJOMY6k5xVqz+wyLJG0dqh2hkKFmJOMkckfjzxWJNDIiktGVGc4KkNt9celbS6ZKY0ne3ljgjUfK8LFckdc8d6cowikk7FOMVFtNq+unqv1/y6haXNvDi6ijtvMkcK6SQswjz2zk5HHWte3EV5pp+0W8GyV2AeOE4XBzwSQRn2rBkjKXUfmOkiIceUm4gc+3OPyqd5biW0kSH7OtrGdzJGGRefUnnNZTp8yvH7z1cBXpUZ2nC8WvvaejfX8PvNT4aKi/Ebw9CIlZF1K3YPtb/notforB96T61+dPwwtCnjvwzM7gBtSt9rc7T+9XjPTNfotB96T6110+tjGv0urbnN+Hf+R78Xf9uf8A6KNdVXnsPh2y1r4geKZLyfVY2jW0UCz1S5tAR5Z6iGRQT7nNdZofh+z0Rpms5tTkMoAb7bqdzdgYz90TSNt69sZrU5zyDX/AXiEa58UNR0CG9hutTksfsTrftGbqELG1yiEvhWJVlDHG0HapVTUdvofjbTYbXUNL0vVxpdv4iW7g0STUENylkYSjKzGQqQZDu2Fzj+W746+J97aao9h4c06Uw2Ws2emXuoy7PKDysu6NVJ3E7WHzY4P51k6t8R/Ed0dFsPDivJcalrt5pz3cltDmJYCfkVDKAeBncTyFPGSBQBW0fwf4s1vUvD8PiiHWbfSnvtZl1CJNTZCkchQ2ys0cmSMggAEgc9jXMah4M8e3/g6ztPEGk6zq0x8OyWdvFHqCKLW881/nmBlXfmPYAfm6YxXU6F8ZdTto7++8TWDr9r1SfT9LsFMESp5JbzN8xkIyoABJABYjbkHjsNE+LNnrl9olppWhaxcz6nZG+2qsa/Z41n8hzJuccKwJyM5GMZzQBU+KvhPUNf8AhBp2mWljPc6jZtZTG1huPKdvLKiQA7lBO3fgE9QCOQK5rUvDHi+bxWk+nWGtQhptOfS7uXUgY9OtI0UXEE6GUl3OGB4k3k53Vr2fx70K7F7NFpt+1lFa3F3BOjxMZlhyWBQNmMkAld2Mj06VF4m+NF1YeG/EFzaeGby11PTrS2v4or6SJkkt5n2rIfLc4/3c55HvgA9norzSX4hy2OpeJP7StJ7dtMsLS5bT7mS3iETSsy4M/mFCeB3wO2ScVhXHxquLzTdJuNB8OXE082vJo11byyx5BMZcCNt4BLDoTwNrbscZAPaKK8xtfjDpNz43Hh6PT7s/6e2lvch4zsuV6gxht+wEbd+MZ9ua9OoAKKKKACiiigAooqOeVIIZJZnCRRqWZj0AAyTQBJRXI+FvG9j4jnkWyUqnPlFzzIB147HGDj0+hrrI3DrkflVzpypu0kZ06sKq5oO6HV5h4z+B3g3xh4lvNd1qC9bULvZ5hiuSinaioMDtwor0+ioNDxX/AIZo+Hn/AD7al/4GH/Cj/hmj4ef8+2pf+Bh/wr2qigDxX/hmj4ef8+2pf+Bh/wAK8N8cfs++I5fiNqmn+CdFmHh6EwiC6u51VOYkLHcxy2HLDgHGMV9uUUAfJvhj9k67fZJ4o8Rwwj+KDT4TISP+uj4x/wB8mvZvAvwR8F+DLmO7020u57+PpdXN05f/AL5Xan/jtemUUAfNX7bn/IueGP8Ar7l/9BFfMsMtsjh9QuZLiFovKaK3Yo/3flBJGCFOOOen419Nftuf8i54Y/6+5f8A0Ba+eNOuzDb213Fpd5M8UflicEhFZV6jA7A857VyYt2S0/QTVznRJvZQ5DhV2jP8IHSpYp4ljaNnZUcjeAgbODxzkEV3txrBvY4bOLwpYW7rJ+7aRpBk7ASVPcnG7dk5z71XhiuDa393NDpdy1xG6SxNDKJLd2KqV4A2vg8DPOMdcVw/XHb3oW+af5XD2V3ocRGYlmQxz7RjlpFI2nPbGT+NOa5iS4DYMwVCreZIcFsEBh0OOhAP4100t7LZ6wl5Jp9kIprRoxbyeZDE8Y+Q7jwTnB6HqefSr9j4h+xXhvING0w2v2cRyR72ZY156Zyw689eDwRnIqWIla6hfTul8g5UnqcJBMYZFeOWSNuheM4IBGD+mRVgy2htiDJNLKVIG5cCM5zwd3Oec5HGfxrei1cI6w3UWks6sMySW7ORkr3HQAADA7Ejmpde1P7dbBmtbOeMwMxaKCVBGfuqwYnnnA9DgA5q3Wk5JOP4/wDACyRy8sxNnApugyoxxDlv3Z7nnjn29OaiM7FSDIecZ5646V6HF4xtYNK0yDTtEhaS0hVHuJ5JF+YfNgMr9+fvdO2Knsteubuc3Vv4d0mVJWEe+VXBHlhc/dxgHemR046DJzj9bqRTbpaebXf+mVyrozzq3lQkCSZ0UgqwRc5XrzyM81NJNG8ysjLEgG1CONq5PXGSev1r0WW/utZtZop9H0lr+MCORvss6s0iR4ClQNpdRj5cDJIJzWXrmpS6fr3nwadpaSrYRIAkcsasuT82xyCCwxkfQgdaUMZKcuXk19V/X9bA4K176HIXV8kl0J7fzIGGckNgglj0IA7HFQPPFI/zjq2S3U4+nArqX1OeKe4uH0e0ZXZ2/foJQOxAB54zx6Z78VM+tXwiVLlrO2cski7rNTK6gkgs2cjkjj0HoOdFWkrWj+P+SYrW3OSlkgkA2+aPk5Jwct68YwPz/Gvbf2Mxj4p6v/2B5P8A0dDXl2pXhm0mVJIoXuFk+edYseuRu/vHOePTgcV6j+xkc/FPV/8AsDyf+joa7MNJyvpYlb6HvvjP4HeDfGHiW813WoL1tQu9nmGK5KKdqKgwO3CisT/hmj4ef8+2pf8AgYf8K9qorrKPFf8Ahmj4ef8APtqX/gYf8K8Au/2e/Geo+L9ZttE0j7JokV/PFa3N/OEBhWRgjY5dgVAOQvNfdNFAHyx4Y/ZOjGyTxT4kZv78GnQ4/KR8/wDoFe1+AfhP4S8CyifQbKdbvGGuJrl3ZvqM7fyArvK5zXfHHhfQNUg03Wte06yv5sFIJpgrYPQkdgfU4oA5Pxn8DvBvjDxLea7rUF62oXezzDFclFO1FQYHbhRWJ/wzR8PP+fbUv/Aw/wCFe1UUAeK/8M0fDz/n21L/AMDD/hXgF3+z34z1HxfrNtomkfZNEiv54rW5v5wgMKyMEbHLsCoByF5r7pooA+WPDH7J0Y2SeKfEjN/fg06HH5SPn/0Cva/APwn8JeBZRPoNlOt3jDXE1y7s31Gdv5AV2dhqFnqMUkmn3dvdRxyNC7QSBwrqcMpIPBB4I6irNABXmP7SbbPgz4ibeyYSL5lGSP30denV5f8AtLHb8FvEZAB+SLg9P9dHSewep8M30yy+VsuHuBtLHbFtGB6jOcVDYXqQz5dd8Y52MuFI9DjnH0NWYtQuIigP2aQyRshH3eDxjHHNU7l2gmLb0lwoxjP7v/Z59PbP1rlSv7rG6d17OSTj31/T+uxpQu8Jt5C6tBPFJ5RkXaR1Bw2Mnn3rM1KK3Qx7JXL+WN+5V5fv0PI9zWtbwySxWy21xYSmSGR3iIKlNueW29+4rIM7LKmHV8ABst8jL6Y6/wBamn8Wn9b/ANeZnQdGzs238l36X/HQmYpLCsbiGN8qAUYgnn+Id/w6VJqMI025nRLi3kEkZU+WSw5Pqcc8deaqWVxNbGVIHiQSdXI7egOMjrimrKv2tA8cc8KfwKxAxn+91/GtHFqXkdire4+aF9rO/byL2mXDidnIa5CKOAgVemOav3N1KmnK0zwKzpkI7ESN1+bgcVkJ5EkN1sSBCNu1VlbJ57A9cd6ngvJltvJ81mkjGIyGbgf3QMYx9ah005XSN6GPqSh7N3tf/L7/ALyvcRLDhJJBmVQxxhwB1HINMt4AqCSaQoWG5MYOSOxFElxhVkWKNDnBXHOfXParYYXBjkV0a5jjYysyHdnP3gR97Ax6VbckjgnONvfb0fbdffp93zEu3draBZlS2XO4ELknI+8fr+FN027W2Z/nGAQfMEeQx7DkcelW9QkH/COoDLAzmUt5sasGkBA+VsgdOvU1X0WSFf8AXzrAADGrrbrLw3XOe/oe1RF3g20ZQrJ03JKzjfv069X5jp7n7XJNdTExSEbECgnvnjjA69OBUN3cbrS2gZZGmG7OSVK5PH51Yvru4DzQgIU8vyI3ChSyA8HjqfpUaahKUVIbeONn4dssdx7Z+lUm2k7Gicq0eaT/ABf+X9P0doLx7iaCCCWPaYj5WME5b1J559hxUsF9cCQL9qMUO3BCliF47Zz19qZqCXECK8kp3D1yefYkVb0q3F5eeTcXSIgjLFovmJ+UkAD8OaG4qPN0DkjShJPVLXTXbV/1/kVLKaS3vlltn37PnORhgoPIIz/I5q1e3aT2EgdoQJGJLAFSeQcbQO3qaZYXUhPkq6QRr86gOQpPvUUzyRWL+W9ud7sZSkoLNyMbgewPSne717nVShOEXUhbVf8AA7b/ANXN/wCGL48deGDNKhX+0rcJFIhOP3q8r6V+isH3pPrX51fDOZp/iT4d2yKv/EwtyRcHdn94vA4PPpX6Kwfek+taw3Oecm5We6Ob8O/8j34u/wC3P/0Ua6quV8O/8j34u/7c/wD0Ua6qtCThdQ8AeENa8TXl86yPqUdzBd3UFvfyKgnQAxSSQq23dtAwSvI+prRsvAXh+zuLGe3tZFksr6fUoSZnO2eYESN15B3HjoK8p8W+BfEY8RfFCfw/p+qJeazb282l38OolIyVVPNjIMgIcspC5XAGQCo4Mut6b488QHxjdLpms6SuoTaObK2+3oHjRHb7QVMb4TjBOCCeO/FAHpU/w48NS6etp9knjCX0uoxTQ3UsU0M8hJd0kVgy5yeAce1XdG8G6Po+rW2p2iXT38Fm9gs9xdSTu0Ty+a24uxLEvzk89hxxXk2ieBvE+k+JLO6sv7XSK18T3McHnajJNGmltDlSUaQhgZCeTl6qaF4U8e2+naqpttWttR/sHULe+uJtSEq6jfPnyJIB5h2kdmITGcdqAPT/APhVvhdYL22jgv47C6SVHsk1CcWyeaCHKQ79ik5PQcZ4xVvUvh54b1Jb5b6xaVL2wi0yZTM4DQRtuQcHgg85HNeS+MvA/iqLQvDi6PF4h1O9Fp5t3b3F+ZoHu2SNSJGNzE8YG04ZCyjnCjqffNIjmi0qyju1VbhIUWVVcuAwUZAY8sM9zyaAOWuPhn4aure+ivLe7uTewwQTyzXkrysIWLRtvLbgwY53ZzUX/CrfDH9mTWRhvyJb9dUNwdQnNwLpV2iUS794bGec967migDlIPAOg22vPq1pHfW1xJOLqWKC/nSCaYY/ePEH2M3AySOcc5rq6KKACiiigAooooAKguW+Xbxz1z6VPXm+p+PfL1C4jhaxMaOVUvuyQDjnBrWlSlUfumdSpGmveOK8XaRP4B8Tpqemq40S8kyAn/LvJ12+3cr+Ir1/wzrEWr6fDdwsp3AB9vTPr9P/ANVefaz4th1nS7nT79dOe2uEKMMPkehHPBB5Fcv8M9efw/rsmm3c4kticBweGX+9+XP1HvXozozrUvfXvL8TzPaxoVeaHwy38vM+h6KbG26MHOeKdXknrhRRRQAUUUUAFFFFAHzV+25/yLnhj/r7l/8AQVr580TV9QsdLSKE3sCf62OYNlFUEKz7dp4ySCQehxX0H+23x4c8L4/5+5f/AEFa+b7bUjDocEdtJbwSoz72cAu5Oeg2njbgZJ+mOa4sbDnik1fUOpdn1iaedY4obqGCDYBDJMZEjzjPAVSA2O2OvWkk1PWrE/aUSS2QvviVdwQFlDbl3HLHbt5OeCOelZKao6W7eWAkzf3MKq4xjjHPTOCTz+ssN+lreteW0rFEk+WGbBZ+MjdjAxnrXL9XS05Vb7xKWt2WoNSvI72AK0kKrE6uCGYshbcQyDgAnsBitNdXtbGORrTFw7EtGSpxAGAHOVxuwPf65Nc/HqksoYtOsEsEX7jy4l+Zt6kgnPHQnODzx3oj1Nd8sjtKryKyMihTvDcnLMD/ABAHp7cdaU8Pzbr+vu/rYE3saFvqmoJqBlRVupzjdcyRHcQVwFPI4zjHuo57VJJPrU2i3RNtcPYMCjSHf5SNxu53Y35A45HPTpXOJPIAP3zBlxs5+7g5GD2weasNfs8UsbMrRFRmPJAd9u3f/vc5z3xWksPqnFLoHMdfoHiPUbbThbiC6vLVVWEr5C7GRW4xmNicZ79M8GrOp+I9XtfDkVvortPo7yqpuGtsh2VNoUKUGzKjBG4llAzXJ2+tXdrar5a2oSQBF+SNmULjOQQTznqcZ9eKrWd2QjQNdSW8E826Ty8/KB32jAPXjnjB6ZrmeBg5ubgt797/APBX9dC3U91p3OktP+ElttLu1tU1CS0QgyTQtJtbewDAZHO44U8dVwadbG41fXbhr/Uri1a4tv3H2uNijRhyEUeWCUC44AUgEEcVHdeLL23MN5p2v3b3LwCKaOTcTnYQzbs+4xj0BPSudtr69lmkke9YggI5kYMxUtnChuvJJ4x1ohQqTUpNKL79fPdeREXZW/r/AIJ0Mzaa2+2ttTWCC1lkYTGOV94wdu3gdeeoXp9ah0z7c2pWqJItxFINkbXmyJGTdgkM7YXoBkn27VhvevKpjvHaWEBtiqVUhsYUng8eo9OhHWo57qSaOQTS5LHdtCAA9Acn8BWyw8krXv66/omK+t7HWak73OhzMEe3nggkS4e4kX96N4wqjIJb9OK779jLH/C0tXx/0BpP/R0NeKQyjyHiSXyw6nIPR/QDA4PuePpXtn7Gox8VdYB7aPJ/6OhrqwlL2V4jvdn2XRRRXaMKKKKACvII9E8TeGvH/i+8s/C1v4j0/wAQywypdNeRQmAKgQxSq/JUdRtB4HTnj1+vNNd+K1vo/j638OS6YZ4Jr63077XBcq5jlmC7d6AfKMtjBYNwSARigDntE8GeLLf4lRahPbzIU1i6u7nWTfBo7qxdSIrYQ7twIyowVCrtyCa4/T/hJ4nPh6BL+xv21CTw5ex3QbVyd+oBybUHEuDgYx/AO9dl4X+LGotpFnBc6dJrOszyajcSeW6W6Q2tvMybiSME4CgADnuRV+4+NNsNNTULTQby5s4NNt9V1FxMitawzHChQf8AWNgEkDAx3oA8+1/RPE2veJdY0OCzvrvXo9G0kLcnUhEmnXODvnY7/mOQ3KBiefWun1nw549XWtVsbbT57uwuvENnqiakmoRxgQL5YkTyywYfdJI6HJxnv0niL4myrD4wh0zSb9YNBgZp9UjeEpGfIEqFUc7mJyBjaR61gX/xO8Stb+PYrbT4oodE0e3vbW+yhdXkgaQGRSSG3EcBVGMHPUUAc8vwy8UWPhnVtL0rSZ4APEBvJVXUFK6nZbpdiKDJwV3KSsmzdkZJxW54a+HmuS6j4Vtdag1ldBs4r4XEc2phHTe6NCjeTLkrkNgAsABgntWpF8Y5dN0XU5PEHh29gvtOsrK88tZ4mN1HcSLEHG07UO5s7Sfxq3p3xdlm1u107UfC17Yh9YGhzzG7hkWG5ZC8YAU5YFRkngD1NAHq1eZ/tHpC/wAG/EK3MhihKRZcDJH75McfWpvh18UIfGviC90yPTG09reN5PLublRcrtcLh4MBlJznI3AdCQSMx/tFypD8HvEEkkYlRUiyhUHP75OxqZ/C7Ezvyu258SHTCsxtNROGijMqSxsvyAc4XJAI57ZNaVv4YaeVlM1tOlzbI0UpYDZk5+Ybs5x6A/Sqd5/ZRuLeeK+aG2kQsqrZ5KkHHHygN357VYvb61e6ImW4hthaR4YwuGk5/wBYecLn6EV5M51ZW5W1fyf9fceRUq4ir7tO6vrs7aeT1v6P8NSteWbQXdrFYzC1tpIZdrzYBIHDZAORznGcVh6jZxxGFrfySojAO18s5/v4PTNdLrqwaq9lNYx30qKpS4Y27Flcn5AWAwc9q5jU7OWyv5ILuGeKRWLfvjsJTPHBrfDT5rXevb+v669TuwFTmp+/JejtzaN/P57feOAe485fkQjaWBwFGOnzVWa4RJ5diKwdSnPO3nqMYz+VaNrbMml6jG0Gwq0RZ2bAQHJ5+vaiKEsUGnWE5ZlwxV925fYFR7etb86V0dU5pyb5tO7a9dev4GVbbQsjPGWjGNxDAEfh3qxBJHCQ0aN5Lna5cA8Ht0/lVmPSr6XdNHp7zRg4Lrkgexwad5U0VtIrwTRbfkYLuKhcck8EYqvaRb0f4mkMRBe6pRevzIJJ4TEqwxq6RsW8tkxnPuMk/TNSxqiKQ8rRyhS7BYcqCOxx1+tRQTy2iYt5eW/g2ZMg/wA880k7yJctLOk0bScSq7bMj2/D2qbPZFydOKck7Sbureuv6ff8y3dxodMieAzS27t9xodv73A3YI7VHp9sl1bSrDE32xnVo1AJwBnP9OTUbBPsaS2tuYsSFRLktngfLjp+OKnggjV7uFk3yIAfmBWTGMkADt65qVorXClhp20jv+b1XXrbur+RJqNjdWcbG/OJmQMqtGGI59QcAe9MitIXaK5mljgtz0SNS5DDoGHbJokWeREnjhcwwxjKEFo1H+0cY796JkSI26XlyyYydir3PIPOMfjU3lazevkOVXl/c1FeyWyf+d0tV1+7RqXVrRjfxNctGizIHUQwgBVJ6bRjH1JpBfNZT/ubpvNK4NwibWUY4XpkenvUeo3EcqA+ZOZkbyzJLMXRx1xx0/PFWLR1WyuJHtIrkIU3zrKQvsMY/DoalX5Fzfoa4ag1GVLryvo/N2+7Rt6aXv3z2YT3UTSxNHuIDOyFhnP8OBk/rUs7TMhaHa6KdquIdpH6Yqe5RrvUPPls2hj2GQAuyJgHqMDgU2/ljk0xY4pMsGO1RJ8o6fdHGT6k1qp3SViFTcoXT3Xm+mvTvobXw7aP/hYnhsNJJvXUrbahg4/1i8nn9a/RGD70n1r89vhTbS2PxH8P/aoZHme7hwGyAF8xeckc4r9Cbf7z/WtaTu2kYShVi71P6tv/AMMc34d/5Hvxd/25/wDoo11Vcr4d/wCR78Xf9uf/AKKNdVWxIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAUdcvV03Rr69fpbwvJ9SASBXEad4V8G3un2t0dPsd08SSHM7DkgE/xV0HxJtprvwPq8VrnzfJ3gD+IKQxH4gEV4/oVlrV7aKuhWMF5aoisHd41YBs8HcRnBBH4V34anzU3JSs7nnYitKFdQ5bpr8f8Ahj0f/hDPBn/QPsP/AAIP/wAVXKfEbwnoun6PFqnh+O2gntJQZkjm3eZGxweCT0OD+dVf7B8Y/wDQDtf+/sP+NZ2uWOv2NnjWdOtbW2myhcSRscAZOApz0FdNKDU01Uv8/wDgmWJmvZS5oWVv66Hr3w41E6n4N06dyS6oYmJ7lCVz+ldNXEfB+J4PBFlvG3zWklUf7Jc4rt68yukqsku7O/DScqMJS3svyCiiisjcKKKKACiiigD5q/bc/wCRb8Mf9fcv/oC1826da6eYbV7y0vfMkI/gPlMueW3ZX0I444POa+kv23P+Rc8Mf9fcv/oC14BYakIdGh+zvsWWE2ck01r5nltjLbGycYViOMcHkd64sbKSiuULdS7bweCLe+ubjUU1KS1ilaGGC2jJjnIH3jKZOFODgDJwc892pbeERKrXdhqsNnNH9ojaNg8gT5gRyyg4I4PfnjpVRJktGFvFulhbbOscc5jG7Zw45IJLYI78e9VW1t51uDd2GnbpRt3unKsTuz3PvkY9OnB8xUqktVKX/gX6d/Uamk72IZbXRXnSPThfTbYWaX7QgX5g2QV2t02frx71pvpfha3V7e4utRF6NgUyxCFG3KDu+Y8Y/EEd1rBha4vr1xBtDRQMRtYRnYoySSCMnGeuSenJrp/DU8dtfQymKe8MbF5YFieVkXADA5Yb1CZJA98jHTXEc8I/E9Ol/wDgfISaTMO3i0BbKSScXbSggAdBkEZOQehyR3Peo57OwFoZYrTUBuR3V+AgAHB568kZPp2zWtceIWge0vlsHlljV4o5prhj8oPy/Kp+Xg4weCOnrWFGxuoblFaBBsZyHOWwCG2pnOOfTBxuzWlP2j96V0vW/wCQSaNXRn0BbS3fUtJllkYeWxjaQ5YfxY8xeoP0+XjvUF6dAjnna0guHV/nitpyRsGTx5gYZ4244OcnnIBqzpdnG+mQHUp0tIZUMVvK8Jdd/J+8pwCAR19e3Jq/DbDy1i0vy9UhBeF4E6uwUKrcnJ5cAEAYJyDxWMqijNvmf3u337AlpczLaz0eeMr9iuYgd7iV5w7KAAAvVQ2ST2HYc1DcW2hJrkkCLqMVj5RAa4RXkR/XCMBj8TWuL/zdFju7/TbMxRyGKBWljLKy4P3AN3Y5Z+D0zWBO4udSt/tMKWyKoUpCApI3kYwPunr1+tXSc5N3bS1W9/8AMJPobhsPB0NwsU02svGYgTILcRsHDAMNpdgxxnkEDikm/wCENhktxBb6nKCMublRGGUDggLIeWOc84HYHPElvNbyagy2dnLP9nMixwFfMXHTD9ABnBJBPzdOtJrSC3kS5vrSdYNSy6z3jrlnCqWbYhOOGAAPZx6VgnJyUZSld+a/L010B2Wuhna0fDYhY6fZ6jFKyAxGSQBcHJywyST90cYHBPfj1H9jL/kqer/9geT/ANHQ15GhhewuZWWKHEQKx+Vli3K8FskjkkkHj5fTj139jT/kqer/APYGf/0dDXqYRct43b9XchO7Psuiiiu0sKKKKACvOLnw78PdQ+IskTwiTxRFPDqcsMVxcBEmQAxyuit5QfAB5GSOuc16PXhniH4ca7LrPxO1DRbaSCfVnsjYuL0p9qhCxtcxghvkLFSoLAdcDCk0AdF4y+EGnavYafaaDNBoyWrXLFzFNPIfPIL7XEyEAncSrblOfu8VrwfCrwmdM0e0v9O+2tptnDZLLJK6+fHHgqJVUhZBuG7awIBPArz618AeJrk2ED2N9pugSeIftR0yPU8SWdl9nKMDIkmcM/OxGOM/Wu6+LOg6ne+B7LSvDWmrfpFcwJLA837wWygglDI6q7j5f9Y2DyTk4oA6GfwdoVxDr8Utjuj17/kIjzpB5/yBP73y/KAPlxVK8+Hfhe7uLuafTGL3lkun3Gy6mRZoAu1VZVcAkLwGI3D1rynwt8NvElyvhHTPFNpfnRLOfVheRHUgCsMmw2ysYpAWGQ3AyB3AFc7rXw++I974O0Kxl0ieXUrLSvKjuYr+Hz4rgTuQru0uAoTbgxgnoCwAwAD2tvC/gjxLfazYm1W6ubaK202/jE0ylEiZZoUPzDodrZHJ6EnpWrJ4G8OyXhun07M51NNYLefJ/wAfapsWTG7HCnG37vtXkXjbRtb8N6D488U3TGxubfVLDV7CVpgVuGijjjZGCnOGJZNpxkkVS8RfD3xhceE/C4tbe+1LVVt5bq9Sa5jNubqZg5EiPIjLtztDoSQBwvqAeu+DfC3hPStWvbnw/aSrf2ubGSSeWeUxLwxjjMrEKvIOE4/Ksb9o5Ef4OeIVkk8tCkeW2k4/fJ2FcRrXgXxndeH9YtZrS9eSXW47qGKzvY5I3hW3VcFJZF3xbwflZ1bgNzV74g6Vqlh+zBc6drdnDDqcdugmt7N2kVT9oUgAlic4IzgkA5A4AqZbMmfws+QFC3luzQqDIAdiOoYKnc/7PNGmXRhvVN1bJJEVEZydsZA9WPb8RW5quj3B06B00aRIyhIlaUFzyfmIwMY+gFFlo93/AGzpQlZ5cRo7SCNJYkjION2Mgn1BFeb9YpuLu1169vQ8xYyjyyaa67vt6N/5oi1bUBYrp5mgCr5Uim2QshjJPDNtIye4rG1AO19ZbpnkeSBGV5V24Bzj7x/Umui1mSaPQ7VIYI0hAdWvEOwyEscAZAOOx4xXLXK3A8iRUWTYoHAJwfTOOvsDRhldX66r+u359xYFXjzLR6r8/u9N+5Nugt4r7bKX+aPCNGxyfUkEAY/HNQTSiZmkaXbOoyxI2q/9c1NLcXEcF8vlum8xGQqCAPTPBx+Yqtcb2nhZHLOAMCRicDPTkDiuqK6v+tD0aWk+Zq/3dvS39fIZaTI06oRtQ5J+dgOlattbxNDcXCyQwyiNisRctn39qqWc97JZ3SKoaJMbmG35Mn9fwpLe3mjeNpbj7IJBlZHBBaPuQAOR+NTPW+tvxPRwmIi26c4Rbv3S6fIglRBbs6yJJ3cg4K/QHrzVuwsnuI7ZmZEJBI8wk+YM8gDH4daoSrkn94GUsQsjZUcd/wAasXUrylHYbZGU7pA+7zV75x+XSrle1kzz61ObSUX3+Xy6j7/fbh7N4rdBuMm6MgsQegyCcdOlQWu5YpJEkWQAjcHU/N9D1/lUl1LGLCOGEAbD5hPyg5IA9Mn6Z/CmRkPmR96kDoRkD68fLRG/LqdNFSUbSeq7X/pXLM0yPavnbHDt4Rs/f7lR9PWmTpBGLdWIzgh3iOevTOTzSXXl+UXKxyEp8pViQDnp0HNO3x3t+gnuVEaoeUhJxx6f/XqVorrY3i5VGowXbVv8NX+Pl5kUwSKUQW08uxuN7AgHnsOav2vkm3T51jSQkFWVyile7Y5Oe3pRBaWckigXaSmV/LTKMpXvuxiktLO2+yXU2oSTjy3VV2jcTyR349KiU011OyFKtTcnZNcr69ld7Pqvvv32iCxpqgMzu8PWRtp2Fc84xUd08EsM0yNtCHESlTh+ex7YHrRNcbb4tZpJFHN9wYH7xc/Spcwx2LSsEa5Vj+6LFSvI5Axgk9+nSr1Vmc2HjB0/fffV36+m7XotfI3/AIfxtF8QfDUsq/aCdStlYOeVYyrg8Yxj0NfofB96T61+eHgGS3f4i+Fdku4G/t8hGztbzVwMkciv0Pg+9J9a1o3tqZ43k9r7n+Zzfh3/AJHvxd/25/8Aoo11Vcr4d/5Hvxd/25/+ijXVVscgUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAQXWCgVgCp6g9xXiGl3Nz4J8YX2kR7TEWLW3mAlWjbkDgjsMf7y+9e3XR5UV5l8aNGjn0SLWUdIrqxIQ5ODKjH7o/wBoHkfjXbg5pS5JbS0ODH0pShzw+KOqGyfEORR8htJJDwsaROWY+gG7rXHand6n418TQWAZTdTYR/K5jtogctj6dSe5wKybGSbUEefSzbreXG2K4dyF25OPMDfwg5+Y9vxr2vwP4TtfC2nlEYT30wBuLnGN/oq+ijsPxruq+zwqvFe8zzKPtcwlappBbrudDpVrFYW9taWy7YIIxGg9gMCtKqUXEi/WrteNLc+hiFFFFSMKKKKACiiigD5q/bc/5Fvwx/19y/8AoC185w6g8FnE1w8AaK0CQRRybHILKSSUXB3KWUhjnrnoAfoz9tz/AJFvwx/19y/+gLXzc2nrJZxj+10YtaCbySoZhtJ/d5BOODwDjPoK5MUovl5w6Fv+1dHVRHPaPerIyM8hdoTGeCxUL15ZhjgcD14puYHu45I1hhjwsjQuzszHcRjOw4OPmx0x6nimHSLNN6XGtW0TrnDtG7RuME8FQTnIx0wMjmrGoadawvM9j4kivXUrsKh0aQkDoT6ZI/CuNKnF2i3r/it+VkRs9SsZYrDVQt9CjCBVAEKqyynOdx3DnIJ7enan6Vdw292l09k7ytJvgW3nKNHt6nIOR+mcU+2WeTWLRhrMc8s0aebPJ85gGdu1vM4JAwRg4xjmtkeCLY6rLaR+KdJMUcbySS5I2bRkqR0J7ZUkZ4JpVKtKCtUdrr+9032Wn6lxT+z0OYvDF5nlRW624aZgztL5q44GM45A5ORnrVuW7lbT3t9guIEDtuKn9ySVGc4zzgc98itk+GPD8UkCz+LxbOGInLWLuLfB4JMZYHI6Y74HqRUmsrWSz8z/AISpp5H81ZY/KlIAQZj5PB3YxjqPShV6U7Wvp/dl+dv17d0RYpHUFu9P8tbV2mjESgxuFUIFKkMAvJZiCD1HI560R3tlbW0ccmmK8sbbizzt85GPlYAcdG4B70620eW8sIpF1OxESJ5giM6LIpI+YYJHPHAzzxVi68PWMKW4i8R6fN5iFpFyVELYJCkdS3GCQNuSOTVOVFPlv93N+n9fMbi2QqDf3kVzBatHI8fmb48yAOpALMCv3RjLAA9aq29xJaXFwzeVHJ9nkiZTHzMHbBHI+VsMcHAwBxzV5dIhs7txaeJbeOQrmJ0EsfmZzxnAx0A9OevFNhjlh1l5E1hnuvLO6WRfnVySAreZ36EkE4z60KcLNLa3VP8AVFWVr9Sppc0RZklUmZV3oWfbyvODk4IwMgdSQAOtDTxSm2aR9sk0n76SRixHIy5yCehPQn7uetX5tEskjeRvENvNIqKSiDc2c4K5zgkAAjB5yB1qHUNJ0uG4EcOtMysQqvNatGASxBLcnAAwfxx2oVSnKV1f7n/kTyt/8OW9RudYuNMEWZp7CCNojLKAIkALEBDwOVAIB+bI47V6Z+xnj/haer4/6Az/APo6GvK9UI+yPKniWe8V4/LO4SjzSvRME52gbcbgOvTivVf2Mxj4patyDnRnPH/XaGt8Ekk7K3ya/Ow2rM+y6KKK7xhRRRQAUUUUAFFFFABRRRQAUUUUAFcF8c78aZ8MdZvCSBEsZ6Z6yoP613teZ/tHzNB8HPEMifeVIv8A0clRVgpwcX1RnWgqlOUGr3TR8xf8J46SyiHR2y7BlUIRgAfxAE7f04pU8fTXDn/iU/vF4CR7nBPuOAB9a4sX9rbzTXkX2iXzCE3hdkKkj7rc85x1478GjSdTiuNSFrLFZKk7mMyRlmde/wAuMcV89PLaOr5NvNnys8ow6vL2d7dbv5+p02oePbm2sXtba0WEr9yV4XdgDySdwwME+9cVe63e306S3OpTzhDlvmABHqBgfyra1Cz3zrbHe0sMT+aPMAdsjIIGTkAYye1cRcqUnCEqdpwpypG33x1rswWGoK7hFXPTy7AYZQc4RV+vV69fnuad1fyTTXTyziFnMfyJHuHHQ57Hv707VLz7ZMhkvpLpY48ZKbWVQehNZccfmQPMBs8sgZVfl5Pc06ZAJd7gSbhhmJyA3tj+td/sopq3Q9lYeEIpxW3Xt0t+HqdDp2qKnhrU4BsEz+WAHchyA3b/AOvWZqhllt7OS8njYRgIscT7n25JyT0zVS0iWS2u3bAZNuPkJxz69qtytaSR2H2FQHXabhpY8IHye+TxjFZxpxhNuK3f6HNRoU6dZuO7eum2i/CxUuwq2yf6S2c58rPQcY6cZ/WmRPGCu3cjbTufOSx+nb9aW+ilV2YJCUY4DxD5Se+DTVVGgXfEdw4XC43fX1rZW5TttFarVf1/X/BItqGcFfNdCeT3J9q09qTvNJLeyeSMDcXyScdCcZ/SqgYNayKbchgflK9jxwQaWCeBd6+WgQDcrMmTkDoR060NXNqCSal+Hz/rqWnCRqj20zyhVBVBtY7vfjpTLi7RrkvBvjtsA8IqHOO+0Edc012tli8xZEa5mXLLs+VM9lx0NJcNEzRiJYWj6uEBG7HYn/DFZqKvqjrq1HHSFujt/T/Aljkt3KSu8sUjv87g/wAHrwD3rQd9OXR5oYr13ldgxZ+CMHIxx/n2rJEkReYm3SFHy8aRruwfTLckfnT4WhdGBEUaj7ykc57Yz+tTKF9ddDali5RptuKu09Ou3rYVJpZLu2cyXDXAceWd3QZ9++at6jHbAzf8TZ2ZwvmKIyu9s/d44ODVOCMpeLGhQvuAysW4/gB3+lSPCIrZpJFEjSSMvC5PB/Q/nVNLmVnb+vQ5IVPZ0pWhzK/d2WltLPz9Df8Ah8Uj+JPhcCSUyfbrcSOX27j5q+o6Y7frX6Jwfek+tfnR8M13eP8Aw286rsTU7ZFbAzkyKR0/nX6Lwfek+tb00c1aTlPVf15HN+Hf+R78Xf8Abn/6KNdVXK+Hf+R78Xf9uf8A6KNdVWhkFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAFa55dR7V4Z4z1w+J/EflR5k0mxk8uGMHAnl6ZPscHnsoPrXpnxP1V9J8K3kkBIuJgLaIjqC/BI/DNedeHPAeq3um215ZX9tZxkMqCRGZjzgtx6kfkBXpYOMYR9rP0R5OPlOrJYan11foZXijw0NGjh1jQNSS6ux815bxoVG49WjGMbexX059a6/4Z+Nre9gjsbmQJgYQMf9X7D/AGfb+H6dGf8ACAeIv+g/af8Afp/8a5bxJ8Oda0C3l1q0uoLownzJY7ZGVlHdwD1x3FdHPSrR9nOV2ZujVov2lONrfie8rwwq9XnPwz8UrrlgttMR9oijDqc/eUHBH4ZH4MPSvRh0FeVWpunLlkepQqxrQU49QooorI2CiiigAooooA+av23P+Rb8Mf8AX3L/AOgLXy6Yrc21tkruAHmMM5Az7nB4x0r6i/bc/wCRb8Mf9fcv/oC18wQsESFbhtscq4E7fvAikFcbR0PBx0NYV76AXpIrXTpmms7qSSMTqbaQMELqMneV+bb24P8A+qws0cnkyONQubLzWaUpxyORtbaQSAA3T8qxreWKOF45lbynJIaEYYYPTnsevfoOnNXbWTTbO58x2uHiQKQiNuUuRk88cdvXr9a4p0+92/zGkPutSiudShNrPdW6G28ndNKshGSS3IAwOTxzW9NpdlDBYpqAuLSaNo47iSWIQeQpGdzKMtJkEEfLkAHPvzU4tZdRii8p4B5OwtlWzJuOWyPvDOcc+nPFdFqFppkdywn8Q3NwYEEojltDGBLhQi4D8hhj5h25NYVrRcYxuvRNv71f8fx2Y1dO7JNPbQy0anxA8dw8czybLLIacEiNckYKkY5PTJ6ZqxdamzWOrQ397fGBicI5SAmUJgBvkOTxnaMcYweaxf7Us7eSSExWF3C5Kt9ohb5C5X5kCkHCbByCCSTnIOKJ9R02WG9iuLTT5GTKJOhkVnOCAyqTjsCfr054xdBuV2m/ku/TRArS3f33K2iWlldJbQ3AZc7md0jLuxwNqAA8nIPbjcc9OI7W2s0eCSWZWViuI+FzyQc4yBjg5PXpUFlIkkdvb5mDYLMy5bIx2UdMYxx1zSpdRArFepLHLFEIgYhsdCuRgk/rXa4yu9X/AFcnoam42EUd5ZzPewybmkMcP+p6Aj5we54as+e2tptUcNJPDBIN8MkoL+YATls4GeQaIjo+25iZrjeS2yTjBx938+TjHpSSS6cb5PJ+1eWY1QMwztfPUL3A44J5qYxcW7Xv3sNXe5pjT47W0+2RXUIiUmNXkhUB2C/3DyTzjOOOp5q3aNoTzQBdQETNH95bcu3mfMCrKwO7dkYI4XniqBksraCSP+1r25gP3oRa+UpOMBiQ55GRwevemahPpVldXcFnH9uVyNs15DhowOflCtj5uPoKwcXU0bfyVvvuv6/ANhdZkF1DdzI80kAG+J3bYFUkZUoq4BJx3Feo/sZHPxT1g4x/xJ5On/XaGvGprq0+wpHDagXDI3nOx4DE8beeg/GvZP2MP+Spav8A9geT/wBHQ16OFhyKwup9m0UUV2DCiiigAooooAKKKKACiiigAooooAK84/aHlWH4Ra/I5AVUj5P/AF1SvR68w/aV2n4L+IxIxVdkWSBn/ltHUzV4tMmSummfGl5rUQEbJLcMZomWT5QsYboCwxjgelOh1K1uZPKWZ4pIrZB5qWy5lYcFcbcbe4JGT3NZt42nrDarFZuDsMUoklH32Jw3cLgdjg1PJZWttcROJI2t1hTLPKhZX7hRu+YD3IrzJU6V9f07/wBfLzPKqYanGSUk03tt0dv68vMfd6ovm2zF5nkZWjaaZcOVJwc54PHtWFqqxtdmG1Eskocoh2jDp2xj/CtXxHDYQ3NsuniEQmJv3gZW3E+uGNZDRzyz2oQRuyqqKS4YHH9K6KSjZTjoerhJRnRjCKtd6d/uvb5DY4XVJPPhnVkK52xj5c9NwI/L1p2qTxSSBSJVcL82UCBn9SueP88VLE806GO4naMQuoVB3JPpxn86vahYT3d7c+cj77eIyybYNvyg8k4bpz15q3UUZe8bTa5b62Vru2ib7/p+RixRmWC4GWaRQpXa3Xnv60W8ZEG4bhIJB0Tovc7ugrS0XS7m4eWS0tpLhIxlzCfmQHIHGR1q1/Zl/Fp90raRJEMGTLjJAA6jOD+NP20OZxuZSnRptxc0pdrmM7yGI/vWEQJK7xxnvjGefpVqGNVS3eSC5W3ZSzeWB82D1BNVLd5Y03r5aGPnc33hng8Hr+VWrgxW4EcTx3MQYBXYYeMemAfx4Jol2Rt7Jyipa/1fVfc/JdyG5micYihk2hiFdwCxH909jj1qxpgtkhlkd2ckhSDAGC5zyScjFE0NsYYgoBaU4MsnyheM/wAJP681JawQQ3Qt7yOPYyna6ScO3bPPv6ilzRtY2hQn7O697pvfV+e2v9ale5dYZy8Ex8xRhJohsUc9f/1VdtZ4IryOd7ZGjmjcBF3AAgYycYzzziqt3brCJ1EbEhMAGMDbz1GWPHvRIsFta+XeLKtyzKc7OVX0JJ7jGOKlqMo2RMoOMnGsrOV979Px79eqEuBaojBLp2uG5IERRB+HB/Sp4y6wqfsjvEoyrC3JDHvnPpUf2ZLhi9jEZY85QSnOT/d47+2atWcVuYY3u4LuK1+YK2wkOw6jIIzg4+lJuNrFyxipNOKS6aeXq31/Ip2ywT32ZpLiNJju3JErFlzj7q9PpVm4i00qEWWfchOI/J2/j0zViK3E2o2/kFFjdM4kkUOo3fwkHJPpmor+NpbOXzre5SaByA6IFTaTgFj6n1701NPrbyMZxnG6nd62b6a/5+f3Gx8MVs5PiBoBd7wt/aVuy7YVHIkXGeDgV+h9v96T61+evwoW3HxE0FbmKNwL6DyyDu+bzFwdqk/meK/QqD7z/WtqbV3YirO82tdO5zfh3/ke/F3/AG5/+ijXVVyvh3/ke/F3/bn/AOijXVVsQFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHmXxyZ00OwlUZEd4CR77GxXJaf4svksbdbZNYMKooTyw5XAGOMCvU/Hmk/21oF5aqm+ZdssQ9WXnH4jI/GvLvh/wCM38LzzaFqwle0L7rRwwGwnnacn7p6j0Nerh3zULJXaZ5FaPJirydlJL8Lk3/CX6n/AM89c/75k/wo/wCEu1P/AJ563/3zJ/hXe/8ACaWv/Pvcf9/E/wDiqR/G1oiljBcYH/TRP/iqXNL/AJ9m1of8/DyfwRO2mfEDTxDDPb289xgRyoVIDqVI5HTP8q+jU+6PpXidvfnxT8TNJmRGCxMZjk5wkYJH4bs/mPWvbE+4v0rLHu8o3WthZbZqbj8PNp9y/UWiiiuA9IKKKKACiiigD5r/AG21ZvDfhnaCf9Ll6DP8Ar5MaSVlUMsjBRhQQeBnPH5mv1HopNJ7gflurN3jf/vk1IJ5FYMqtuHHKZ7Y71+olFLkTA/LhWcHJjY8YxtNWbu+mu5vNmhUMEVPkj2DCgAcDjOBye9fp9RSdOLdwPy8FxNtSPa6xqxPypyM4yR+Qp0d1LEhSOPAORuMQLEHjHNfqDRR7OPYD8uhK4XaEfHT7tHmvjBjcjv8tfqLRRyID8uvNfZs2Pt3bsbO9PjndQfkbPGCUzjHPFfqFRRyIVj8vkupULEK+WUqcpng9etRmR+fkf8A75r9RaKPZxCx+XhmcwiMxnAbdnZz+fpXu/7GAP8AwtDVyVYD+x5Oox/y2hr7MopqKWwWCiiiqGFFFFABRRRQAUUUUAFFFFABRRRQAV5l+0jG8vwa8RJGpdykWFHU/vo69NrzL9pFmT4NeIWRdzBIsDn/AJ7R+lKW2gm2tUfDGoTR2d4sP9kFDj5lnkZmduxBGMfSrd3qH2+5gWTTXmWKBEaIPITgdh6VX8SXEtzrssomS4gaRMMgyDwOBz+mar3UsZvt1oksYRQHC5Ug9+dxxXGoRlytrW3dnOlzum5p3aXfTbzL09xaytbxyWF00ccT7czsCe/HYAHrVCW6SAq0MbRO0QQFZ2yOevQfkc1Ws5hGX+dkYKwBbkDIPGKbdOGjgVZ2ciMHaOcN6VUaSTt/mehTTpU1yNfh+t2XvNt3jdLSOWIHaZInkOJCOh4/H86s2+sR2IuY20+4ilnjKgmdk3A/3h3HHbFULHesrtZzSDDIC4Ko/PoM5/KptWtbi21plvEnZc74zcg/OueDz1HXmlKEG+SX5swq1VVqulKyUt7f8DZ+g7TtbnhLIiXDhvvxrcuN/p0ORitVNXuL3SprhHvYzEdmxJXYBMEk7i2PwxzXMxAiG7dCEK4xxzyex7Vp2VtI3hqWdseWtysZMikqMqT9M0qlKmmpNdUctajR51JrW6Xl0+Xqyhd3ckiMjCQAgE7pCS31zx+VWbC28yS3UW5eScbAs0hUFycArjv7VnqIhdDa58sZyxXP6UyCWVGDxuyMvG4dq2cLxtHQ7KvO1aHn/WljR1JHtbnEkRV4jsYqQPmHBGRnn9ans7tXmYy2bTADCI0hO0noT0qrqDuIYfMdJMjzMq+4Ekd++fWo9NdDHOsiRsxGQ0nQcHjOetSo3hdnVCc23SnLV7201LNzfvJcNEICFHyOqn5iQeSDziknuJJJ0e4tdwIwvms7BfxOc0w3IaSGOzlltoigWTMuRu7noOOnFS3dzFBHbvb75JlV1cvLvVs/3cYPSlbZJEqTqv2lW+ul/Ld3Xy/Icuq3EUTRQFFKP8jRMUwfUYA/z2qe2EmqW0KYuG8lmaTfNtDE9MZ47c1imfaiAEqN2/AyAP1ra8PXdot4IZpZIrbax8wrglip4OCR14HFTOHIuaK1MP3cKbUeibWl9d/X9fvGqWk1NkaOe3DzhBIrn5CfU8g/Sr1vZXt7pWsLa3LtFEUDRyfKZfn/AIR+pqnooM18luJLglZVlWMyZTA4+Ydj75HFXryEPFLJOt5GnmMsW1hywPzYJzx061E2vhXkefiazc2nvvsn5/e/w36Fj4VxKfiR4eCblxfQbvKfgHzF45PI9a/ROD7z/Wvz2+EumWs/xG0Qy3Ulskd7DLFJLhPMIkXCdepNfoTb/ef61005KTaR0U6kZ+6unl/Vzm/Dv/I9+Lv+3P8A9FGuqrlfDv8AyPfi7/tz/wDRRrqq2NQooooAKKKKACiiigAooooAKKKKACiiigAooooAqXH+tNeYfFHwZDfQNqFqqxsPvnoBnufQZ79ifTp6fcf61qiIBBVgCpGCCMgiuijVlSkpI5sRQjXjyv5eR85eEoNOOsNpXiu51CykZgkM8coVAf7r5U4z2Ocfzrf8Z+HtH0VxFa3uoSyJiSXzJlKqnTso5Y8KPQE9Kn+JPh2ysr2O38xPs867oSeWtTnARv8ApmT90nkc9hWD4M0ttc8RWuh6zceXbRM0rqxO+4Kgfu89zgY/3QcV7Caa9td27HhyqTlfC2XPe1/6/r57egfB7RpIrO5127j2S32Et1x92Edx7EgY9lHrXqkf3F+grPRVRFSNQqKAqqowAB0ArQT7i/SvFr1HVm5s9/D0o0YKnHoLRRRWJsFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXmP7SiSSfBjxEsWd5SLHOP8AltHXp1eX/tMDd8FfEY/2Iv8A0dHSewNN6I+HvEEcVhrKLB9jlhiZTH9nZirDgnnOeue9W9Ulkup5M2MKCS1jc7SRtBPXLHn681W1qGNQkLkhhgpOy4Eidz0z14qK0wNShBui0axqC2C5x6ADP5GuFRUlF9UcdOlGoqcr7Le29rO+/wCY1bSWG4a2URojoXIYnD4GeO4rNcrv6JBu+Vl+YjHr3rsLu80yTVJDp8srQ+UQs72wLg7emD79+1c7qVvEJYjFMhLxjzvMcBt/f/8AXWlOpd+8rXOyhUdSKdtXra1unXZ/iWLKyLRyzwTRt5MkRPDDdk8YH+OPar3jSWWXWpZr1GkeVDsE0TRGIknCqueg96zreaJoLnypWjnLRlAIhg7epyOFx+Oas69JDcOJ7fU5Lu+m/wBc7SYABzkfdHfHes3H96pPz/T+vwOevFzxkZNd0rL0e9vxv5FOTUJESZHMbFlQBYy2049f/wBdX4LyObw1dQS2byySTA+Y8p+WTaQDzxj2NVLOKKC2ure7u7UxyBSGjky2c54OD3xmn2umW6aRdXM97BJdK2yOFXVhyM7sk9c1UlS2fdd/0Na+Hpp2nFxSa/4Gvy9DKeKW3n8seWHKgnaQV/HtTraV0wiEmVThQANuO+TTltnLJAbi2ww3bjINq5569j2q1CLdL1ftS2/kxjJMRyG/nk/lWrkrWep3yU6MXVirW6XIdQt0t4hIzQ+bJyUjIYfoTj8/wqTTfO2go0eZ1YFSMg445C8g+lS3K2dxYiQTSBxO+UCZCx4G0/8A1s0WLRRxTR3B/dPhhLs3kEA8HHQGkndcoqMpyi6z0av/AF89vMZe6fc2oYLAAywiZ9ob5FJxzn39aguQYI490K5f7pByrfXB5Iq+8UM0cos7yyiRoQsiOrJznnHy/Tmq+sLGHggtpBLGgJKqfkB4Pyn+dEZO9mcdOpzySteS+X4dSnMC88Ij8szH7y9t3vuAA+nSrcCTyzci3IAwxbOBxxkD9MU0K11ppWKOP91Jl8DLquOuf7vt61qwy6fvhWK4iVI04YwkOWI5wfrS5/ssfPOlG1nZ3/Dz+duhBpbS22oW8V2kNzEki7UJ29+oAHI9uRV6505Gsrq58iFxDIWJlZ1XDNgADIHHtVGCRYr6Fxdhi0yuVcbtreu0jr74rQ1PyRaSPBfyyNcNhxK6R5wQcYz0Has5JJ9n8zCtGpVmnfWVktXt2/OxN8MVtpPHvh4eVAG/tO2KtHvY8SLwATgL6k5NfojB95/rX56/DjZB8TPD8s0sShr+BRtk3YJkXAwOma/QqD7z/Wumma+ydKTi73Ob8O/8j34u/wC3P/0Ua6quV8O/8j34u/7c/wD0Ua6qtSgooooAKKKKACiiigAooooAKKKKACiiigAooooAqXH+tNYXijXE0Sy3KEkvJQRDGxwOOrseyL1J/Dqa27+VIFeWVtsaLuY+gFeBeJdRuPFfieSwguI7eOQ/v53bCxRr/D9B6fxMSfTHZhaKqO8tkcGNryppQp/FL+rmVfXk/ibWGh+1E24fzLm6c7TIfUDtxwq9h+NXdWtjb3CXulSnz7JhLC2/c+xTxuOBkr9OV+hrurPwT4Hito0e53OB8zfbiMn1wDipJfCnhK3ikl0u8SO+VSYWkvSy7sdGBOCD0Psa9BYuF7JO3oefUy58l01zLW/W52vh/VI9a0Wz1GHAW4jDFR/C3Rl/Agit5fuj6V5V8Jb5YZ9R0dSfJOLy2BOcK3Dr+Bx+terDpXlYin7Obievha3tqSn3CiiisDoCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArzT9o5ZH+DniFYAxkKRYC9f9clel1leJ9A07xNo1xpOtW4udPuABLCWKhsMGHIIPUA0mrqwPyPzojtXurkrHLLK0hCCWQmMAHgg5/ljmrcMNzDqUj3F3b262UaoWhfY5UHA2jgMfrxX2pL8C/h3M5aTw7CzHuZ5v/i6JPgX8PJWjaTw7ExRQi5uJuAOg+/XNKhKT1ZVW09n+C+evmvWzPi2doLXXLa4sLwyGdSCUtWj2k8cAnn3qhrbPFfzRyizn2uXZj95znGev6Cvt9PgR8O0cOnh5FYdxczZ/wDQ6kPwP+H5bcdAUt/eNzNn6539aSw7TTvey/rYxUXGmqSd0vv8trLReR8LW175UeTagE9NhYH/AIFg8+2ajmWd3dyrT5HmF/KJVV/HnFfdc3wL+Hkz7pfD6M3/AF8zf/F1IvwS8AKSV0CPcRt3/aJt2PrvzV+ya1Rsmled/etZHwJGs4b/AFIbdwQ6nn0+ntV1be8jtZo5YbtT1VNh6Y+9mvvVPg74ISCWH+xt0UuNwa6mbocjGX4/CoH+CPgCSWOSbQhM0eNvm3U7gY9i/T2p8s29kKnUmn766vr5ene/c+FbmwNhasLtYDJKitGOu3ODkkHg4qALEFQktGEBCzJGTvHq3P4cV91P8Bvhw7sx8NxZJzxcTAflvp//AAov4d+UIx4di2Dpi4m/+LoVKVtXqZwpq3vvXy/yf9dT4l1eOO10uGWO7jnR0U+U/wAwyQCSF7H60/SY0u7q6maUHcB5QZdkbfLgnBPUHpX2oPgP8OQGA8ORYbr/AKRNz/4/Vhvgl4BaPyzoKFP7puJsH/x+s/q8lG19TZSS5Yq6it0n8Xd+T9P1PiG5s512SSRwTHfsLBgX/EEkY+tA0mdrixtpWtFjZJWjZWXt1BII719sf8KJ+HPOfDcByMczSn/2elb4F/Dsgf8AFOQjt8s8wJ+uHp+xnayf4F1KkG+aMdfPv39LXVvO9z4xvPDxi09pLi+s/wB2hbyowMgenBzn6ilGnGeQPNqayvHGDHE4AXG3tzjP619mP8Cfh24QP4djOwbV/wBIm4Hp9+lHwK+HQVV/4RuDC5x+/m/X5+ahYeolrLX0RpSrUbJ1aautrNrr8+mn6Xdz4pKRxizb7ZcpJdSq20x4KZyPvMSe1SWFvdXdvOI5muIo5GDRzKD5nPGMnt14xX2p/wAKO+HvmI48PRKyjA2zzAY64+/SH4G/D7fv/sEBs5yLqcf+z1bozs0mZL2NndO3RX2079NdT5C8Cxx23xG8N/aZ45Ln+0LcFZISHH7xeSeufrX6Bwfek+tcBafBfwJaX9pe2+hIt1ayrNDIbiYlXU5U8vzgjvXRah4i/sy/mtv7G1u724/fW1pvjbIB4OeeuPqK2pwcFZsxjflSlq11IPDv/I9+Lv8Atz/9FGuqrkPBj3F54j8SalLp99Y29y1usQu4vLZ9kZDHGTxmuvrQYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcD8YtZ/snw6saNiW5JA/3V5P6la4Pw94A8SQ2okt7jT4XnVJpBIz7hkZCnC9QK6r45WiyWWkXZBbyJmBQfxDAYj8lrmE8Waso/1OtZJyTtl5P5V61BSVCPs+t7nkVGpYmftFe1kvuv+Zq/8IZ4u/6COmf99yf/ABNH/CGeLv8AoI6Z/wB9yf8AxNZn/CXav/zw1r/vmX/Cj/hL9XwSYdawP9mX/CrtW7or91/KxmjWGo+FfiXpMepSQu92SC0JJUiTKnqB/EAa94r598Pau/if4g6C8jTSJBJw0jFicZbv24r6Crlx9+aPNvYrLLJVFH4ebT7k/wAwooorgPTCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA4j4wW7yeD2uI03taTJMR/s8q34YasTw98QR/ZsENzA0kscY/fGcIJFHGee46H3+tem3UEV1bS29wgkhlUo6N0YHgiuGX4X+HGt5rTfdvGSGKGYEofUcZHH512UatL2fs6q2eh52IoVlWVag91ZowdS+MWn2rPHb2E91MBx5c4KZ92x/LNcRrPi3xR4xJtQTbWbdbe1yoI/239PqQPavV7L4VeGrWTeIrmTHQSSAj8gOfxrodN8MaZp+DFEXIOV34wv0UAKPrjNbRr4alrCN2ROli6vutpI4r4V+DDpVwuoXiAPGhEK46s33n9hj5R9Se4r1CmJGEJIzz60+uKtVdafNI7sPQjQgoRCiiisjYKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvGPF1rfHxvrt2tvcCziurDddwhzLAnljc0YHBGRg9cccV7PRQcuLwqxMVFu1nf8ABr9TzbUdY8Qnxi8MdybW0FzEsCGJmSeBgNxG2FsscnneAMcjHNYumprGi6BFc2hnRr7UJxfXXkhZVVWfYWZYnbBJJyVbGcDANex1xPibx4mhatd2baeZ0tYo5ZHFwqMQ5wAqkfMfbNBxYjDql+9q1Wt7b6X1/JW9Cp4fvvEWo6rpVtcakUh/s9rieWO0wszrPtH30UjKew9QOhrDt/EHiwRX8s9w8V2tvcF7RoGYxuoJjKDyQoAwOrtuz68V1Wq+PbXTNb1LTri0kU2lqbhJS2FkbyzII+nysQGx9Kdrfjq20lNGeW1kdb6JLiYq/FrExRd7ccjL4/CgiXs7P9+1y77+S79/zZiXGpeKbFNTjhubm+kNlbXMbm1UtCzviTaqqA2FycHPT84dX1nWI47ZNI1W/m05mlBv7i2MbLIFTahIgbK5JP3BnkbuK9SooOqWCm1ZVH+Pe/f5FDQZri40SxmvGV7l4UaRlRkDNjkhWAIz6ECr9FFB3RVkkwooooKCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArkPEHgWy1rVLrUJriaK6lSIRSRgBoHjOQ6n1rr6KDKrRhWXLUV0cjqvge11aPVxqFzJJLqKW4aQIAY3iUgOv13HI9yKhuvh7p16tx9vuLmdntIrOIiRkEKIuBwpAbLfNhsjNdpRQZPBUJauN/6f+bKumWrWWnWtq8zTtDGsZlYYL4GMn3q1RRQdKSSsgooooGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    One approach to gene expression profiling is illustrated here. A) RNA from a tumor and reference sample is processed, fluorescently labeled, and hybridized to a microscope-sized chip, to which probes for thousands of genes have been affixed. B) The red (relative overexpression in tumor) and green (relative underexpression in tumor) intensities can be analyzed simultaneously. C) Depending on the supervision of the analysis, tumors can be subtyped (as shown here), or can be analyzed for gene sets associated with clinical outcome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_39_14967=[""].join("\n");
var outline_f14_39_14967=null;
var title_f14_39_14968="Fascioliasis life cycle";
var content_f14_39_14968=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F50779&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F50779&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 608px\">",
"   <div class=\"ttl\">",
"    Fascioliasis life cycle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 588px; height: 477px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Immature eggs are discharged in the biliary ducts and in the stool",
"    <strong>",
"     (1)",
"    </strong>",
"    . Eggs become embryonated in water",
"    <strong>",
"     (2)",
"    </strong>",
"    , eggs release miracidia",
"    <strong>",
"     (3)",
"    </strong>",
"    , which invade a suitable snail intermediate host",
"    <strong>",
"     (4)",
"    </strong>",
"    , including the genera",
"    <em>",
"     Galba",
"    </em>",
"    ,",
"    <em>",
"     Fossaria",
"    </em>",
"    , and",
"    <em>",
"     Pseudosuccinea",
"    </em>",
"    . In the snail, the parasites undergo several developmental stages (sporocysts",
"    <strong>",
"     (4a)",
"    </strong>",
"    , rediae",
"    <strong>",
"     (4b)",
"    </strong>",
"    , and cercariae",
"    <strong>",
"     (4c)",
"    </strong>",
"    ). The cercariae are released from the snail",
"    <strong>",
"     (5)",
"    </strong>",
"    and encyst as metacercariae on aquatic vegetation or other surfaces. Mammals acquire the infection by eating vegetation containing metacercariae. Humans can become infected by ingesting metacercariae-containing freshwater plants, especially watercress",
"    <strong>",
"     (6)",
"    </strong>",
"    . After ingestion, the metacercariae excyst in the duodenum",
"    <strong>",
"     (7)",
"    </strong>",
"    and migrate through the intestinal wall, the peritoneal cavity, and the liver parenchyma into the biliary ducts, where they develop into adults",
"    <strong>",
"     (8)",
"    </strong>",
"    . In humans, maturation from metacercariae into adult flukes takes approximately three to four months. The adult flukes (",
"    <em>",
"     Fasciola hepatica",
"    </em>",
"    : up to 30 mm by 13 mm;",
"    <em>",
"     F. gigantica",
"    </em>",
"    : up to 75 mm) reside in the large biliary ducts of the mammalian host.",
"    <em>",
"     Fasciola hepatica",
"    </em>",
"    infect various animal species, mostly herbivores.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. Parasites and Health: Fascioliasis. Available at:",
"     <a href=\"file://www.dpd.cdc.gov/dpdx/html/fascioliasis.htm\" target=\"_blank\">",
"      file://www.dpd.cdc.gov/dpdx/html/fascioliasis.htm",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_39_14968=[""].join("\n");
var outline_f14_39_14968=null;
var title_f14_39_14969="AVNRT via Mahaim pathway";
var content_f14_39_14969=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F58895&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F58895&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 561px\">",
"   <div class=\"ttl\">",
"    AVNRT via Mahaim pathway",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 541px; height: 304px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The QRS complexes in this extremely rapid (approximately 450 beats/min) and regular tachycardia are widened or aberrant. The mechanisms for the arrhythmia include an atrioventricular nodal reentrant tachycardia with aberration or an antidromic atrioventricular reentrant tachycardia (AVRT) in a patient with the Wolff-Parkinson-White syndrome and antegrade conduction to the ventricle via a Kent pathway. At electrophysiologic testing, the etiology was determined to be an AVNRT with antegrade conduction to ventricle via an atriofascicular (Mahaim) accessory pathway.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_39_14969=[""].join("\n");
var outline_f14_39_14969=null;
var title_f14_39_14970="Epidemiology and clinical features of basal cell carcinoma";
var content_f14_39_14970=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology and clinical features of basal cell carcinoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/39/14970/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/39/14970/contributors\">",
"     Peggy A Wu, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/39/14970/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/39/14970/contributors\">",
"     Robert S Stern, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/39/14970/contributors\">",
"     June K Robinson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/39/14970/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/39/14970/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/39/14970/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 17, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Basal cell carcinoma (BCC) is a common skin cancer arising from the basal layer of epidermis and its appendages. These tumors have been referred to as \"epitheliomas\" because of their low metastatic potential. However, the term carcinoma is appropriate, since they are locally invasive, aggressive, and destructive of skin and the surrounding structures including bone (",
"    <a class=\"graphic graphic_picture graphicRef68274 graphicRef81632 \" href=\"UTD.htm?6/30/6632\">",
"     picture 1A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The epidemiology, pathogenesis, clinical presentation, and differential diagnosis of BCC will be reviewed here. The treatment and prognosis of BCC are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/23/13690?source=see_link\">",
"     \"Treatment and prognosis of basal cell carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/8/24712?source=see_link\">",
"     \"Treatment of basal cell carcinomas at high risk for recurrence\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estimates of the incidence of BCC are imprecise since there is no cancer registry that collects data on BCC. The American Cancer society estimates that more than two million nonmelanoma skin cancers were treated in the United States in 2006, of which the majority would have been BCC [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/1\">",
"     1",
"    </a>",
"    ]. A population-based study with several methodological limitations estimated a higher number of lesions, reporting that approximately 3.5 million nonmelanoma skin cancers were treated in the United States during the same year [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, an incidence-based mathematical model supports a high prevalence of nonmelanoma skin cancer in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/3\">",
"     3",
"    </a>",
"    ]. According to the model, approximately 13 million white non-Hispanic individuals living in the United States in 2007 may have had a personal history of at least one nonmelanoma skin cancer. &nbsp;",
"   </p>",
"   <p>",
"    Individuals with a history of BCC are at increased risk for subsequent lesions. Approximately 40 percent of patients who have had one BCC will develop another lesion within five years [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/23/13690?source=see_link&amp;anchor=H36#H36\">",
"     \"Treatment and prognosis of basal cell carcinoma\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Multiple epidemiologic observations provide insights into the etiology of BCC:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      BCC is particularly common in Caucasians; it is very uncommon in blacks and other dark-skinned populations. In white populations in the United States, the incidence of BCC has increased by more than 10 percent per year, and the lifetime risk of developing a BCC is 30 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/6\">",
"       6",
"      </a>",
"      ]. An increasing incidence over time has also been noted in other countries, such as Canada, Finland, and Australia [",
"      <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/7-9\">",
"       7-9",
"      </a>",
"      ]. Of greater concern, there may be an increasing incidence of aggressive-growth histologic subtypes, which are more difficult to treat [",
"      <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The incidence in men is 30 percent higher than in women, particularly with the superficial type [",
"      <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/7,11,12\">",
"       7,11,12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There is striking geographic variation in incidence. States closer to the equator, such as Hawaii and California, have an incidence of BCC at least twice that of the Midwestern United States [",
"      <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/12,13\">",
"       12,13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There are also prominent global variations in incidence. Northern European countries, such as Finland, have an incidence one-fourth that of the Midwestern United States. This contrasts with Australia where rates are 40 times that of Finland [",
"      <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/7,8,11\">",
"       7,8,11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The incidence of BCC increases with age; persons aged 55 to 75 have about a 100-fold higher incidence of BCC than those younger than 20 [",
"      <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/14\">",
"       14",
"      </a>",
"      ]. Although increasing longevity may underlie some of the increasing incidence of BCC, the incidence of BCC among Americans younger than 40 also appears to be increasing, particularly among women [",
"      <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both environmental and genetic factors contribute to the development of BCC. Exposure to ultraviolet (UV) radiation in sunlight is the most important. Other established risk factors include chronic arsenic exposure, therapeutic radiation, immunosuppression, and the basal cell nevus syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     UV light exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sun exposure is the most important environmental cause of BCC, and most risk factors relate directly to a person's sun exposure habits or susceptibility to solar radiation. These risk factors include having fair skin, light-colored eyes, red hair, northern European ancestry, older age, childhood freckling, and an increased number of past sunburns [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. The use of tanning beds, particularly among young women, may place them at risk for early development of BCC [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. As an example, a cohort study of approximately 73,000 female nurses found that women who used tanning beds more than six times per year during high school or college were more likely to develop BCC than women who did not use tanning booths during these time periods (adjusted hazard ratio 1.73, 95% CI 1.52-1.98) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/21\">",
"     21",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    A contribution of ultraviolet light exposure from indoor tanning to BCC is also suggested by the results of a 2012 meta-analysis of observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/22\">",
"     22",
"    </a>",
"    ]. Subjects with a history of any tanning bed use were more likely to develop BCC than those who had never used tanning beds (relative risk 1.29, 95% CI 1.08-1.53). The relative risk for BCC for individuals who began tanning prior to age 25 was 1.40 (95% CI 1.29-1.52).",
"   </p>",
"   <p>",
"    The type, quantity, and timing of sun exposure associated with an increased risk of BCC are not clearly defined. Childhood sun exposure appears to be more important than exposure during adult life [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/16,23\">",
"     16,23",
"    </a>",
"    ]. Evidence supporting this hypothesis comes from case control studies and clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/17-19,23\">",
"     17-19,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a Canadian case control study that included 226 men with BCC and 406 age-matched controls, the development of BCC was strongly correlated with childhood and adolescent sun exposure but",
"    <strong>",
"     not",
"    </strong>",
"    cumulative or recent sun exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/23\">",
"     23",
"    </a>",
"    ]. In other studies, however, adult sun exposure also was a risk factor for BCC [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The frequency and intensity of sun exposure may also be important. Solar exposure in intermittent, intense increments increases the risk of BCC more than a similar dose delivered more continuously over the same period of time [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/24\">",
"     24",
"    </a>",
"    ]. Evidence in renal transplant recipients provides additional support to the concept that acute or intermittent sun exposure increases the risk of BCC [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34170?source=see_link&amp;anchor=H14#H14\">",
"     \"Development of malignancy following solid organ transplantation\", section on 'Sun exposure and skin cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional, indirect support for an important role for sun exposure is derived from a large, nested case-control study of female nurses [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/26\">",
"     26",
"    </a>",
"    ]. In the study, a contributory role of extensive sun exposure was suggested by the finding that women in the highest quartile for baseline serum vitamin D levels were at greater risk for the subsequent development of BCC than women in the lowest quartile (OR 2.07, 95% CI 1.52-2.80). The authors proposed that the plasma vitamin D level was a potential indicator of the degree of long-term sun exposure.",
"   </p>",
"   <p>",
"    It has been estimated that aggressive sun protection before the age of 18 years could reduce the number of nonmelanoma skin cancers by almost 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/27\">",
"     27",
"    </a>",
"    ]. Several trials provide evidence that sunscreen use decreases the incidence of SCCs and that there are no adverse effects from sunscreen use [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. However, a randomized trial evaluating the effects of sunscreen and the antioxidant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"     beta-carotene",
"    </a>",
"    over a four-year period found that those using topical sunscreen had a 40 percent reduction in SCCs but no decrease in BCCs [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18073?source=see_link\">",
"     \"Primary prevention of melanoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18073?source=see_link&amp;anchor=H10#H10\">",
"     \"Primary prevention of melanoma\", section on 'Status of sun protection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Therapeutic exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapeutic exposure to psoralen plus ultraviolet A light (PUVA) for cutaneous disorders such as psoriasis increases the risk of nonmelanoma skin cancer, particularly SCC [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/31\">",
"     31",
"    </a>",
"    ]. The risk of BCC in patients treated with PUVA is lower than the risk for cutaneous SCC. A 20-year prospective cohort study documenting the incidence of nonmelanoma skin cancer in patients given PUVA for psoriasis revealed that a significant increase in the incidence of BCC occurred only in patients who received very high levels of PUVA (&ge;337 treatments) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Broad band ultraviolet B (UVB) and narrow band UVB phototherapy appear to be less likely to promote the development of nonmelanoma skin cancer than PUVA [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/32\">",
"     32",
"    </a>",
"    ], but further research is necessary to determine the true carcinogenic potential of these therapies. Although some observational studies have reported a small increased risk for BCC after UVB therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/33,34\">",
"     33,34",
"    </a>",
"    ], others have reported no increased risk [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/35-38\">",
"     35-38",
"    </a>",
"    ]. As an example, in a retrospective study of 3867 phototherapy patients (of which 352 received &ge;100 narrow band UVB treatments) narrow band UVB was not associated with an increased risk of BCC, except in cases where patients were treated with both narrow band UVB and PUVA [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Chronic arsenic exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Superficial multicentric BCC occurs 30 to 40 years after chronic exposure of arsenic, which may occur as a result of ingesting contaminated drinking water, seafood, or medications [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8730?source=see_link&amp;anchor=H8#H8\">",
"     \"Arsenic exposure and poisoning\", section on 'Chronic toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Ionizing radiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Superficial therapeutic ionizing radiation, as for facial acne, psoriasis, or tinea capitis, increases the risk of nonmelanoma skin cancer, including BCC [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. The latency period for development of BCCs is about 20 years, and lesions are limited to sites within the radiation field. Due to the advent of other effective therapies, the use of ionizing radiation for the treatment of inflammatory skin conditions has declined.",
"   </p>",
"   <p>",
"    Ionizing radiation used to treat childhood cancers also increases the risk for the subsequent development of BCC. This was illustrated in a study of 776 subjects, five of whom developed BCCs, approximately 10-fold more than was expected in this population [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/45\">",
"     45",
"    </a>",
"    ]. All of the BCCs were located within the radiation field. In addition, a case-control study of 199 patients with a history of both childhood cancer and BCC and 597 controls with a history of childhood cancer without BCC found a linear dose-response relationship between the radiation dose and risk for BCC [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/46\">",
"     46",
"    </a>",
"    ]. An increase in risk was detected among patients who received at least 1 Gy of radiation to the skin, and patients who received 35 Gy or more were 40 times more likely to develop BCC than those who were not treated with radiation (odds ratio 39.8, 95% CI 8.6-185). The treatment of other noncutaneous disorders with radiation therapy, such as thymic enlargement in infancy and ankylosing spondylitis, as well as the use of radiation therapy for myeloablative conditioning prior to hematopoietic stem cell transplantation, have also been associated with the appearance of BCC [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/43,47,48\">",
"     43,47,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies of survivors of the atomic bomb explosions in Japan support the role of exposure to ionizing radiation in the development of BCC [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/49-52\">",
"     49-52",
"    </a>",
"    ]. In a retrospective study of bomb survivors, the incidence of subsequent BCC increased with proximity to the hypocenter of the explosion [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Immunosuppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic immunosuppression (as occurs with solid organ transplantation and with human immunodeficiency virus [HIV] infection) may increase risk for the development of BCC, although the increase in risk is less than that observed for SCC [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. The risk for BCC after solid organ transplantation appears to increase linearly over time, whereas the risk for SCC rises exponentially [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/53\">",
"     53",
"    </a>",
"    ]. As in other populations, sun exposure, phenotype, and other factors influence the likelihood that an organ transplant recipient will develop BCC [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37832?source=see_link&amp;anchor=H7860393#H7860393\">",
"     \"Epidemiology and risk factors for skin cancer in solid organ transplant recipients\", section on 'Squamous cell and basal cell carcinoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The increased risk for skin cancer in organ transplant recipients is thought to be related to chronic exposure to immunosuppressive agents [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. The specific impact of systemic glucocorticoid therapy on BCC risk is uncertain; studies performed in patients without a history of organ transplantation conflict on whether systemic glucocorticoid therapy significantly increases risk for BCC [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/57-60\">",
"     57-60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Support for an increased risk for BCC among HIV-positive individuals was demonstrated in a retrospective cohort study of HIV-positive (n = 6560) and HIV-negative (n = 36,821) non-Hispanic white patients in a northern California healthcare system. The study found that patients with HIV infection were approximately twice as likely to develop BCC than patients without HIV infection (adjusted rate ratio 2.1, 95% CI 1.8-2.3) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Genetic variants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic variation may play a role in susceptibility to BCC. Some gene sequence variants that are affiliated with increased risk of BCC correlate with light skin pigmentation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/61\">",
"     61",
"    </a>",
"    ]. In addition, genome-wide association studies have identified genetic variants that may influence BCC risk through other pathways, such as an effect on the growth or differentiation of basal layers of the epidermis or an effect on the P53 tumor suppressor gene [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/62-65\">",
"     62-65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Genes that affect the immune response may also impact susceptibility to BCC. Cytotoxic lymphocyte-associated antigen-4 (CTLA-4) is expressed on regulatory T cells and is involved in UV-induced immune tolerance. In a case-control study, genetic variation at the CTLA4 locus influenced the risk of BCC, particularly among patients with a higher number of severe sunburns [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2896064\">",
"    <span class=\"h2\">",
"     Blood type",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood type may slightly influence the risk for BCC. In a cohort study of 71,000 women and 25,000 men, the risk of developing BCC was 4 percent lower among patients with A, AB, or B blood types compared to those with type O blood (HR 0.96, 95% CI 0.93-0.99) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/67\">",
"     67",
"    </a>",
"    ]. The reason for this observation is unknown, and additional studies are necessary to confirm this finding. Associations between blood type and risks for SCC and pancreatic cancer also have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/13/27866?source=see_link&amp;anchor=H8#H8\">",
"     \"Epidemiology and risk factors for exocrine pancreatic cancer\", section on 'Other inherited risk factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/56/25482?source=see_link&amp;anchor=H45395983#H45395983\">",
"     \"Epidemiology and risk factors for cutaneous squamous cell carcinoma\", section on 'ABO blood group'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Inherited disorders",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Basal cell nevus syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The basal cell nevus syndrome (nevoid basal cell carcinoma syndrome, Gorlin syndrome) is a rare disorder of autosomal dominant inheritance that is due to germline mutations of the human patched gene (PTCH). Affected patients have both developmental anomalies and postnatal tumors, especially multiple BCCs, usually by age 35. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/5/44121?source=see_link\">",
"     \"Nevoid basal cell carcinoma syndrome\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H18\">",
"     'PTCH1 gene'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Most have the following clinical features:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Macrocephaly, frontal bossing, and hypertelorism",
"     </li>",
"     <li>",
"      Bifid ribs",
"     </li>",
"     <li>",
"      Palmar and plantar pitting (",
"      <a class=\"graphic graphic_picture graphicRef72687 \" href=\"UTD.htm?25/24/25989\">",
"       picture 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Bone cysts, especially in the mandible",
"     </li>",
"     <li>",
"      Calcification of the falx cerebri",
"     </li>",
"     <li>",
"      Medulloblastoma (typically the desmoplastic subtype) in 3 to 5 percent (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/23/41332?source=see_link\">",
"       \"Histopathology and molecular pathogenesis of medulloblastoma\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The histologic appearance of the BCCs in basal cell nevus syndrome does not differ from those seen in sporadic cases. The diagnosis should be suspected in patients who present with multiple BCCs, especially when these occur at an early age and are located on the trunk.",
"   </p>",
"   <p>",
"    These patients require aggressive approaches to therapy and frequently are disfigured from surgical treatments by the third decade of life.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Epidermolysis bullosa",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidermolysis bullosa (EB) syndromes are a group of mechanobullous skin diseases that share a common feature of blister formation occurring with little or no trauma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24586?source=see_link&amp;anchor=H13#H13\">",
"     \"The genodermatoses\", section on 'Epidermolysis bullosa'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Dowling-Meara simplex form of EB is associated with an increased risk for basal cell carcinoma during mid-adulthood, with a cumulative risk of 8 percent by age 40 years and 44 percent by age 55 years [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8406955\">",
"    <span class=\"h2\">",
"     Nevus sebaceus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nevus sebaceus is an uncommon congenital hamartoma of the skin composed of epidermal, follicular, sebaceous, and apocrine elements. BCC may develop within nevus sebaceous, though this occurrence is rare. In a retrospective study of 596 nevus sebaceous excisions from adults and children, BCC was detected in specimens from five adults (0.8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/70\">",
"     70",
"    </a>",
"    ]. A separate review of 631 children with 651 lesions of nevus sebaceous found that BCC may also develop within nevus sebaceous in children; BCC was found in excisional specimens from five patients (0.8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/71\">",
"     71",
"    </a>",
"    ]. (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/13/22745?source=see_link&amp;anchor=H20#H20\">",
"     \"Benign skin and scalp lesions in the newborn and young infant\", section on 'Nevus sebaceus of Jadassohn'",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Actinic keratosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Actinic keratoses are cutaneous lesions that are associated with sun exposure, and occasionally progress to squamous cell carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/72\">",
"     72",
"    </a>",
"    ]. A study assessing the natural history of actinic keratoses suggested that actinic keratoses may also progress to BCC [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/73\">",
"     73",
"    </a>",
"    ]. However, the diagnosis of actinic keratosis was not confirmed histologically in this study, and it is conceivable that lesions initially diagnosed as actinic keratoses may have represented early BCCs. Thus, sufficient data are not yet available to conclude whether actinic keratoses are capable of progression to BCC. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/49/18200?source=see_link\">",
"     \"Epidemiology, natural history, and diagnosis of actinic keratosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Lifestyle factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Smoking increases the risk of SCC [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/5\">",
"     5",
"    </a>",
"    ] and has been evaluated for an association with BCC [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/19,74\">",
"     19,74",
"    </a>",
"    ]. Although a case-control study performed in 333 disease-discordant twin pairs found an increased risk of BCC in smokers and in females compared to males [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/74\">",
"     74",
"    </a>",
"    ], a subsequent meta-analysis failed to find a significant association between BCC and smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other lifestyle factors that are possibly associated with increased risk for BCC include higher education and coffee consumption [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/74\">",
"     74",
"    </a>",
"    ]. Additional studies are needed to confirm these findings before firm conclusions can be drawn.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H371909\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although some studies suggest that eczema may be a risk factor for BCC [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/76,77\">",
"     76,77",
"    </a>",
"    ], other studies have failed to find statistically significant associations between these conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/74,78,79\">",
"     74,78,79",
"    </a>",
"    ]. The relationship between eczema and risk for BCC remains uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary approach to the prevention of BCCs is protection from sun exposure. The various techniques to minimize solar exposure are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/27/30136?source=see_link\">",
"     \"Sunburn\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Data conflict on the impact of nonsteroidal antiinflammatory drugs (NSAIDs) on the risk for BCC [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/80-83\">",
"     80-83",
"    </a>",
"    ]. The results of an 11-month randomized trial suggested that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    (a cyclooxygenase-2 inhibitor) may be beneficial for chemoprevention. In this trial of 240 patients with actinically damaged skin, patients treated with celecoxib (200 mg twice daily for nine months) developed fewer BCCs than patients who were given placebo (adjusted rate ratio = 0.40, 95% CI 0.18 to 0.93) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/84\">",
"     84",
"    </a>",
"    ]. In contrast, a Norwegian population-based case-control study failed to find an association between the use of celecoxib or other prescription NSAIDs and overall risk for BCC [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/85\">",
"     85",
"    </a>",
"    ]. Additional studies are necessary to explore the efficacy and safety of NSAIDs in the prevention of BCC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     MOLECULAR PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the causative role of UV irradiation in the pathogenesis of BCC, genetic factors influence the risk and manner of presentation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     UV-induced inflammation",
"    </span>",
"    &nbsp;&mdash;&nbsp;UV light induces inflammation of the skin that clinically results in visible erythema. On a molecular level, prostaglandin synthesis is markedly increased [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/86\">",
"     86",
"    </a>",
"    ], in part through induction of cyclooxygenase-2 (COX-2) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/87\">",
"     87",
"    </a>",
"    ]. Two isoforms of COX exist: COX-1 appears to be constitutively expressed, while COX-2 is highly regulated and induced by inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/88\">",
"     88",
"    </a>",
"    ]. The key role of COX in the skin is highlighted by in vivo murine studies of UV-induced skin carcinogenesis, in which selective COX-2 inhibitors markedly decrease the incidence of both SCC [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/89,90\">",
"     89,90",
"    </a>",
"    ] and BCC [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/89,91\">",
"     89,91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     PTCH1 gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our understanding of the pathogenesis of BCC was greatly enhanced with the discovery of mutations in the tumor suppressor gene, patched 1 (PTCH1), on chromosome 9 in patients with the familial basal cell nevus syndrome. Subsequently, acquired mutations in PTCH1 were also identified in both sporadic BCC and BCC associated with xeroderma pigmentosum. In a manner similar to the retinoblastoma gene, two somatic \"hits\" in the same cell are required for sporadic cases, while one somatic \"hit\" plus the inheritance of one defective allele is responsible for the familial cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/5/44121?source=see_link\">",
"     \"Nevoid basal cell carcinoma syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/56/25482?source=see_link&amp;anchor=H16#H16\">",
"     \"Epidemiology and risk factors for cutaneous squamous cell carcinoma\", section on 'Xeroderma pigmentosum'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The only known function of the PTCH proteins is as a receptor for the hedgehog (HH) protein, an important component of the sonic hedgehog (SHH) signaling pathway that directs embryonic development of a variety of organs (",
"    <a class=\"graphic graphic_figure graphicRef69105 \" href=\"UTD.htm?13/37/13904\">",
"     figure 1",
"    </a>",
"    ). SHH signaling activates a receptor complex that is formed by PTCH and a second protein, smoothened (SMO), thus activating the SHH pathway. PTCH-induced repression of SMO limits the effects of the SHH signal. Dysregulation in hedgehog signaling, through inactivating mutations in the PTCH gene or in the coreceptor SMO, lead to constitutive overexpression of the SHH signal, which has been implicated in the development of BCC and other tumors. However, the mechanism whereby SHH signal overexpression leads to tumorigenesis is unclear. One mediator may be activation of the transcription factors Gli1",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    Gli2. This topic, as well as the SMO inhibitor of the Hedgehog pathway",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/59/18357?source=see_link\">",
"     vismodegib",
"    </a>",
"    , are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/5/44121?source=see_link&amp;anchor=H3#H3\">",
"     \"Nevoid basal cell carcinoma syndrome\", section on 'Molecular pathogenesis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/61/14293?source=see_link&amp;anchor=H7#H7\">",
"     \"Systemic treatment of advanced cutaneous squamous and basal cell carcinomas\", section on 'Vismodegib'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Other genetic abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;P53 mutations are less frequent in BCCs than in cutaneous squamous cell cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/92,93\">",
"     92,93",
"    </a>",
"    ]. Their incidence in BCC is not much higher than that detected at baseline in the adjacent sun-exposed skin [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most BCCs remain localized, and the growth rate is variable. However, a few become locally aggressive or metastatic, and the acquisition of cytogenetic aberrations may be associated with aggressive biological behavior. In one series, for example, trisomy 6 was identified in none of 22 nonaggressive, two of four locally aggressive, and all four metastatic BCCs [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Truncal BCC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with truncal BCCs at initial presentation have other unique clinical characteristics. They tend to be younger, male, and have more clusters of BCCs compared to those with BCCs arising in sun exposed sites [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/96\">",
"     96",
"    </a>",
"    ]. Specific gene polymorphisms associated with the truncal phenotype and multiple clustering have been identified involving the detoxifying enzyme genes cytochrome P-450 CYP2D6 and glutathione S-transferase, and in the vitamin D receptor, and tumor necrosis factor [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/97-100\">",
"     97-100",
"    </a>",
"    ]. The link between these genetic polymorphisms, tumorigenesis, and the clinical phenotype is not clear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 70 percent of BCCs occur on the face, consistent with the etiologic role of solar radiation. Fifteen percent present on the trunk, and only rarely is BCC diagnosed on areas like the penis, vulva, or perianal skin.",
"   </p>",
"   <p>",
"    The clinical presentation of BCC can be divided into three groups, based upon lesion histopathology: nodular, superficial, and morpheaform.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Nodular",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nodular BCCs, which represent about 60 percent of cases, typically present on the face as a pink or flesh-colored papule. The lesion usually has a pearly or translucent quality and a telangiectatic vessel is frequently seen within the papule. Ulceration is frequent, and the term \"rodent ulcer\" refers to these ulcerated nodular BCCs (",
"    <a class=\"graphic graphic_picture graphicRef65704 graphicRef61190 graphicRef59407 \" href=\"UTD.htm?30/22/31081\">",
"     picture 3A-C",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Superficial",
"    </span>",
"    &nbsp;&mdash;&nbsp;About 30 percent of BCCs are superficial. These BCCs are most likely to occur on the trunk. Superficial BCC typically presents as a slightly scaly papule or plaque that is light red in color; the lesion may be atrophic in the center and usually is rimmed with fine translucent micropapules (",
"    <a class=\"graphic graphic_picture graphicRef57990 \" href=\"UTD.htm?16/50/17188\">",
"     picture 4",
"    </a>",
"    ). For unclear reasons, men have a higher incidence of superficial BCC than do women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Morpheaform",
"    </span>",
"    &nbsp;&mdash;&nbsp;Morpheaform or sclerosing BCCs comprise 5 to 10 percent of BCCs. These lesions are typically smooth, flesh-colored, or very lightly erythematous papules or plaques that are frequently atrophic; they usually have a firm or indurated quality with ill-defined borders (",
"    <a class=\"graphic graphic_picture graphicRef56527 \" href=\"UTD.htm?0/33/533\">",
"     picture 5",
"    </a>",
"    ). Some authors group morpheaform, infiltrative, and micronodular as \"aggressive-growth\" BCC, because they behave similarly [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/10\">",
"     10",
"    </a>",
"    ]. Infiltrative and micronodular subtypes are less common than the morpheaform BCC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Other subtypes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other BCC subtypes have been described. Basosquamous cell carcinoma is a rare tumor that behaves aggressively. It is probably best classified as a squamous cell carcinoma. Both nodular and superficial BCCs can produce pigment. These lesions are referred to as pigmented BCCs. Some lesions have a mixed histology and have features of more than one histologic subtype. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31209?source=see_link\">",
"     \"Treatment and prognosis of cutaneous squamous cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Multiple basal cell carcinoma syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several rare syndromes have been described that present with multiple BCCs. The most common is the basal cell nevus syndrome. Bazex syndrome is another rare disorder characterized by multiple BCCs and follicular atrophoderma [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/101\">",
"     101",
"    </a>",
"    ]. Rombo syndrome presents with atrophoderma vermiculatum and vellus hair cysts with milia-like appearance [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/102\">",
"     102",
"    </a>",
"    ]. Patients with xeroderma pigmentosum are at increased risk for BCC as well as squamous cell carcinomas and melanomas. The incidence of these malignancies for individuals under the age of 20 is approximately 2000 times that seen in the general population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/5/44121?source=see_link\">",
"     \"Nevoid basal cell carcinoma syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24586?source=see_link&amp;anchor=H523750964#H523750964\">",
"     \"The genodermatoses\", section on 'Xeroderma pigmentosum'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians who are familiar with the clinical manifestations of BCC are often able to make the diagnosis based upon clinical examination. A skin biopsy is usually performed to provide histological confirmation of the diagnosis.",
"   </p>",
"   <p>",
"    In cases in which the clinical diagnosis of BCC appears certain and the tumor lacks clinical features associated with a high risk for tumor recurrence, clinicians experienced in the diagnosis of BCC sometimes elect to perform the biopsy at the same time as definitive treatment (eg, immediately prior to electrodesiccation and curettage). In addition, some clinicians choose to treat lesions without a biopsy when high-risk clinical features are absent and the patient has a history of multiple similar low-risk BCCs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/8/24712?source=see_link&amp;anchor=H12329758#H12329758\">",
"     \"Treatment of basal cell carcinomas at high risk for recurrence\", section on 'Features associated with high risk for recurrence'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the decision not to perform a biopsy prior to definitive treatment is not without risk. Because the histological features of a tumor provide additional information on the risk for tumor recurrence following treatment, not performing a biopsy prior to definitive treatment may result in a failure to detect a tumor with aggressive histologic features that might be best managed with a different approach to therapy. The misdiagnosis of a different tumor as BCC (eg, amelanotic melanoma) is an additional risk of deferring a biopsy (",
"    <a class=\"graphic graphic_picture graphicRef62791 graphicRef51998 \" href=\"UTD.htm?23/1/23575\">",
"     picture 6A-B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/23/13690?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment and prognosis of basal cell carcinoma\", section on 'Approach to treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/8/24712?source=see_link&amp;anchor=H12329774#H12329774\">",
"     \"Treatment of basal cell carcinomas at high risk for recurrence\", section on 'Approach to treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    To reduce the risk for patient mismanagement, we suggest always performing a biopsy in the following situations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis is uncertain or the lesion exhibits features atypical for BCC",
"     </li>",
"     <li>",
"      The patient lacks a prior history of BCC",
"     </li>",
"     <li>",
"      The lesion exhibits clinical features suggestive of a BCC with a high-risk for recurrence",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Shave biopsies, punch biopsies, and excisional biopsies can be used for the diagnosis of BCC. Although shave and punch biopsies are frequently performed for diagnosis due to the simplicity of these procedures, clinicians should be aware that biopsies that remove only a portion of the lesion do not always provide an accurate assessment of the histological subtype of a tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/103-107\">",
"     103-107",
"    </a>",
"    ]. With punch biopsies, an aggressive histological subtype may be missed in up to 20 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/103-105\">",
"     103-105",
"    </a>",
"    ]. A retrospective study in which the majority of biopsy procedures were shave biopsies (230 shave biopsies and 27 punch biopsies) found that an aggressive histological subtype was missed in 7 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/106\">",
"     106",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40264?source=see_link&amp;anchor=H5#H5\">",
"     \"Skin biopsy techniques\", section on 'Biopsy techniques'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although biopsies are required for a definitive diagnosis, dermoscopy may be used to aid in the clinical evaluation of lesions that are suspicious for BCC [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/108-110\">",
"     108-110",
"    </a>",
"    ]. Common dermatoscopic features of BCC include, &ldquo;arborizing&rdquo; blood vessels (discrete, thickened, red blood vessels that branch like a tree) and blue-gray ovoid nests. In a retrospective study of 609 BCCs, these features were recognized in 57 and 48 percent of pathology specimens, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/108\">",
"     108",
"    </a>",
"    ]. Pigmented BCCs often demonstrate brown &ldquo;maple leaf&rdquo; shaped blotches on dermatoscopic examination, which represent heavily pigmented aggregates of tumor cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/11/13497?source=see_link\">",
"     \"Dermoscopic evaluation of skin lesions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/11/13497?source=see_link&amp;anchor=H610193#H610193\">",
"     \"Dermoscopic evaluation of skin lesions\", section on 'Criteria for basal cell carcinoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H371894\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis varies with the subtype of BCC:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early nodular variants with little ulceration clinically may be identical to benign growths such as dermal nevi, small epidermal inclusion cysts, or even sebaceous hyperplasia. A single lesion of molluscum contagiosum has a similar appearance, as does amelanotic melanoma.",
"     </li>",
"     <li>",
"      Larger lesions with central ulceration can appear cup-shaped. These can resemble squamous cell carcinoma, keratoacanthomas, or dermal metastases from internal organs such as the colon [",
"      <a class=\"abstract\" href=\"UTD.htm?14/39/14970/abstract/111\">",
"       111",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Superficial BCCs may not be rimmed by pearly micropapules. These lesions can be mistaken for contact or nummular dermatitis. Psoriatic plaques may not always present with characteristic micaceous scale. These minimally scaly lesions can imitate superficial BCC. The most difficult differential, however, is from lichenoid keratoses (inflamed seborrheic and actinic keratoses).",
"     </li>",
"     <li>",
"      Morpheaform BCCs frequently appear similar to a scar or other site of trauma. The induration of the lesion simulates localized scleroderma.",
"     </li>",
"     <li>",
"      Pigmented nodular or superficial BCCs resemble melanoma or less likely a benign nevus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/26/26018?source=see_link\">",
"       \"Patient information: Skin cancer (non-melanoma) (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/20/23874?source=see_link\">",
"       \"Patient information: Sunburn (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?18/30/18913?source=see_link\">",
"       \"Patient information: Sunburn (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basal cell carcinoma (BCC) is a common skin cancer arising from the basal layer of epidermis and its appendages. Although these tumors have a low metastatic potential, they are locally invasive and can be destructive of skin and the surrounding structures (",
"      <a class=\"graphic graphic_picture graphicRef68274 graphicRef81632 \" href=\"UTD.htm?6/30/6632\">",
"       picture 1A-B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      BCC is the most common malignancy of Caucasians, and its incidence is increasing worldwide. BCC has been linked to exposure to ultraviolet (UV) light, especially during childhood. Most other risk factors act through an interaction with UV exposure. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      About 70 percent of BCCs present on the face and head. The most common presentations for BCC are the nodular and superficial forms, which together account for about 90 percent of cases. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Biopsies are useful for confirming a diagnosis of BCC and determining the histological subtype of a tumor. A biopsy is particularly indicated in cases in which the diagnosis is uncertain, the patient lacks a history of BCC, the lesion exhibits features suggestive of an increased risk for tumor recurrence after treatment, or when the tumor exhibits atypical clinical features. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once the diagnosis is established, appropriate treatment offers a high probability of cure, although the patient remains at increased risk for additional skin malignancies. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/23/13690?source=see_link\">",
"       \"Treatment and prognosis of basal cell carcinoma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/8/24712?source=see_link\">",
"       \"Treatment of basal cell carcinomas at high risk for recurrence\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29443712\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Drs. David Wrone and Robert Stern, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     American Cancer Society Cancer Facts and Figures 2010. file://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-026238.pdf (Accessed on October 04, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/2\">",
"      Rogers HW, Weinstock MA, Harris AR, et al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol 2010; 146:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/3\">",
"      Stern RS. Prevalence of a history of skin cancer in 2007: results of an incidence-based model. Arch Dermatol 2010; 146:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/4\">",
"      Robinson JK. Risk of developing another basal cell carcinoma. A 5-year prospective study. Cancer 1987; 60:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/5\">",
"      Karagas MR, Stukel TA, Greenberg ER, et al. Risk of subsequent basal cell carcinoma and squamous cell carcinoma of the skin among patients with prior skin cancer. Skin Cancer Prevention Study Group. JAMA 1992; 267:3305.",
"     </a>",
"    </li>",
"    <li>",
"     American Cancer Society. Cancer facts and figures 2000. www.cancer.org.2001 (Accessed on March 08, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/7\">",
"      Hannuksela-Svahn A, Pukkala E, Karvonen J. Basal cell skin carcinoma and other nonmelanoma skin cancers in Finland from 1956 through 1995. Arch Dermatol 1999; 135:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/8\">",
"      Marks R, Staples M, Giles GG. Trends in non-melanocytic skin cancer treated in Australia: the second national survey. Int J Cancer 1993; 53:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/9\">",
"      Demers AA, Nugent Z, Mihalcioiu C, et al. Trends of nonmelanoma skin cancer from 1960 through 2000 in a Canadian population. J Am Acad Dermatol 2005; 53:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/10\">",
"      Wrone DA, Swetter SM, Egbert BM, et al. Increased proportion of aggressive-growth basal cell carcinoma in the Veterans Affairs population of Palo Alto, California. J Am Acad Dermatol 1996; 35:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/11\">",
"      Green A, Battistutta D, Hart V, et al. Skin cancer in a subtropical Australian population: incidence and lack of association with occupation. The Nambour Study Group. Am J Epidemiol 1996; 144:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/12\">",
"      Chuang TY, Popescu A, Su WP, Chute CG. Basal cell carcinoma. A population-based incidence study in Rochester, Minnesota. J Am Acad Dermatol 1990; 22:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/13\">",
"      Reizner GT, Chuang TY, Elpern DJ, et al. Basal cell carcinoma in Kauai, Hawaii: the highest documented incidence in the United States. J Am Acad Dermatol 1993; 29:184.",
"     </a>",
"    </li>",
"    <li>",
"     Scotto J, Fears TR, Fraumeni JF Jr, et al. Incidence of nonmelanoma skin cancer in the United States in collaboration with Fred Hutchinson Cancer Research Center. NIH publication No. 83-2433, U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, National Cancer Institute, Bethesda, MD 1983:xv. p.113.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/15\">",
"      Christenson LJ, Borrowman TA, Vachon CM, et al. Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. JAMA 2005; 294:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/16\">",
"      Vitasa BC, Taylor HR, Strickland PT, et al. Association of nonmelanoma skin cancer and actinic keratosis with cumulative solar ultraviolet exposure in Maryland watermen. Cancer 1990; 65:2811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/17\">",
"      van Dam RM, Huang Z, Rimm EB, et al. Risk factors for basal cell carcinoma of the skin in men: results from the health professionals follow-up study. Am J Epidemiol 1999; 150:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/18\">",
"      Zanetti R, Rosso S, Martinez C, et al. Comparison of risk patterns in carcinoma and melanoma of the skin in men: a multi-centre case-case-control study. Br J Cancer 2006; 94:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/19\">",
"      Boyd AS, Shyr Y, King LE Jr. Basal cell carcinoma in young women: an evaluation of the association of tanning bed use and smoking. J Am Acad Dermatol 2002; 46:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/20\">",
"      Ferrucci LM, Cartmel B, Molinaro AM, et al. Indoor tanning and risk of early-onset basal cell carcinoma. J Am Acad Dermatol 2012; 67:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/21\">",
"      Zhang M, Qureshi AA, Geller AC, et al. Use of tanning beds and incidence of skin cancer. J Clin Oncol 2012; 30:1588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/22\">",
"      Wehner MR, Shive ML, Chren MM, et al. Indoor tanning and non-melanoma skin cancer: systematic review and meta-analysis. BMJ 2012; 345:e5909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/23\">",
"      Gallagher RP, Hill GB, Bajdik CD, et al. Sunlight exposure, pigmentary factors, and risk of nonmelanocytic skin cancer. I. Basal cell carcinoma. Arch Dermatol 1995; 131:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/24\">",
"      Kricker A, Armstrong BK, English DR, Heenan PJ. Does intermittent sun exposure cause basal cell carcinoma? a case-control study in Western Australia. Int J Cancer 1995; 60:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/25\">",
"      Ramsay HM, Fryer AA, Hawley CM, et al. Factors associated with nonmelanoma skin cancer following renal transplantation in Queensland, Australia. J Am Acad Dermatol 2003; 49:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/26\">",
"      Liang G, Nan H, Qureshi AA, Han J. Pre-diagnostic plasma 25-hydroxyvitamin D levels and risk of non-melanoma skin cancer in women. PLoS One 2012; 7:e35211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/27\">",
"      Stern RS, Weinstein MC, Baker SG. Risk reduction for nonmelanoma skin cancer with childhood sunscreen use. Arch Dermatol 1986; 122:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/28\">",
"      Green A, Williams G, Neale R, et al. Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: a randomised controlled trial. Lancet 1999; 354:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/29\">",
"      Naylor MF, Boyd A, Smith DW, et al. High sun protection factor sunscreens in the suppression of actinic neoplasia. Arch Dermatol 1995; 131:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/30\">",
"      Dennis LK, Beane Freeman LE, VanBeek MJ. Sunscreen use and the risk for melanoma: a quantitative review. Ann Intern Med 2003; 139:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/31\">",
"      Stern RS, Liebman EJ, V&auml;kev&auml; L. Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA Follow-up Study. J Natl Cancer Inst 1998; 90:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/32\">",
"      Patel RV, Clark LN, Lebwohl M, Weinberg JM. Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol 2009; 60:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/33\">",
"      Lim JL, Stern RS. High levels of ultraviolet B exposure increase the risk of non-melanoma skin cancer in psoralen and ultraviolet A-treated patients. J Invest Dermatol 2005; 124:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/34\">",
"      Black RJ, Gavin AT. Photocarcinogenic risk of narrowband ultraviolet B (TL-01) phototherapy: early follow-up data. Br J Dermatol 2006; 154:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/35\">",
"      Hearn RM, Kerr AC, Rahim KF, et al. Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy. Br J Dermatol 2008; 159:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/36\">",
"      Weischer M, Blum A, Eberhard F, et al. No evidence for increased skin cancer risk in psoriasis patients treated with broadband or narrowband UVB phototherapy: a first retrospective study. Acta Derm Venereol 2004; 84:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/37\">",
"      Stern RS, Laird N. The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy Follow-up Study. Cancer 1994; 73:2759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/38\">",
"      Lee E, Koo J, Berger T. UVB phototherapy and skin cancer risk: a review of the literature. Int J Dermatol 2005; 44:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/39\">",
"      Karagas MR, Tosteson TD, Blum J, et al. Design of an epidemiologic study of drinking water arsenic exposure and skin and bladder cancer risk in a U.S. population. Environ Health Perspect 1998; 106 Suppl 4:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/40\">",
"      Tao SS, Bolger PM. Dietary arsenic intakes in the United States: FDA Total Diet Study, September 1991-December 1996. Food Addit Contam 1999; 16:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/41\">",
"      Boonchai W, Green A, Ng J, et al. Basal cell carcinoma in chronic arsenicism occurring in Queensland, Australia, after ingestion of an asthma medication. J Am Acad Dermatol 2000; 43:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/42\">",
"      Karagas MR, McDonald JA, Greenberg ER, et al. Risk of basal cell and squamous cell skin cancers after ionizing radiation therapy. For The Skin Cancer Prevention Study Group. J Natl Cancer Inst 1996; 88:1848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/43\">",
"      Lichter MD, Karagas MR, Mott LA, et al. Therapeutic ionizing radiation and the incidence of basal cell carcinoma and squamous cell carcinoma. The New Hampshire Skin Cancer Study Group. Arch Dermatol 2000; 136:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/44\">",
"      Ron E, Modan B, Preston D, et al. Radiation-induced skin carcinomas of the head and neck. Radiat Res 1991; 125:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/45\">",
"      Levi F, Moeckli R, Randimbison L, et al. Skin cancer in survivors of childhood and adolescent cancer. Eur J Cancer 2006; 42:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/46\">",
"      Watt TC, Inskip PD, Stratton K, et al. Radiation-related risk of basal cell carcinoma: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 2012; 104:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/47\">",
"      Hildreth NG, Shore RE, Hempelmann LH, Rosenstein M. Risk of extrathyroid tumors following radiation treatment in infancy for thymic enlargement. Radiat Res 1985; 102:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/48\">",
"      Schwartz JL, Kopecky KJ, Mathes RW, et al. Basal cell skin cancer after total-body irradiation and hematopoietic cell transplantation. Radiat Res 2009; 171:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/49\">",
"      Naruke Y, Nakashima M, Suzuki K, et al. Genomic instability in the epidermis induced by atomic bomb (A-bomb) radiation: a long-lasting health effect in A-bomb survivors. Cancer 2009; 115:3782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/50\">",
"      Sadamori N, Mine M, Honda T. Incidence of skin cancer among Nagasaki atomic bomb survivors. J Radiat Res 1991; 32 Suppl 2:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/51\">",
"      Preston DL, Ron E, Tokuoka S, et al. Solid cancer incidence in atomic bomb survivors: 1958-1998. Radiat Res 2007; 168:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/52\">",
"      Ron E, Preston DL, Kishikawa M, et al. Skin tumor risk among atomic-bomb survivors in Japan. Cancer Causes Control 1998; 9:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/53\">",
"      Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003; 348:1681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/54\">",
"      Silverberg MJ, Leyden W, Warton EM, et al. HIV Infection Status, Immunodeficiency, and the Incidence of Non-Melanoma Skin Cancer. J Natl Cancer Inst 2013; 105:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/55\">",
"      Dantal J, Hourmant M, Cantarovich D, et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998; 351:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/56\">",
"      Otley CC, Coldiron BM, Stasko T, Goldman GD. Decreased skin cancer after cessation of therapy with transplant-associated immunosuppressants. Arch Dermatol 2001; 137:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/57\">",
"      Baibergenova AT, Weinstock MA, VATTC Trial Group. Oral prednisone use and risk of keratinocyte carcinoma in non-transplant population. The VATTC trial. J Eur Acad Dermatol Venereol 2012; 26:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/58\">",
"      Karagas MR, Cushing GL Jr, Greenberg ER, et al. Non-melanoma skin cancers and glucocorticoid therapy. Br J Cancer 2001; 85:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/59\">",
"      Jensen A&Oslash;, Thomsen HF, Engebjerg MC, et al. Use of oral glucocorticoids and risk of skin cancer and non-Hodgkin's lymphoma: a population-based case-control study. Br J Cancer 2009; 100:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/60\">",
"      S&oslash;rensen HT, Mellemkjaer L, Nielsen GL, et al. Skin cancers and non-hodgkin lymphoma among users of systemic glucocorticoids: a population-based cohort study. J Natl Cancer Inst 2004; 96:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/61\">",
"      Gudbjartsson DF, Sulem P, Stacey SN, et al. ASIP and TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinoma. Nat Genet 2008; 40:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/62\">",
"      Stacey SN, Gudbjartsson DF, Sulem P, et al. Common variants on 1p36 and 1q42 are associated with cutaneous basal cell carcinoma but not with melanoma or pigmentation traits. Nat Genet 2008; 40:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/63\">",
"      Rafnar T, Sulem P, Stacey SN, et al. Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat Genet 2009; 41:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/64\">",
"      Stacey SN, Sulem P, Masson G, et al. New common variants affecting susceptibility to basal cell carcinoma. Nat Genet 2009; 41:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/65\">",
"      Stacey SN, Sulem P, Jonasdottir A, et al. A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. Nat Genet 2011; 43:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/66\">",
"      Welsh MM, Applebaum KM, Spencer SK, et al. CTLA4 variants, UV-induced tolerance, and risk of non-melanoma skin cancer. Cancer Res 2009; 69:6158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/67\">",
"      Xie J, Qureshi AA, Li Y, Han J. ABO blood group and incidence of skin cancer. PLoS One 2010; 5:e11972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/68\">",
"      Wolpin BM, Chan AT, Hartge P, et al. ABO blood group and the risk of pancreatic cancer. J Natl Cancer Inst 2009; 101:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/69\">",
"      Fine JD, Johnson LB, Weiner M, et al. Epidermolysis bullosa and the risk of life-threatening cancers: the National EB Registry experience, 1986-2006. J Am Acad Dermatol 2009; 60:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/70\">",
"      Cribier B, Scrivener Y, Grosshans E. Tumors arising in nevus sebaceus: A study of 596 cases. J Am Acad Dermatol 2000; 42:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/71\">",
"      Rosen H, Schmidt B, Lam HP, et al. Management of nevus sebaceous and the risk of Basal cell carcinoma: an 18-year review. Pediatr Dermatol 2009; 26:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/72\">",
"      Marks R, Rennie G, Selwood TS. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet 1988; 1:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/73\">",
"      Criscione VD, Weinstock MA, Naylor MF, et al. Actinic keratoses: Natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer 2009; 115:2523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/74\">",
"      Mil&aacute;n T, Verkasalo PK, Kaprio J, Koskenvuo M. Lifestyle differences in twin pairs discordant for basal cell carcinoma of the skin. Br J Dermatol 2003; 149:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/75\">",
"      Leonardi-Bee J, Ellison T, Bath-Hextall F. Smoking and the risk of nonmelanoma skin cancer: systematic review and meta-analysis. Arch Dermatol 2012; 148:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/76\">",
"      Dyer RK, Weinstock MA, Cohen TS, et al. Predictors of basal cell carcinoma in high-risk patients in the VATTC (VA Topical Tretinoin Chemoprevention) trial. J Invest Dermatol 2012; 132:2544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/77\">",
"      Olesen AB, Engholm G, Storm HH, Thestrup-Pedersen K. The risk of cancer among patients previously hospitalized for atopic dermatitis. J Invest Dermatol 2005; 125:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/78\">",
"      Ming ME, Levy R, Hoffstad O, et al. The lack of a relationship between atopic dermatitis and nonmelanoma skin cancers. J Am Acad Dermatol 2004; 50:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/79\">",
"      Hagstr&ouml;mer L, Ye W, Nyr&eacute;n O, Emtestam L. Incidence of cancer among patients with atopic dermatitis. Arch Dermatol 2005; 141:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/80\">",
"      Torti DC, Christensen BC, Storm CA, et al. Analgesic and nonsteroidal anti-inflammatory use in relation to nonmelanoma skin cancer: a population-based case-control study. J Am Acad Dermatol 2011; 65:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/81\">",
"      Nunes AP, Lapane KL, Weinstock MA, VATTC Trial Group. Association between non-steroidal anti-inflammatory drugs and keratinocyte carcinomas of the skin among participants in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Pharmacoepidemiol Drug Saf 2011; 20:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/82\">",
"      Grau MV, Baron JA, Langholz B, et al. Effect of NSAIDs on the recurrence of nonmelanoma skin cancer. Int J Cancer 2006; 119:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/83\">",
"      Butler GJ, Neale R, Green AC, et al. Nonsteroidal anti-inflammatory drugs and the risk of actinic keratoses and squamous cell cancers of the skin. J Am Acad Dermatol 2005; 53:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/84\">",
"      Elmets CA, Viner JL, Pentland AP, et al. Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst 2010; 102:1835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/85\">",
"      Johannesdottir SA, Chang ET, Mehnert F, et al. Nonsteroidal anti-inflammatory drugs and the risk of skin cancer: a population-based case-control study. Cancer 2012; 118:4768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/86\">",
"      Hruza LL, Pentland AP. Mechanisms of UV-induced inflammation. J Invest Dermatol 1993; 100:35S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/87\">",
"      Buckman SY, Gresham A, Hale P, et al. COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis 1998; 19:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/88\">",
"      Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 1996; 271:33157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/89\">",
"      Pentland AP, Schoggins JW, Scott GA, et al. Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition. Carcinogenesis 1999; 20:1939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/90\">",
"      Orengo IF, Gerguis J, Phillips R, et al. Celecoxib, a cyclooxygenase 2 inhibitor as a potential chemopreventive to UV-induced skin cancer: a study in the hairless mouse model. Arch Dermatol 2002; 138:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/91\">",
"      Fischer SM, Lo HH, Gordon GB, et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinog 1999; 25:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/92\">",
"      Wikonkal NM, Berg RJ, van Haselen CW, et al. bcl-2 vs p53 protein expression and apoptotic rate in human nonmelanoma skin cancers. Arch Dermatol 1997; 133:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/93\">",
"      Gailani MR, Leffell DJ, Ziegler A, et al. Relationship between sunlight exposure and a key genetic alteration in basal cell carcinoma. J Natl Cancer Inst 1996; 88:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/94\">",
"      Ouhtit A, Nakazawa H, Armstrong BK, et al. UV-radiation-specific p53 mutation frequency in normal skin as a predictor of risk of basal cell carcinoma. J Natl Cancer Inst 1998; 90:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/95\">",
"      Nangia R, Sait SN, Block AW, Zhang PJ. Trisomy 6 in basal cell carcinomas correlates with metastatic potential: a dual color fluorescence in situ hybridization study on paraffin sections. Cancer 2001; 91:1927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/96\">",
"      Ramachandran S, Fryer AA, Smith A, et al. Cutaneous basal cell carcinomas: distinct host factors are associated with the development of tumors on the trunk and on the head and neck. Cancer 2001; 92:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/97\">",
"      Ramachandran S, Lear JT, Ramsay H, et al. Presentation with multiple cutaneous basal cell carcinomas: association of glutathione S-transferase and cytochrome P450 genotypes with clinical phenotype. Cancer Epidemiol Biomarkers Prev 1999; 8:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/98\">",
"      Yengi L, Inskip A, Gilford J, et al. Polymorphism at the glutathione S-transferase locus GSTM3: interactions with cytochrome P450 and glutathione S-transferase genotypes as risk factors for multiple cutaneous basal cell carcinoma. Cancer Res 1996; 56:1974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/99\">",
"      Hajeer AH, Lear JT, Ollier WE, et al. Preliminary evidence of an association of tumour necrosis factor microsatellites with increased risk of multiple basal cell carcinomas. Br J Dermatol 2000; 142:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/100\">",
"      Ramachandran S, Fryer AA, Lovatt TJ, et al. Combined effects of gender, skin type and polymorphic genes on clinical phenotype: use of rate of increase in numbers of basal cell carcinomas as a model system. Cancer Lett 2003; 189:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/101\">",
"      Goeteyn M, Geerts ML, Kint A, De Weert J. The Bazex-Dupr&eacute;-Christol syndrome. Arch Dermatol 1994; 130:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/102\">",
"      Castori M, Morrone A, Kanitakis J, Grammatico P. Genetic skin diseases predisposing to basal cell carcinoma. Eur J Dermatol 2012; 22:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/103\">",
"      Wolberink EA, Pasch MC, Zeiler M, et al. High discordance between punch biopsy and excision in establishing basal cell carcinoma subtype: analysis of 500 cases. J Eur Acad Dermatol Venereol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/104\">",
"      Roozeboom MH, Mosterd K, Winnepenninckx VJ, et al. Agreement between histological subtype on punch biopsy and surgical excision in primary basal cell carcinoma. J Eur Acad Dermatol Venereol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/105\">",
"      Mosterd K, Thissen MR, van Marion AM, et al. Correlation between histologic findings on punch biopsy specimens and subsequent excision specimens in recurrent basal cell carcinoma. J Am Acad Dermatol 2011; 64:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/106\">",
"      Haws AL, Rojano R, Tahan SR, Phung TL. Accuracy of biopsy sampling for subtyping basal cell carcinoma. J Am Acad Dermatol 2012; 66:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/107\">",
"      Russell EB, Carrington PR, Smoller BR. Basal cell carcinoma: a comparison of shave biopsy versus punch biopsy techniques in subtype diagnosis. J Am Acad Dermatol 1999; 41:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/108\">",
"      Altamura D, Menzies SW, Argenziano G, et al. Dermatoscopy of basal cell carcinoma: morphologic variability of global and local features and accuracy of diagnosis. J Am Acad Dermatol 2010; 62:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/109\">",
"      Zalaudek I, Kreusch J, Giacomel J, et al. How to diagnose nonpigmented skin tumors: a review of vascular structures seen with dermoscopy: part II. Nonmelanocytic skin tumors. J Am Acad Dermatol 2010; 63:377.",
"     </a>",
"    </li>",
"    <li>",
"     Johr R, Soyer HP, Argenziano G, et al. Dermoscopy - The essentials, Mosby, Philadelphia 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/39/14970/abstract/111\">",
"      Sariya D, Ruth K, Adams-McDonnell R, et al. Clinicopathologic correlation of cutaneous metastases: experience from a cancer center. Arch Dermatol 2007; 143:613.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5335 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-EBC78AF0D7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_39_14970=[""].join("\n");
var outline_f14_39_14970=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      UV light exposure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Therapeutic exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Chronic arsenic exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Ionizing radiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Genetic variants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2896064\">",
"      Blood type",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Inherited disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Basal cell nevus syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Epidermolysis bullosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8406955\">",
"      Nevus sebaceus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Actinic keratosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Lifestyle factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H371909\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      MOLECULAR PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      UV-induced inflammation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PTCH1 gene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Other genetic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Truncal BCC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Nodular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Superficial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Morpheaform",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Other subtypes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Multiple basal cell carcinoma syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H371894\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29443712\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/5335\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/5335|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/37/13904\" title=\"figure 1\">",
"      Shh Gli pathway medulloblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/5335|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/13/43217\" title=\"picture 1A\">",
"      Large basal cell carcinoma on nose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/28/44483\" title=\"picture 1B\">",
"      Large basal cell carcinoma on ear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/24/25989\" title=\"picture 2\">",
"      Palmar pits BCC nevus syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/56/17283\" title=\"picture 3A\">",
"      Nodular basal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/1/21523\" title=\"picture 3B\">",
"      Nodular basal cell carcinomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/57/30623\" title=\"picture 3C\">",
"      Ulcerated basal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/50/17188\" title=\"picture 4\">",
"      Superficial basal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/33/533\" title=\"picture 5\">",
"      Infiltrative basal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/57/24464\" title=\"picture 6A\">",
"      Amelanotic melanoma 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/38/42595\" title=\"picture 6B\">",
"      Amelanotic melanoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8730?source=related_link\">",
"      Arsenic exposure and poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/13/22745?source=related_link\">",
"      Benign skin and scalp lesions in the newborn and young infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/11/13497?source=related_link\">",
"      Dermoscopic evaluation of skin lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34170?source=related_link\">",
"      Development of malignancy following solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/56/25482?source=related_link\">",
"      Epidemiology and risk factors for cutaneous squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/13/27866?source=related_link\">",
"      Epidemiology and risk factors for exocrine pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37832?source=related_link\">",
"      Epidemiology and risk factors for skin cancer in solid organ transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/49/18200?source=related_link\">",
"      Epidemiology, natural history, and diagnosis of actinic keratosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/23/41332?source=related_link\">",
"      Histopathology and molecular pathogenesis of medulloblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/5/44121?source=related_link\">",
"      Nevoid basal cell carcinoma syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/26/26018?source=related_link\">",
"      Patient information: Skin cancer (non-melanoma) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/30/18913?source=related_link\">",
"      Patient information: Sunburn (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/20/23874?source=related_link\">",
"      Patient information: Sunburn (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18073?source=related_link\">",
"      Primary prevention of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40264?source=related_link\">",
"      Skin biopsy techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/27/30136?source=related_link\">",
"      Sunburn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/61/14293?source=related_link\">",
"      Systemic treatment of advanced cutaneous squamous and basal cell carcinomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24586?source=related_link\">",
"      The genodermatoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/23/13690?source=related_link\">",
"      Treatment and prognosis of basal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31209?source=related_link\">",
"      Treatment and prognosis of cutaneous squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/8/24712?source=related_link\">",
"      Treatment of basal cell carcinomas at high risk for recurrence",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_39_14971="Hepatic hydrothorax features";
var content_f14_39_14971=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F52482&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F52482&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Characteristics of hepatic hydrothroax",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Location",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Right side (85 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Left side (13 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bilateral (2 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Fluid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cell count &lt;250 PMN cells mm3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Protein &lt;2.5 g/dL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pleural fluid/serum total protein ratio &lt;0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pleural fluid/serum LDH ratio &lt;0.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serum-to-pleural-fluid albumin gradient &gt;1.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pleural fluid/serum bilirubin ratio &lt;0.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        pH &gt;7.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glucose level similar to that of serum",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Andres Cardenas, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_39_14971=[""].join("\n");
var outline_f14_39_14971=null;
var title_f14_39_14972="Phototoxic and photoallergic reactions";
var content_f14_39_14972=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F50323&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F50323&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differences between phototoxic and photoallergic reactions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Feature",
"       </td>",
"       <td class=\"subtitle1\">",
"        Phototoxicity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Photoallergy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Incidence",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amount of agent required for photosensitivity",
"       </td>",
"       <td>",
"        Large",
"       </td>",
"       <td>",
"        Small",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Onset after exposure to photosensitizer and light",
"       </td>",
"       <td>",
"        Minutes to hours",
"       </td>",
"       <td>",
"        24 hr or more",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Requirement for immunization",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clinical characteristics",
"       </td>",
"       <td>",
"        Exaggerated sunburn",
"       </td>",
"       <td>",
"        Acute, subacute, or chronic dermatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Distribution",
"       </td>",
"       <td>",
"        Exposed skin only",
"       </td>",
"       <td>",
"        Exposed skin; may spread to unexposed skin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pigmentary changes",
"       </td>",
"       <td>",
"        Frequent",
"       </td>",
"       <td>",
"        Unusual",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Histopathologic features",
"       </td>",
"       <td>",
"        Epidermal cell degeneration; dermal edema and vasodilatation; sparse mononuclear infiltrate",
"       </td>",
"       <td>",
"        Epidermal spongiosis; exocytosis of mononuclear cells; dermal mononuclear cell infiltrate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Development of persistent light reaction",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cross-reactions to related agents",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Covalent binding with carrier protein",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Gould JW, Mercurio MG, Elmets CA. Cutaneous photosensitivity diseases induced by exogenous agents. J Am Acad Dermatol 1995; 33:551. Table used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_39_14972=[""].join("\n");
var outline_f14_39_14972=null;
var title_f14_39_14973="Elemental iron content";
var content_f14_39_14973=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64634&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64634&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Elemental iron content of selected iron preparations",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Preparation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Elemenal iron content",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Ferrous sulfate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\" rowspan=\"1\">",
"        Generic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        324 mg tablet",
"       </td>",
"       <td class=\"sublist_other\">",
"        65 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        325 mg tablet",
"       </td>",
"       <td class=\"sublist_other\">",
"        65 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        159 mg exsiccated timed release capsure",
"       </td>",
"       <td class=\"sublist_other\">",
"        50 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Elixir, 220 mg/5 mL",
"       </td>",
"       <td class=\"sublist_other\">",
"        44 mg/5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Liquid drops, 75 mg/0.6 mL",
"       </td>",
"       <td class=\"sublist_other\">",
"        15 mg/0.6 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fer-Gen-Sol, 75 mg/0.6 mL",
"       </td>",
"       <td>",
"        15 mg/0.6 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\" rowspan=\"1\">",
"        Fer-In-Sol&reg;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Infant drops: 75 mg/0.6 mL",
"       </td>",
"       <td class=\"sublist_other\">",
"        15 mg/0.6 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Syrup,90 mg/5 mL",
"       </td>",
"       <td class=\"sublist_other\">",
"        18 mg/5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fer-Iron&reg;, 75 mg/0.6 mL",
"       </td>",
"       <td>",
"        15 mg/0.6 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Feratab&reg;, 300 mg tablet",
"       </td>",
"       <td>",
"        60 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Slow FE&reg;, 160 mg exsiccated tablet",
"       </td>",
"       <td>",
"        50 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\" rowspan=\"1\">",
"        Feosol&reg;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        200 mg exsiccated tablet",
"       </td>",
"       <td class=\"sublist_other\">",
"        65 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Elixir 220 mg/5 mL",
"       </td>",
"       <td class=\"sublist_other\">",
"        44 mg/5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Ferrous gluconate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\" rowspan=\"1\">",
"        Generic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        300 mg tablet",
"       </td>",
"       <td class=\"sublist_other\">",
"        34 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        325 mg tablet",
"       </td>",
"       <td class=\"sublist_other\">",
"        38 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fergon&reg;, 240 mg tablet",
"       </td>",
"       <td>",
"        27 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Ferrous fumarate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        Generic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        325 mg tablet",
"       </td>",
"       <td class=\"sublist_other\">",
"        106 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Femiron&reg;, 63 mg tablet",
"       </td>",
"       <td>",
"        20 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ferretts, 325 mg tablet",
"       </td>",
"       <td>",
"        106 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemocyte&reg;, 324 mg tablet",
"       </td>",
"       <td>",
"        106 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ircon&reg;, 200 mg tablet",
"       </td>",
"       <td>",
"        66 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nephro-Fer&reg;, 350 mg tablet",
"       </td>",
"       <td>",
"        115 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\" rowspan=\"1\">",
"        Feostat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        100 mg chewable tablet",
"       </td>",
"       <td class=\"sublist_other\">",
"        33 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        oral suspension, 100 mg/5 mL",
"       </td>",
"       <td class=\"sublist_other\">",
"        33 mg/5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\" rowspan=\"1\">",
"        Ferro-Sequels&reg;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        150 mg timed release tablet",
"       </td>",
"       <td class=\"sublist_other\">",
"        50 mg",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_39_14973=[""].join("\n");
var outline_f14_39_14973=null;
var title_f14_39_14974="Thyroid tests in pts with renal failure";
var content_f14_39_14974=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F68252&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F68252&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 593px\">",
"   <div class=\"ttl\">",
"    Thyroid testing in patients with suspected hypothyroidism and renal failure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 573px; height: 261px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Algorithm for the evaluation of thyroid status in patients with renal failure suspected of possible hypothyroidism because of a decreased serum free T4 concentration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_39_14974=[""].join("\n");
var outline_f14_39_14974=null;
var title_f14_39_14975="Joints psoriatic arthr PI";
var content_f14_39_14975=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F69282&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F69282&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Psoriatic arthritis on the joints of the fingers",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 375px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This person has psoriatic arthritis affecting the middle and little fingers, on the joints furthest from the palm. The person's nails are also separating from the nail bed, which is also a symptom of psoriatic arthritis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dafna D Gladman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_39_14975=[""].join("\n");
var outline_f14_39_14975=null;
           